<body> <document>  <type>   10-K   <sequence>    1    <filename>     f10k2020_actiniumpharma.htm     <description>      ANNUAL REPORT      <text>       <title>       </title>       <p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center">       </p>       <!-- Field: Rule-Page -->       <div align="LEFT">        <div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">        </div>       </div>       <!-- Field: /Rule-Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">        <b>         UNITED STATES        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">        <b>         SECURITIES AND EXCHANGE COMMISSION        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">        <b>         Washington, D.C. 20549        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">        <font style="font-size: 7pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">        <b>         FORM 10-K        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">        <font style="font-size: 7pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">        (Mark One)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">        ☒ Annual Report Under Section 13 Or15(d) Of The Securities Exchange Act Of 1934       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">        <font style="font-size: 7pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">        For the fiscal year ended        <b>         December 31,2020        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">        <font style="font-size: 7pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">        or       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">        <font style="font-size: 7pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">        ☐ Transition Report Under Section 13Or 15(d) Of The Securities Exchange Act Of 1934       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">        <font style="font-size: 7pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">        For the transition period from _____ to _____       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">        <font style="font-size: 7pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">        <b>         COMMISSION FILE NUMBER: 000-52446        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">        <font style="font-size: 7pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">        <b>         ACTINIUM PHARMACEUTICALS, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">        (Exact name of registrant as specified in itscharter)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">        <font style="font-size: 7pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font-size: 10pt; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 49%; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           <font style="font-size: 10pt">            <b>             Delaware            </b>           </font>          </td>          <td style="width: 2%; font: 10pt Times New Roman, Times, Serif; text-align: center">          </td>          <td style="width: 49%; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">           <font style="font-size: 10pt">            <b>             74-2963609            </b>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">            (State or other jurisdiction of           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">            incorporation or organization)           </p>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">          </td>          <td>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">            (I.R.S. Employer           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">            Identification No.)           </p>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">        <font style="font-size: 7pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">        <b>         275 Madison Avenue, 7         <sup>          th         </sup>         Fl.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">        <b>         New York, NY 10016        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">        (Address of principal executive offices) (ZipCode)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">        <font style="font-size: 7pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">        <b>         (646) 677-3870        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">        Registrant’s telephone number, includingarea code       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">        <font style="font-size: 7pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">        <b>         Securities registeredpursuant to Section 12(b) of the Act:        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">        <font style="font-size: 7pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr>          <td style="white-space: nowrap; vertical-align: bottom; width: 32%; border-bottom: Black 1.5pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             Title of each class            </b>           </font>          </td>          <td style="vertical-align: top; width: 2%; padding-bottom: 1.5pt; text-align: center">          </td>          <td style="vertical-align: top; width: 32%; border-bottom: Black 1.5pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             Trading symbol            </b>           </font>          </td>          <td style="vertical-align: bottom; width: 2%; padding-bottom: 1.5pt; text-align: center">          </td>          <td style="white-space: nowrap; vertical-align: bottom; width: 32%; border-bottom: Black 1.5pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             Name of exchange on which registered            </b>           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            <b>             Common stock, par value $0.001            </b>           </font>          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            <b>             ATNM            </b>           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            <b>             NYSE American            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">        <font style="font-size: 7pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">        <b>         Securities registeredpursuant to Section 12(g) of the Act: None        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">        <font style="font-size: 7pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        Indicate by check mark if the registrant isa well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐  No ☒       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        <font style="font-size: 7pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        Indicate by check mark if the registrant isnot required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐  No ☒       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        <font style="font-size: 7pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        Indicate by check mark whether the registrant:(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to suchfiling requirements for the past 90 days. Yes ☒  No ☐       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        <font style="font-size: 7pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        Indicate by check mark whether the registranthas submitted electronically every Interactive Date File required to be submitted pursuant to Rule 405 of Regulation S-T (Section232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submitsuch files). Yes ☒  No ☐       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <font style="font-size: 7pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        Indicate by check mark whether the registrantis a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company.See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,”and “emerging growth company” in Rule 12b-2 of the Exchange Act.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <font style="font-size: 7pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 25%; text-align: justify">           <font style="font-size: 10pt">            Large accelerated filer           </font>          </td>          <td style="width: 35%; text-align: justify">           ☐          </td>          <td style="width: 25%; text-align: justify">           <font style="font-size: 10pt">            Accelerated filer           </font>          </td>          <td style="width: 15%; text-align: justify">           ☐          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">           <font style="font-size: 10pt">            Non-accelerated filer           </font>          </td>          <td style="text-align: justify">           ☒          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            Smaller reporting company           </font>          </td>          <td style="text-align: justify">           ☒          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            Emerging growth company           </font>          </td>          <td style="text-align: justify">           ☐          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <font style="font-size: 7pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        If an emerging growth company, indicate bycheck mark if the registrant has elected not to use the extended transition period for complying with any new or revised financialaccounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <font style="font-size: 7pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        Indicate by check mark whether the registrantis a shell company (as defined in Rule 12b-2 of the act): Yes ☐  No ☒       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">        <font style="font-size: 7pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        The aggregate market value of voting stockheld by nonaffiliates of the registrant as of June 30, 2020, the last business day of the registrant’s most recentlycompleted second fiscal quarter, based on the closing price of the common stock on the NYSE AMERICAN on June 30, 2020 was $138,896,884.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">        <font style="font-size: 7pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        As of March 31, 2021, 19,245,638 shares ofcommon stock, $0.001 par value per share, were outstanding.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <!-- Field: Rule-Page -->       <div align="LEFT">        <div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">        </div>       </div>       <!-- Field: /Rule-Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 1 -->       <div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 100%; text-align: center">           </td>          </tr>         </tbody>        </table>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 100%">            <page>             <page>             </page>            </page>           </td>          </tr>         </tbody>        </table>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">        <b>         Table of Contents        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr>          <td style="vertical-align: top; text-align: justify; width: 10%">          </td>          <td style="vertical-align: top; text-align: justify; width: 80%">          </td>          <td style="width: 2%">          </td>          <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center; width: 8%">           <b>            Page           </b>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td colspan="4" style="text-align: center">           <a href="#aph165213a001">            PART I           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; text-align: justify">           <a href="#aph165213a002">            Item 1.           </a>          </td>          <td style="vertical-align: top; text-align: justify">           <a href="#aph165213a002">            Business           </a>          </td>          <td>          </td>          <td style="vertical-align: bottom; text-align: center">           1          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; text-align: justify">           <a href="#aph165213a003">            Item 1A.           </a>          </td>          <td style="vertical-align: top; text-align: justify">           <a href="#aph165213a003">            Risk Factors           </a>          </td>          <td>          </td>          <td style="vertical-align: bottom; text-align: center">           12          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; text-align: justify">           <a href="#aph165213a004">            Item 1B.           </a>          </td>          <td style="vertical-align: top; text-align: justify">           <a href="#aph165213a004">            Unresolved Staff Comments           </a>          </td>          <td>          </td>          <td style="vertical-align: bottom; text-align: center">           42          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; text-align: justify">           <a href="#aph165213a005">            Item 2.           </a>          </td>          <td style="vertical-align: top; text-align: justify">           <a href="#aph165213a005">            Properties           </a>          </td>          <td>          </td>          <td style="vertical-align: bottom; text-align: center">           42          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; text-align: justify">           <a href="#aph165213a006">            Item 3.           </a>          </td>          <td style="vertical-align: top; text-align: justify">           <a href="#aph165213a006">            Legal Proceedings           </a>          </td>          <td>          </td>          <td style="vertical-align: bottom; text-align: center">           42          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; text-align: justify">           <a href="#aph165213a007">            Item 4.           </a>          </td>          <td style="vertical-align: top; text-align: justify">           <a href="#aph165213a007">            Mine Safety Disclosures           </a>          </td>          <td>          </td>          <td style="vertical-align: bottom; text-align: center">           42          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td>          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td colspan="4" style="text-align: center">           <a href="#aph165213a008">            PART II           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td>          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; text-align: justify">           <a href="#aph165213a009">            Item 5.           </a>          </td>          <td style="vertical-align: top; text-align: justify">           <a href="#aph165213a009">            Market for Registrant’s    Common Equity, Related Stockholders Matters, and Issuer Purchases of Equity Securities           </a>          </td>          <td>          </td>          <td style="vertical-align: bottom; text-align: center">           43          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; text-align: justify">           <a href="#aph165213a010">            Item 6.           </a>          </td>          <td style="vertical-align: top; text-align: justify">           <a href="#aph165213a010">            Selected Financial Data           </a>          </td>          <td>          </td>          <td style="vertical-align: bottom; text-align: center">           44          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; text-align: justify">           <a href="#aph165213a011">            Item 7.           </a>          </td>          <td style="vertical-align: top; text-align: justify">           <a href="#aph165213a011">            Management’s Discussion and    Analysis of Financial Condition and Results of Operations           </a>          </td>          <td>          </td>          <td style="vertical-align: bottom; text-align: center">           45          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; text-align: justify">           <a href="#aph165213a012">            Item 7A.           </a>          </td>          <td style="vertical-align: top; text-align: justify">           <a href="#aph165213a012">            Quantitative and Qualitative Disclosures    About Market Risk           </a>          </td>          <td>          </td>          <td style="vertical-align: bottom; text-align: center">           50          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; text-align: justify">           <a href="#aph165213a013">            Item 8.           </a>          </td>          <td style="vertical-align: top; text-align: justify">           <a href="#aph165213a013">            Financial Statements and Supplementary    Data           </a>          </td>          <td>          </td>          <td style="vertical-align: bottom; text-align: center">           F-1          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; text-align: justify">           <a href="#aph165213a014">            Item 9.           </a>          </td>          <td style="vertical-align: top; text-align: justify">           <a href="#aph165213a014">            Changes in and Disagreements with    Accountants on Accounting and Financial Disclosure           </a>          </td>          <td>          </td>          <td style="vertical-align: bottom; text-align: center">           51          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; text-align: justify">           <a href="#aph165213a015">            Item 9A.           </a>          </td>          <td style="vertical-align: top; text-align: justify">           <a href="#aph165213a015">            Controls and Procedures           </a>          </td>          <td>          </td>          <td style="vertical-align: bottom; text-align: center">           51          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; text-align: justify">           <a href="#aph165213a016">            Item 9B.           </a>          </td>          <td style="vertical-align: top; text-align: justify">           <a href="#aph165213a016">            Other Information           </a>          </td>          <td>          </td>          <td style="vertical-align: bottom; text-align: center">           51          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; text-align: justify">          </td>          <td style="vertical-align: top; text-align: justify">          </td>          <td>          </td>          <td style="vertical-align: bottom; text-align: center">          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td colspan="4" style="text-align: center">           <a href="#aph165213a017">            PART III           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td>          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; text-align: justify">           <a href="#aph165213a018">            Item 10.           </a>          </td>          <td style="vertical-align: top; text-align: justify">           <a href="#aph165213a018">            Directors, Executive Officers and    Corporate Governance           </a>          </td>          <td>          </td>          <td style="vertical-align: bottom; text-align: center">           52          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; text-align: justify">           <a href="#aph165213a019">            Item 11.           </a>          </td>          <td style="vertical-align: top; text-align: justify">           <a href="#aph165213a019">            Executive Compensation           </a>          </td>          <td>          </td>          <td style="vertical-align: bottom; text-align: center">           67          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; text-align: justify">           <a href="#aph165213a020">            Item 12.           </a>          </td>          <td style="vertical-align: top; text-align: justify">           <a href="#aph165213a020">            Security Ownership of Certain Beneficial    Owners and Management           </a>          </td>          <td>          </td>          <td style="vertical-align: bottom; text-align: center">           71          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; text-align: justify">           <a href="#aph165213a021">            Item 13.           </a>          </td>          <td style="vertical-align: top; text-align: justify">           <a href="#aph165213a021">            Certain Relationships and Related    Transactions, and Director Independence           </a>          </td>          <td>          </td>          <td style="vertical-align: bottom; text-align: center">           73          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; text-align: justify">           <a href="#aph165213a022">            Item 14.           </a>          </td>          <td style="vertical-align: top; text-align: justify">           <a href="#aph165213a022">            Principal Accountant Fees and Services           </a>          </td>          <td>          </td>          <td style="vertical-align: bottom; text-align: center">           73          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; text-align: justify">          </td>          <td style="vertical-align: top; text-align: justify">          </td>          <td>          </td>          <td style="vertical-align: bottom; text-align: center">          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td colspan="4" style="text-align: center">           <a href="#aph165213a023">            PART IV           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td>          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; text-align: justify">           <a href="#aph165213a024">            Item 15.           </a>          </td>          <td style="vertical-align: top; text-align: justify">           <a href="#aph165213a024">            Exhibits, Financial Statement Schedules           </a>          </td>          <td>          </td>          <td style="vertical-align: bottom; text-align: center">           74          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; text-align: justify">          </td>          <td style="vertical-align: top; text-align: justify">          </td>          <td>          </td>          <td style="vertical-align: bottom; text-align: center">          </td>         </tr>         <tr style="background-color: White">          <td colspan="2" style="vertical-align: top; text-align: justify">           <a href="#aph165213a025">            Signature Page           </a>          </td>          <td>          </td>          <td style="text-align: center">           79          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">       </p>       <!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 100%; text-align: center">            <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->            i            <!-- Field: /Sequence -->           </td>          </tr>         </tbody>        </table>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 100%">            <page>             <page>             </page>            </page>           </td>          </tr>         </tbody>        </table>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">        <b>         CAUTIONARY NOTE REGARDING FORWARD-LOOKINGSTATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        This Annual Report on Form 10-K (this “Report”)contains forward-looking statements that involve risks and uncertainties, principally in the sections entitled “Descriptionof Business,” “Risk Factors,” and “Management’s Discussion and Analysis of Financial Condition andResults of Operations.” All statements other than statements of historical fact contained in this Report, including statementsregarding future events, our future financial performance, business strategy and plans and objectives of management for futureoperations, are forward-looking statements. We have attempted to identify forward-looking statements by terminology including “anticipates,”“believes,” “can,” “continue,” “could,” “estimates,” “expects,”“intends,” “may,” “plans,” “potential,” “predicts,” “should,”or “will” or the negative of these terms or other comparable terminology. Although we do not make forward-looking statementsunless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. These statements are only predictionsand involve known and unknown risks, uncertainties and other factors, including the risks outlined under “Risk Factors”or elsewhere in this Report, which may cause our or our industry’s actual results, levels of activity, performance or achievementsexpressed or implied by these forward-looking statements. Moreover, we operate in a very competitive and rapidly changing environment.New risks emerge from time to time and it is not possible for us to predict all risk factors, nor can we address the impact ofall factors on our business or the extent to which any factor, or combination of factors, may cause our actual results to differmaterially from those contained in any forward-looking statements. All forward-looking statements included in this document arebased on information available to us on the date hereof, and we assume no obligation to update any such forward-looking statements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        You should not place undue reliance on anyforward-looking statement, each of which applies only as of the date of this Report. Before you invest in our securities, you shouldbe aware that the occurrence of the events described in the section entitled “Risk Factors” and elsewhere in this Reportcould negatively affect our business, operating results, financial condition and stock price. Except as required by law, we undertakeno obligation to update or revise publicly any of the forward-looking statements after the date of this Report to conform our statementsto actual results or changed expectations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 3; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 100%; text-align: center">            <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->            ii            <!-- Field: /Sequence -->           </td>          </tr>         </tbody>        </table>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif">         <tbody>          <tr style="vertical-align: top; text-align: left">           <td style="width: 100%">            <page>             <page>             </page>            </page>           </td>          </tr>         </tbody>        </table>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">        <a name="aph165213a001">        </a>        <b>         PART I        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <a name="aph165213a002">         </a>         Item 1. Business.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         Business Overview        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Actinium Pharmaceuticals,Inc. is a clinical-stage, biopharmaceutical company applying its proprietary platform technology and deep understanding of radiobiologyto the development of novel targeted therapies known as Antibody Radiation-Conjugates (“ARCs”). Radiation is an effectivetherapeutic modality that is used in the treatment of over fifty percent of all cancer patients and is often combined with chemotherapy,immunotherapy and other treatments for greater therapeutic effect. Radiation is typically administered via an external beam sourcefrom outside the body, leading to off-target exposure to normal healthy tissue and organs, which can constrain the amount of radiationthat can be administered to patients due to associated dose-limiting toxicities. In addition, use of external beam radiation islargely limited to solid tumors and cannot be used in blood cancers, which are diffuse throughout the body of a patient. ARCs combinethe cell-killing ability of radiation via a radioisotope payload with a targeting agent, such as a monoclonal antibody to deliverradiation in a precise manner inside the body to specific, targeted cells, to potentially achieve greater efficacy with lower toxicitythan with external beam radiation. ARCs enable a broader usage of radiation than external beam radiation as they can be used inthe treatment of both solid tumors and blood cancers. Blood or hematologic cancers are known to be highly sensitive to radiation.Our clinical pipeline is focused on ARCs targeting the antigens CD45 and CD33, both of which are expressed in multiple hematologiccancers. Our clinical programs are focused on two primary areas: (1) targeted conditioning prior to a bone marrow transplant (“BMT”),adoptive cell therapy (“ACT”) such as CAR-T or gene therapy and (2) ARC therapeutic combinations with other agents.Our product development strategy is actively informed by clinical data with our ARCs in over 500 patients, including our ongoingPivotal Phase 3 SIERRA trial. Our clinical pipeline has emanated from our Antibody Warhead Enabling (“AWE”) technologyplatform, which is protected by over 140 issued and pending patents, trade secrets and know-how and is being utilized in a collaborativeresearch partnership with Astellas Pharma, Inc. (“Astellas”).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         Targeted Conditioning        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        To the best of ourknowledge, we are advancing the only multi-target, multi-indication, clinical-stage pipeline for targeted conditioning and theonly ARC-based targeted conditioning regimens in development. Our ARCs for targeted conditioning are intended to potentially enableimproved access and outcomes to cell-based therapies with curative potential, including BMT, ACT, and Gene Therapy. Conditioningin the context of BMT, ACT or Gene Therapy is the act of depleting certain blood and immune-forming cells, including bone marrowstem cells and, in some cases, cancer cells prior to transplanting new cells into a patient. Currently, conditioning is accomplishedusing a combination of cytotoxic chemotherapeutic agents and external radiation. These non-targeted conditioning regimens are highlytoxic and may prevent a patient from receiving a potentially curative therapy and hinder outcomes. ARCs have the potential to increasepatient access and outcomes by way of their ability to selectively deplete targeted cells while sparing normal healthy cells, resultingin potentially lower systemic and off-target toxicities. We use our ARCs both at high isotope dose levels to achieve myeloablation,which fully depletes bone marrow stem cells and at lower isotope dose levels to achieve lymphodepletion, which spares bone marrowstem cells from depletion. In addition, dosing may be titrated downward from myeloablative doses to achieve partial myeloablation,which may be appropriate for certain gene therapy programs.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">       </p>       <!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         1         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         CD45 Targeted Conditioning Program        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Our CD45 ARC is comprisedof the anti-CD45 monoclonal antibody known as apamistamab (formerly BC8) and the radioisotope Iodine-131 (“I-131”).CD45 is an antigen expressed on leukemia, lymphoma and myeloma cancer cells, as well as nucleated immune cells including bone marrowstem cells, but is not expressed outside of the hematopoietic, or blood forming, system. This unique expression on blood cancerand immune cells enables simultaneous depletion of both cell types, making CD45 an optimal antigen for targeted conditioning applications.CD45 is a cell surface antigen with an average expression of 200,000 copies per cell, however, it only internalizes at a rate of10-15%. We believe our ARC approach is the most effective method to target CD45 positive cells, as the radioisotope payload linearenergy transfer can readily ablate a targeted cell without requiring payload internalization like an antibody drug conjugate orwithout relying on biological effector function processes like a naked antibody. Furthermore, since CD45 expression level variesfrom low to high antigen density as the immune cells become more terminally differentiated, we can selectively condition dependingon the therapeutic application, from full myeloablation to transient lymphodepletion, by adjusting the dose or intensity of theI-131 isotope payload. Full myeloablation can be achieved with high doses of I-131, as its energy pathlength and crossfire effectcan penetrate into bone marrow niches to target and deplete blood and immune system forming bone marrow stem cells. Myeloablationis applicable to autologous or allogeneic BMT and to autologous gene-edited or modified therapies that can reconstitute a patient’sblood and immune systems. Alternatively, low doses of I-131 can be transiently lymphodepleting and spare a patient’s bonemarrow stem cells, which we believe is ideal for ACT applications such as CAR-T. We intend to develop our CD45 targeted conditioningprogram for BMT, ACT and Gene Therapy applications for malignant and non-malignant diseases and believe that multiple radioisotopesbeyond I-131 may be utilized including alpha and beta emitters.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Our lead CD45 targetedconditioning product candidate is Iomab-B, which uses high doses of I-131 to achieve myeloablative conditioning prior to a BMT.Iomab-B is currently being studied in the pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory AML (“SIERRA”),clinical trial for targeted conditioning prior to an allogeneic BMT for patients with active, relapsed or refractory (“r/r”)Acute Myeloid Leukemia, (“AML”), who are age 55 or older. Patients with active, r/r AML are not normally consideredeligible for BMT and the SIERRA trial is the only randomized Phase 3 trial to offer BMT as a treatment option for this patientpopulation. The SIERRA trial compares outcomes of patients randomized to receive Iomab-B and a BMT (the “study arm”)to those patients randomized to receive physician’s choice of salvage therapy (the “control arm”). The controlarm is also defined as conventional care, as no standard of care exists for this patient population and includes over 20 agentsthat may be used as single agents or in combination including venetoclax, a targeted Bcl-2 inhibitor, Midostaurin and Sorafenib,targeted FLT3 inhibitors, hypomethylating agents and cytotoxic chemotherapies. Patients who fail to achieve a Complete Response(“CR”) on the control arm are ineligible to proceed to a BMT, but the trial design permits these patients to “crossover” to receive the study arm treatment if they meet the eligibility criteria. The primary endpoint of the SIERRA trialis durable Complete Remission (“dCR”) of 180 days and the secondary endpoint is Overall Survival (“OS”).When the crossover patients receive Iomab-B and BMT, they have not achieved remission with their salvage therapy and are consideredto be failures for the primary endpoint of the study. The SIERRA trial is currently active at 5 sites in the United States andCanada, which includes many of the leading BMT sites based on volume. We expect to complete enrollment of the SIERRA trial andhave topline data that we believe will support the submission of a Biologics License Application (“BLA”) with the U.S.Food and Drug Administration (“FDA”). If approved, we expect our initial commercial launch would target the leading50-100 BMT and medical centers that perform the vast majority of BMT’s in the United States. In the European Union (“EU”),we received favorable feedback from the European Medicines Agency (“EMA”) via their scientific advice program thatthe trial design, primary endpoint and planned statistical analysis from the SIERRA trial are acceptable as the basis for a MarketingAuthorization Application, or MAA. Additionally, the EMA commented that it does not anticipate the need for further standalonepreclinical toxicology or safety studies. Overall, transplant procedures in the EU are approximately fifty percent higher thanin the United States with a similar market dynamic, with a majority of BMT volume being conducted in a concentrated number of leadingmedical centers. Currently we intend to secure a partner for Iomab-B in the EU.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">       </p>       <!-- Field: Page; Sequence: 5; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         2         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        The SIERRA trial is poweredto show a two-times difference in the primary endpoint of dCR of at least 180 days at complete enrollment of the planned 150 patients.The SIERRA trial design allowed for up to two interim analyses of the primary endpoint, exercisable at our discretion and triggeredby an enrollment range of 70 to 110 patients. In April 2020, we exercised a single ad hoc analysis on a number of patients representingless than two thirds of full trial enrollment of 150 patients, which required a higher success threshold compared to the two-timedifference in dCR rate at full trial enrollment. In December 2020, we announced that the independent Data Monitoring Committee(“DMC”) completed the single ad hoc interim analysis. Based on the DMC’s review of unblinded data, including the study’sprimary endpoint of dCR of at least 180 days, it was recommended that the study continue as planned to full enrollment of 150 patients.We did not receive the unblinded primary and secondary endpoint efficacy data from SIERRA. By exercising only a single interimanalysis, there was a minimal alpha spend resulting in a p-value threshold of 0.046 for the primary endpoint evaluation at fullenrollment of 150 patients. The SIERRA trial reached 75% enrollment, representing 113 patients, in the third quarter of 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Data from the first113 patients enrolled in the SIERRA trial, which represents 75% of the total of 150 patients to be enrolled in the trial, was presentedin oral presentations at the American Society of Hematology (“ASH”) Annual Meeting in December 2020 and at the Transplantation &amp;Cellular Therapy (“TCT”) Meetings of the American Society for Transplantation and Cellular Therapy (“ASTCT”)and Center for International Bone &amp; Marrow Transplant Research (“CIBMTR”) in February 2021. It was reportedthat 100% of patients (49/49) on the study arm that received a therapeutic dose of Iomab-B received a BMT, with a median time toBMT of 30 days, and all patients achieved neutrophil and platelet engraftment in a median time of 18 days despite a high medianblast count of 29%. On the control arm, only 18% of patients (10/57) achieved remission after salvage therapy, and then receiveda BMT with a median time to BMT of 67 days and median blast count of 20%. Of the 82% of patients failing to achieve a CR with conventionalcare (47/57), 30 patients were eligible to cross over to receive Iomab-B followed by transplant. These patients are consideredas having failed the primary endpoint of the study. All crossover patients who received the therapeutic dose of Iomab-B (30/30)received a BMT, with a median time to BMT of 24 days and they achieved engraftment in a median time of 19 days despite high medianblast count of 22% at time of crossover. It was also reported that 100-day non-relapse transplant-related mortality (100-day TRM)of the study or Iomab-B arm was only 4% (2/45) of patients that received a BMT compared to 20% of patients (2/10) who receiveda BMT after salvage therapy on the control arm. The universal engraftment rate and low 100-day TRM rate of the Iomab-B arm resultedin 43 patients potentially evaluable for the primary endpoint compared to 8 patients in the control arm, a greater than five timesdifference.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Our Iomab-ACT programis intended for targeted conditioning prior to ACT or Gene Therapy and uses the same I-131-apamistamab ARC construct as Iomab-Bat varying doses. At lower doses of one-eighth to one-sixth of the myeloablative dose, it is applicable for lymphodepletion priorto CAR-T or certain Gene Therapy applications where stem cell myeloablation is not necessary. At higher doses it is applicablefor Gene Therapy applications where stem cell myeloablation is necessary.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We believe our Iomab-ACTprogram is highly differentiated when compared to Fludarabine and Cyclophosphamide (“Flu/Cy”) or other chemotherapy-basedregimens that are used as the standard of practice today for lymphodepletion prior to CAR-T. CD45 is an antigen expressed on certainimmune cell types that are relevant to the mechanism of CAR-T therapies including lymphocytes, regulatory T-cells and macrophagesthat have been associated with clinical responses that may limit the safety, efficacy and durability of response of these CAR-Ttherapies including cytokine release syndrome (“CRS”) and neurotoxicity. Some of these limitations may be attributableto the chemotherapy-based conditioning agents that are being used prior to CAR-T therapies. Preclinical data supporting the rationalfor our Iomab-ACT program was presented at multiple medical conferences in 2019. Unlike chemotherapy, Iomab-ACT is targeted innature and, due to this CD45-directed targeting, we expect we can improve CAR-T cell expansion, potentially resulting in responsesthat are more durable, but also resulting in reduced CAR-T related toxicities. Importantly, we expect the Iomab-ACT program constructto enable lymphodepletion through a single-dose, outpatient administration versus Flu/Cy or other chemotherapy-based lymphodepletionregimens that can require multiple infusion cycles over several days. Because of this potentially superior profile, the Iomab-ACTconstruct could result in improved access to CAR-T therapy and better outcomes.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">       </p>       <!-- Field: Page; Sequence: 6; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         3         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In October 2020, weannounced a clinical collaboration with Memorial Sloan Kettering Cancer Center (“MSKCC”) to use our Iomab-ACT for targetedconditioning prior to administration of MSKCC’s 19-28z CD19 targeting CAR-T in patients with relapsed or refractory B-cellacute lymphoblastic leukemia (“ALL”) or diffuse large B-cell lymphoma (“DLBCL”). We received grant fundingfrom the National Institute of Health (“NIH”) to fund this trial with MSKCC being a co-recipient on this grant. Thisis a first of its kind study to use an ARC-based conditioning regimen with CAR-T therapy. MSKCC received clearance from the FDAto initiate this trial and patient enrollment in this study has commenced. The hypothesized rationale for this study is that Iomab-ACTwill exert an anti-tumor effect on the chemotherapy-refractory B-ALL cells that are sensitive to radiation resulting in reduceddisease burden and simultaneously deplete CD45 expressing immune cells implicated in CAR-T related toxicities, resulting in anoptimal homeostatic environment for the CAR-T cells. Results with MSKCC’s 19-28z CD-19 CAR-T in 53 patients with r/r B-ALLpublished in the New England Journal of Medicine reported complete remissions in 83% (44/53) of patients, which compares favorablyto standard chemotherapy regimens that have complete remission rates of 18% - 45% in this patient population. Median event-freesurvival (EFS) was 6.1 months and median overall survival (OS) was 12.9 months at a median follow up period of 29 months (range1 – 65 months). There was a 26% (14/53) rate of Grade 3 or greater CRS and a 42% rate of Grade 3 or 4 neurotoxicity reported.The study will evaluate the feasibility of using an ARC-based conditioning regimen with CAR-T therapy and will evaluate safetymeasures including incidence of CRS and neurotoxicity and efficacy measures including responses and survival outcomes. Proof ofconcept data from this study is expected in 2021.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        In January 2020, we announceda collaboration with University of California Davis to utilize Iomab-ACT conditioning in an ongoing Phase 1/2 trial with a novelanti-HIV autologous stem cell gene therapy for patients with HIV-related lymphoma. We believe this would be the first Gene Therapytrial to use an ARC-based conditioning regimen. I-131-Apamistamab has clinical proof of concept as a targeted conditioning regimenfor patients with high-risk, relapsed or refractory lymphoma prior to an autologous stem cell transplant from a previous study,where a favorable safety profile with no dose-limiting toxicities and minimal non-hematologic toxicities were observed and promisingefficacy with median overall survival not reached (range: 29 months to not reached) and 31% of patients in prolonged remissionat a median of 36 months follow up (range: 25 – 41 months). In this study, Iomab-ACT is intended to replace the chemotherapy-basedcondition regimen known as BEAM (BCNU/carmustine, etoposide, cytarabine, and melphalan) to simultaneously kill the patient’slymphoma cells and deplete the patient’s stem cells to make room for the transplant. Upon engraftment, the transplanted gene-modifiedautologous stem cells containing three anti-HIV genes are intended to equip the patient with a new immune system that is resistantto the HIV virus. We continue to identify additional gene therapies for which Iomab-ACT can be used for targeted conditioning withthe goal of collaborating with multiple academic or industry developers to establish Iomab-ACT as a non-chemotherapy universaltargeted conditioning solution.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        In March 2021, we announcedan Ac-225-based CD45 ARC, a next-generation targeted conditioning agent. Dosimetry results with this Ac-225-based alpha emittingARC showed selective accumulation in immune cell target organs such as bone marrow, spleen, and liver with the potential for lowerexposure to non-target tissues from longer path length beta emitter radioisotopes like Iodine-131 and Lutetium-177. Preclinicaldata demonstrated that conditioning with this Ac-225-based CD45-targeting agent result in depletion of peripheral immune cellsand hematopoietic progenitor cells, thereby enabling engraftment of donor cells. A dose dependent response was observed with lowdoses depleting white blood without effecting hematopoietic progenitor cells, representing a lymphodepletive dose that is relevantfor adoptive cell therapies such as CAR-T, while higher doses eliminated peripheral immune cells and hematopoietic progenitor cells,which is applicable to ex vivo gene therapies and BMT.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 7; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         4         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         CD33 Program: Combinations Trials and TargetedConditioning        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Our CD33 program is evaluatingthe clinical utility of Actimab-A, an ARC comprised of the anti-CD33 mAb lintuzumab linked to the potent alpha-emitting radioisotopeActinium-225 (“Ac-225”). CD33 is expressed in the majority of patients with AML and myelodysplastic syndrome (“MDS”)as well as approximately one-third of patients with multiple myeloma. Our CD33 development program is driven by data obtained fromnearly one hundred fifty treated patients, including results from a Phase 1/2 trial that was conducted in 58 patients with newlydiagnosed AML, which was completed in 2018. This clinical data, as well as our experience with Iomab-B, is shaping a two-prongedapproach with our CD33 program, where at high doses we are exploring its use for targeted conditioning and at low doses we areexploring its use for therapeutic combinations with other treatment modalities.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        We believe that radiationvia an ARC can be synergistic when used in combination with chemotherapy, targeted agents and immunotherapy based on mechanisticrationales supported by our own clinical data, preclinical research and scientific and clinical evidence in the literature. Wehave prioritized our efforts and resources in favor of combination trials for our CD33 program development strategy rather thansingle agent trials at this time. Our CD33 ARC development program encompasses the following ongoing trials:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <u>          Combination Trials         </u>         :        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px; text-align: justify; font-size: 10pt">          </td>          <td style="width: 24px; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Phase 1 investigator initiated Actimab-A + CLAG-M combination trial with the salvage chemotherapy regimen CLAG-M (cladribine, cytarabine, filgrastim and mitoxantrone) for fit patients age 18 and above with relapsed or refractory AML at the Medical College of Wisconsin (“MCW”). The combination of Actimab-A + CLAG-M is supported by mechanistic rationale for combining inhibitors of DNA replication and/or repair processes such as mitoxantrone, a topoisomerase-II inhibitor, and radiation, as imparted by tumor-targeting of Ac-225 with Actimab-A. In September 2020, we announced that we completed the third and planned final dose cohort of 0.75 µCi/kg of Actimab-A. At the 2020 American Society of Hematology Annual Meeting, it was reported that 100% of patients (3/3) receiving 0.75 µCi/kg of Actimab-A, and CLAG-M achieved a complete remission, which is nearly 85% greater than the 55% remission rate observed in a study of CLAG-M alone conducted at MCW in the same r/r AML patient population. Complete Remission (“CR”) or Complete Remission with Incomplete blood count recovery (“CRi”) were observed in all dose cohorts (0.25, 0.50 and 0.75 µCi/kg) with 67% of patients (10/15) achieving CR or CRi. The 0.25 and 0.50 µCi/kg doses of Actimab-A have been shown to be subtherapeutic as a single agent. Of the 10 patients achieving CR or Cri, 70% achieved negative minimal residual disease (“MRD) status with no detectable disease via flow cytometry, indicating that these are deep remissions. No dose-limiting toxicities (“DLTs”) were reported in the third dose cohort of 0.75 µCi/kg and therefore maximum tolerable dose (MTD) was not reached. As a result, MCW amended the study protocol to allow for continued dose escalation and the trial is now enrolling patients at a dose of 1.0 µCi/kg. Upon completion of this Phase 1 trial, we will work to develop a regulatory and development pathway that can potentially support a registration for the Actimab-A + CLAG-M combination. In addition, the Actimab-A + CLAG-M combination study has provided proof of principle that the addition of subtherapeutic doses of Actimab-A to other AML therapies can lead to well-tolerated regimens with improved responses.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            Phase 1/2 Actimab-A + Ven combination trial with the BCL-2 inhibitor Venetoclax (“ven”) for fit and unfit patients age 18 and above with relapsed or refractory AML. This multi-center trial is being led by UCLA Medical Center. In September 2020, we announced that we successfully completed enrollment of the first dose cohort and are continuing to advance to the next cohort of this dose-escalation trial. This combination is supported by mechanistic evidence in preclinical studies using ven-resistant AML tumor cell lines. In these models, we have demonstrated that Actimab-A can deplete Mcl-1 and Bcl-XL, two proteins implicated in mediating resistance to venetoclax, in addition to causing potentially lethal double-stranded DNA breaks in these CD33 expressing cells. Furthermore, in vivo studies in animal models of ven-resistant AML demonstrated robust tumor regression and improved survival in cohorts receiving the Actimab-A ven combination compared to ven alone. The rationale for this clinical study is that the addition of Actimab-A will; 1) have a direct anti-tumor effect via double-stranded DNA breaks and 2) deplete Mcl-1 and BCL-XL making the AML cells more susceptible to ven. At the 2020 ASH annual meeting, data from the first dose cohort of 0.50 µCi/kg Actimab-A in combination with ven were presented. There was a 67% overall response rate (2/3 patients), including one CR and one partial response (“PR”) with blast count reduction of 50%. All 3 patients were poor risk with adverse cytogenetics and each patient had an additional high-risk marker (FLT3-ITD+, antecedent JAK2+ myelofibrosis, or TP53 mutation). The patient achieving a CR was in second relapse and a TP53 mutation as well as multiple other high-risk markers. The trial is now active and recruiting at 4 trial sites in dose escalation cohorts. We expect to have Phase 1 safety and preliminary proof of concept clinical data from this combination study in 2021.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        In addition to these activetrials, we are working to identify additional modalities and agents that can be the basis for Actimab-A therapeutic combinations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 8; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         5         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         Targeted Conditioning        </b>        :       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Actimab-MDS is our secondclinical trial focused on targeted conditioning, in this case for patients with high-risk MDS and is our second pivotal program.Actimab-MDS is informed by prior experience with our CD33 ARC in multiple trials for patients with AML, and for patients that haveprogressed from MDS to AML, which is also known as secondary AML. Data from these trials showed that our CD33 ARC had single-agentactivity capable of producing complete remissions (CRs) in certain patients at varying dose levels with minimal non-hematologicextramedullary toxicities. However, dose-dependent myelosuppression, a class effect of CD33 directed therapies, was seen in manyof these patients. Given that myelosuppression is necessary prior to a BMT and that a BMT can rescue patients with myelosuppression,we decided to pursue a trial in targeted conditioning in high-risk MDS patients with this ARC in combination with Reduced IntensityConditioning, or RIC, regimens. RIC regimens are comprised of low doses of chemotherapies such as fludarabine, cytarabine, busulfanor melphalan. A BMT is the only curative treatment option for these patients with high-risk MDS who have poor, or very poor cytogenetics.However, these patients have poor outcomes due to high relapse rates following a BMT. Based on our interactions with FDA to date,we intend to conduct a Phase 1 dose-finding clinical trial that can be followed by a randomized trial that, depending on the resultsobserved, may potentially serve as a pivotal trial to support the submission of a BLA.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         Antibody Warhead Enabling Technology Platform        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Our proprietary AWE TechnologyPlatform is supported by intellectual property, know-how and trade secrets that cover the generation, development, methods of useand manufacture of ARCs and certain of their components. Our AWE technology patent portfolio includes 34 patent families comprisedof over 140 issued and pending patent applications, of which 10 are issued and 29 are pending in the United States, and 104 areissued or pending internationally. The effective life of the patents in our portfolio range from expirations between 2021 and 2040.Our technology enables the direct labeling, or conjugation and labeling, of a biomolecular targeting agent to a radionuclide warheadand its development and use as a therapeutic regimen for the treatment of diseases such as cancer. Our AWE intellectual propertycovers various methods of use for ARCs in multiple diseases, including indication, dose and scheduling, radionuclide warhead, andtherapeutic combinations. We have particular expertise in the area of ARCs utilizing the alpha emitting isotope Ac-225 includingclinical experience in treating approximately 150 patients with our alpha-emitter ARCs, “gold standard” linker technologyand 5 issued patents in the United States and 49 patents internationally related to the manufacturing or Ac-225 in a cyclotron,which we believe has the potential to produce higher quantities of Ac-225 then currently utilized methods.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        In the third quarter of2020 we enhanced our research and development capabilities around AWE by securing research facilities that were staffed and becameoperational in the fourth quarter. Our research laboratories are focused on applying our AWE technology platform to the developmentof radiation conjugates and to execute on research collaborations. Our R&amp;D efforts employ a multidisciplinary approach leveragingour team’s knowledge and experience in cancer cell biology, radiochemistry, radiation sciences, immunology and oncology drugdevelopment. We intend to focus on generating ARCs using our existing intellectual property, evaluating assets for in-licensingto complement our existing clinical pipeline and securing collaborations and partnerships with biopharmaceutical companies. Byadding research and development capabilities to our clinical development and clinical supply chain capabilities, we seek to enablethe rapid translation of radiotherapies. We have formed a wholly owned research subsidiary for the purposes of advancing certainof our R&amp;D objectives.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        In January 2021, we announceda collaborative research agreement with Astellas that will utilize our AWE technology platform will be utilized with select targetingagents owned by Astellas in the development of theranostics for solid tumor indications, which combine the ability of radioisotopesto be used for both diagnostic and therapeutic purposes.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 9; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         6         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         Intellectual Property Portfolio and Regulatory Protections        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          Intellectual Property         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        We have developed or in-licensednumerous patents and patent applications and possess substantial know-how and trade secrets related to the development and manufactureof our products. As of March 2021, our patent portfolio includes 34 patent families comprised of 143 issued and pending patentapplications, of which 10 are issued and 29 are pending in the United States, and 104 are issued and pending internationally. Severalnon-provisional patent applications are expected to be filed in 2021 based on provisional patent applications filed in 2020. Morethan 90% of our patents are Actinium-owned and the remainder are in-licensed from third parties. These patents cover key areasof our business, including use of actinium-225 and other alpha- or beta-emitting isotopes attached to cancer specific carrierslike monoclonal antibodies, methods for manufacturing key components of our product candidates including actinium-225, an alphaparticle emitting radioisotope and carrier antibodies, or Iodine-131, a beta particle emitting radioisotope, and methods for manufacturingfinished product candidates for use in cancer treatment.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        We own five issued patentsin the United States and 49 patents outside of the United States        <strike>         ,        </strike>        related to the manufacturing of actinium-225in a cyclotron, that will expire between 2024 through 2027. Three related global patents are pending. We own or have licensed therights to five issued patents in the United States and 11 issued patents outside of the United States related to the generation,formulation, or use of radioimmunoconjugates, including patents related to our Iomab-B and Actimab-A programs, that will expirebetween 2021 and 2037. Thirteen related United States or global patents are pending. Further, we own the rights to 57 additionalpending patents in the United States and abroad related to radioimmunoconjugate composition, formulation administration, and methodsof use in solid or liquid cancers. This matter includes composition, administration, and methods of treatment for our productsActimab-A and Iomab-B. In addition, for Iomab-ACT, we own 11 patents pending covering methods of use and composition in cancerand non-malignant disease.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          Regulatory Protections         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        The indications for whichwe are developing our product candidates for are orphan drug designations, which are disease indications that affect fewer than200,000 patients in the United States and less than 5 in 10,000 patients in the EU. We have received orphan drug designation forIomab-B and our lintuzumab-CD33 ARC for patients with AML in both the United States and the EU. As a result, if our products areto be approved, they may receive 7 years and 10 years of market exclusivity in the United States and EU, respectively. In addition,our product candidates are biologics combined with radioisotopes. The Hatch-Waxman Act requires that a manufacturer of genericdrugs, for which a biologic drug is called a biosimilar, demonstrate bioequivalence to the innovator. We believe that the natureof radioisotopes having half-lives combined with the complexities of biologic drugs would make it difficult for a manufacturerto demonstrate bioequivalence to our product candidates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         Competition Overview        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        In the field of targetedconditioning, pharmaceuticals currently used for myeloablation prior to a bone marrow transplant or lymphodepletion prior to CAR-Tare largely generic chemotherapeutic agents and/or radiation. In targeted conditioning, we face competition from Magenta Therapeutics,Inc., who is developing anti-CD45 and anti-CD117 (cKIT) Antibody Drug Conjugates (ADCs) that are in the preclinical stage of developmentand Jasper Therapeutics, Inc, who is developing an anti-CD117 monoclonal antibody that is being studied in a Phase 1 clinical trial.Forty Seven, Inc.(acquired by Gilead), who is developing a conditioning regimen comprised of the anti-CD47 monoclonal antibodyMagrloimab that is being studied in a Phase 2 clinical trial as a therapeutic with an anti-CD117 monoclonal antibody, which isin preclinical development, in collaboration with bluebird bio, Inc., Molecular Templates, who is developing conditioning regimensusing its Engineered Toxin Bodies (ETBs) with two targets that have not been disclosed in collaboration with Vertex. Allogene Therapeutics,who is developing an anti-CD52 monoclonal antibody for use as a lymphodepletion agent in conjunction with CAR-T therapies. To ourknowledge, we are the only company with a pivotal Phase 3 trial for a targeting conditioning agent and the only anti-CD45 ARC inclinical development.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 10; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         7         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        For our CD33 ARC, thereare several companies developing drugs for AML, MDS and Multiple Myeloma based on numerous approaches/modalities, including chemotherapy,targeted agents, antibody drug conjugates, naked monoclonal antibodies, bispecific antibodies, immunotherapies and cellular therapies.Specific to CD33, Mylotarg™, an ADC developed and marketed by Pfizer is the only FDA approved CD33 targeted therapy for adultpatients and children two years and older with relapsed or refractory CD33-positive AML. Seattle Genetics was developing SGN-CD33A,a CD33 targeting ADC, but discontinued the development of its clinical trials associated with this product candidate in June 2017.Amgen is developing a CD3/CD33 bispecific BiTE (AMG330) as is Amphivena (AMV-564), both of which are in Phase 1 clinical trialsfor r/r AML patients age 18 and above. Boehringer Ingelheim developed a CD33 targeting naked antibody (BI836858) that was studiedin patients with r/r AML and MDS with the trial in patients with MDS being terminated and development has been discontinued. Thesedrugs have different safety profiles and mechanisms of action compared to our drug candidates. AML in older patients remains anarea of high medical need that could accommodate many new products with favorable safety and efficiency profiles. We have begunstudying our CD33 ARC in combination with the salvage chemotherapy regimen CLAG-M in fit patients with relapsed or refractory AMLas well as in combination with the Bcl-2 inhibitor venetoclax in fit and unfit patients with relapsed or refractory AML. Combinationtherapies are commonly used in hematologic indications, but we believe we are the only Ac-225 based product candidate that is beingexplored in combination studies in hematologic indications. To our knowledge, we are the only company with a CD33 targeting drugand the only AC-225 based ARC product candidate for patients with multiple myeloma.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         Government Regulation        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Governmental authoritiesin the United States and other countries extensively regulate, among other things, the research, development, testing, manufacture,labeling, promotion, advertising, distribution and marketing of radioimmunotherapy pharmaceutical products such as those beingdeveloped by us. In the United States, the FDA regulates such products under the Federal Food, Drug and Cosmetic Act (“FDCA”)and implements regulations. Failure to comply with applicable FDA requirements, both before and after approval, may subject usto administrative and judicial sanctions, such as a delay in approving or refusal by the FDA to approve pending applications, warningletters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions and/or criminalprosecution.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          U.S. Food and Drug Administration Regulation         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Our research, developmentand clinical programs, as well as our manufacturing and marketing operations, are subject to extensive regulation in the UnitedStates and other countries. Most notably, products that may in the future be sold in the United States are subject to regulationby the FDA. Certain of our product candidates in the United States will require FDA approval of a BLA prior to marketing. Foreigncountries may require similar or more onerous approvals to manufacture or market these products.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <i>         FDA Approval Process for Biologics LicenseApplications        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Prior to testing a biologicalproduct on humans, the product must clear the preclinical testing stage. The goal of preclinical testing is to perform laboratoryevaluations of the product’s chemistry and formulation as well as evaluate the product’s potential for adverse eventsby performing in vitro and animal studies. This information is packaged together and submitted to the FDA as part of an investigationalnew drug (“IND”) application, which must be approved by the FDA before administering the product to human subjectsin clinical trials.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        From there, the productmoves to the clinical stage, where it is administered to healthy volunteers or patients. The data gathered from the preclinicaltesting and clinical trials is used to support the BLA submission. The FDA must approve the BLA prior to commercial marketing ofa biological product. The BLA must include information about product development, laboratory and animal studies, human trials,manufacturing information, the composition of the product, and proposed labeling. The approval process requires significant timeand financial resources and does not guarantee that FDA will accept the BLA filing or ultimately approve the BLA.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 11; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         8         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        The Prescription Drug UserFee Act, as amended (“PDUFA”), requires each BLA to be accompanied by a substantial user fee. The amount of the userfee changes on an annual basis. In addition to the BLA user fee, PDUFA also imposes an annual program fee for biological products.The FDA will waive or reduce the fee under limited circumstances, such as for first applications filed by small businesses.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Within 60 days followingsubmission of the BLA, the FDA reviews the BLA submission for completion to determine if it will accept it for filing. The FDAmay refuse to file the BLA if it deems the submission incomplete or not properly reviewable at the time of submission. For theBLA review process to proceed, the BLA must be resubmitted with the necessary additional information. After the BLA is acceptedfor filing, the FDA commences its substantive review of the BLA. The FDA reviews the BLA to determine, among other things, whetherthe proposed product is safe, potent, and/or effective for its intended use, has an acceptable purity profile, and whether theproduct’s manufacturing is consistent with current Good Manufacturing Processes (“cGMPs”) to ensure that theproduct meets the appropriate standards for identity, safety, strength, quality, potency and purity.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        The FDA may involve anadvisory committee for novel biological products that present complex questions of safety or efficacy. The advisory committee typicallyconsists of a panel that includes clinicians and other subject matter experts that assist with the reviewing and evaluating theproduct. While the advisory committee provides a recommendation for whether the product should be approved and under what conditions,the FDA is not bound to follow the recommendations. However, the advisory committee’s recommendations are usually given significantconsideration.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        The FDA may also considerrequiring a risk evaluation and mitigation strategy (“REMS”) if it determines that one is necessary to ensure thatthe biological product is used safely. If the FDA requires a REMS, the BLA sponsor must develop and submit a proposed REMS forthe BLA review process to move forward.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        The manufacturer of thebiological product is also subject to FDA inspection prior to the approval of the BLA. The purpose of the inspection is to determinewhether the manufacturer adequately complies with the applicable cGMP requirements to ensure that the biological product is manufacturedsafely and within the required specifications. Additionally, the FDA may choose to inspect one or more clinical sites to assesscompliance with IND trial requirements and good clinical practices (“GCPs”). Compliance with cGMP and GCP requirementsinvolves significant expenditures of time, money, and effort for BLA sponsors due to associated training, recordkeeping, production,and quality control needs.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        If the FDA decides notto approve the BLA in the form submitted, it will issue what is called a complete response letter that outlines the specific deficienciesit would like to see addressed. The deficiencies identified can be minor (e.g., labeling changes) or major (e.g., the need foradditional clinical trials). The complete response letter may also include recommended actions the applicant may take to move closertowards securing an approval. At this point, applicants may choose to resubmit the BLA to address FDA’s concerns or withdrawthe application.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        In addition, under thePediatric Research Equity Act, a BLA or supplement to a BLA must contain data to assess the safety and effectiveness of the productfor the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatricsubpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of data or full or partialwaivers.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <i>         Post-Approval Requirements        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        If the BLA is approved,the FDA may include additional conditions as part of its approval, such as limiting the approval by designating specific diseasesfor which the product may be used. Additionally, conditions may include requiring the labeling to include specific contraindications,warnings, or precautions, requiring post marketing clinical trials (sometimes referred to as Phase 4 clinical trials), and implementationof surveillance program to monitor the approved product once commercialized.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Products approved by theFDA under a BLA are subject to ongoing regulatory requirements, including, among other things, record-keeping requirements, adverseevent reporting requirements, responsibility for reporting updated safety and efficacy information to FDA, sampling and distributionrequirements, complying with advertising and promotion requirements, and complying with cGMPs.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 12; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         9         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Quality control and manufacturingprocedures must continue to comply with cGMP requirements even after the BLA is approved. The cGMP regulations include, but arenot limited to, requirements to ensure quality control, maintain appropriate manufacturing records and documentation, and the obligationto investigate and address deviations from cGMPs, when identified. Manufacturers are also required to register their establishmentswith the FDA and certain state agencies. The establishments are also subject to unannounced inspections by regulators.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        The advertising and promotionof drug and biologic products are also subject to specific laws and regulations. These authorities provide standards for direct-to-consumeradvertising, restrictions on promoting products for uses or to patient populations that are not described in the product’sapproved uses, known as “off-label” use, limitations on industry-sponsored scientific and educational activities, andrequirements for promotional activities involving the internet.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <i>         Regulatory Enforcement        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Failure to comply withapplicable regulatory requirements can result in enforcement action by the FDA, the Nuclear Regulatory Commission or other regulatoryauthorities, which may result in sanctions, including but not limited to, untitled letters, warning letters, fines, injunctions,consent decrees and civil penalties; customer notifications or repair, replacement, refunds, recall, detention or seizure of ourproducts; operating restrictions or partial suspension or total shutdown of production; refusing or delaying our requests for BLApremarket approval of new products or modified products; withdrawing BLA approvals that have already been granted; and refusalto grant export.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          Additional Healthcare Laws         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        In addition to FDA regulations,several other types of state and federal laws may restrict our business activities, including certain healthcare laws. These lawsinclude, without limitation, anti-kickback laws, false claims laws, data privacy and security laws, as well as transparency lawsregarding payments or other items of value provided to healthcare providers.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        The federal Anti-KickbackStatute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induceor in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item, good, facilityor service reimbursable under Medicare, Medicaid or other federal healthcare programs. The term “remuneration” hasbeen broadly interpreted to include anything of value. This statute has been interpreted to apply to arrangements between pharmaceuticalmanufacturers on the one hand and prescribers, purchasers and formulary managers on the other hand. Although there are a numberof statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution or other regulatory sanctions,the exceptions and safe harbors are drawn narrowly and arrangements must meet every element to qualify for an exception or safeharbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does notmake the conduct        <i>         per se        </i>        illegal under the federal Anti-Kickback Statute. Instead, the arrangement will be evaluated on acase-by-case basis based on the facts and circumstances involved. Courts have interpreted the statute’s intent requirementto mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare program business,the federal Anti-Kickback Statute has been violated. Additionally, the intent standard under the federal Anti-Kickback Statutewas amended by the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education ReconciliationAct of 2010, collectively the “Affordable Care Act,” to a stricter standard such that a person or entity no longerneeds to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition,the Affordable Care Act codified case law that a violation of the federal Anti-Kickback Statute constitutes a false or fraudulentclaim for purposes of the federal False Claims Act.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Federal false claims laws,including the federal False Claims Act, and civil monetary penalties laws, prohibit any person or entity from, among other things,knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, orcausing to be made, a false statement to have a false claim paid. Whistleblower or qui tam provisions under the False Claims Actpermit whistleblowers to sue in the name of the federal government for False Claims Act violations, and to share in the recoveryfrom any award. Pharmaceutical and other healthcare companies have been prosecuted under these laws for, among other things, allegedlyinflating drug prices they report to pricing services, which in turn were used by the government to set Medicare and Medicaid reimbursementrates, and for allegedly providing free product to customers with the expectation that the customers would bill federal programsfor the product. In addition, certain marketing practices, including off-label promotion, may also violate false claims laws.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 13; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         10         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        The federal Health InsurancePortability and Accountability Act of 1996, or HIPAA, created additional federal civil and criminal statutes that prohibit amongother actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program,including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfullyobstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering upa material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or paymentfor healthcare benefits, items or services. Like the federal Anti-Kickback Statute, the Affordable Care Act amended the intentstandard for certain healthcare fraud under HIPAA such that a person or entity no longer needs to have actual knowledge of thestatute or specific intent to violate it in order to have committed a violation.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        In addition, if we engagein certain activities, we may be subject to data privacy and security regulation under HIPAA, as amended by the Health InformationTechnology for Economic and Clinical Health Act, or HITECH. HIPAA imposes certain requirements on covered entities, which includecertain healthcare providers, health plans and healthcare clearinghouses, and their business associates and covered subcontractorsthat receive or obtain protected health information in connection with providing a service on behalf of a covered entity that involvesthe use or disclosure of individually identifiable health information.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Additionally, the federalPhysician Payments Sunshine Act, created under the Affordable Care Act, and its implementing regulations, require certain manufacturersof drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children’sHealth Insurance Program (with certain exceptions) to report annually information related to certain payments or other transfersof value provided to physicians and any ownership and investment interests held by physicians or their immediate family members.Beginning in 2022, applicable manufacturers also will be required to report such information regarding payments and other transfersof value to physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registerednurse anesthetists and certified nurse midwives during the previous year.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        The majority of statesalso have statutes or regulations similar to the aforementioned federal healthcare laws, including fraud and abuse laws, some ofwhich are broader in scope and apply to items and services reimbursed under Medicaid and other state programs, or, in some states,apply regardless of the payor. Many states also have some form of health information privacy or data security laws that could apply.Further, some state laws require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary complianceguidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturersto report information related to payments or other transfers of value provided to physicians and other healthcare providers andentities, marketing expenditures, or drug pricing. Certain state and local laws also require the registration of pharmaceuticalsales representatives.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        If our operations are foundto be in violation of any of the healthcare regulatory laws described above or any other laws that apply to us, we may be subjectto potentially significant criminal, civil and administrative penalties, damages, fines, disgorgement, imprisonment, additionalreporting obligations and oversight (if we become subject to a corporate integrity agreement or other agreement to resolve allegationsof non-compliance with these laws), exclusion from participation in government healthcare programs, as well as contractual damages,reputational harm, administrative burdens, diminished profits and future earnings, and the curtailment or restructuring of ouroperations, any of which could adversely affect our ability to operate our business and our results of operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         Employees        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">        As of March 31, 2021, we have 32 full-time employeesincluding 13 with M.D., Ph.D. or other advanced degrees.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        We believe that our futuresuccess largely depends upon our continued ability to attract and retain highly skilled employees. We provide our employees withcompetitive salaries and bonuses, opportunity for equity ownership, development programs that enable continued learning and growth,and a robust employment package that promotes wellness across all aspects of their lives, including healthcare, retirement planning,and paid time off. None of these employees are covered by a collective bargaining agreement, and we believe our relationship withour employees is good. We also engage consultants on an as-needed basis to supplement existing staff.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 14; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         11         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <a name="aph165213a003">         </a>         ITEM 1A. RISK FACTORS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        <i>         In analyzing our company,you should consider carefully the following risk factors, together with all of the other information included in this Annual Reporton Form 10-K. Factors that could cause or contribute to differences in our actual results include those discussed in the followingsubsection, as well as those discussed above in “Management’s Discussion and Analysis of Financial Condition and Resultsof Operations” and elsewhere throughout this Annual Report on Form 10-K. Each of the following risk factors, eitheralone or taken together, could adversely affect our business, operating results and financial condition, as well as adversely affectthe value of an investment in our company. The risks and uncertainties described below are not the only ones we face. Additionalrisks not currently known to us or other factors not perceived by us to present significant risks to our business at this timealso may impair our business operations.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         Summary of Risk Factors        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        We are providing the following summary of the risk factors containedin this Annual Report on Form 10-K to enhance the readability and accessibility of our risk factor disclosures. We encourage youto carefully review the full risk factors contained in this Annual Report on Form 10-K in their entirety for additional informationregarding the material factors that make an investment in our securities speculative or risky. These risks and uncertainties include,but are not limited to, the following:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           ●          </td>          <td style="text-align: justify">           We                                         are a clinical-stage company and have generated no revenue from commercial sales to date;          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           ●          </td>          <td style="text-align: justify">           We                                         have incurred net losses in every year since our inception and anticipate that we will                                         continue to incur net losses in the future;          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           ●          </td>          <td style="text-align: justify">           If                                         we fail to obtain additional financing, we will be unable to continue or complete our                                         product development and you will likely lose your entire investment;          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           ●          </td>          <td style="text-align: justify">           We                                         are highly dependent on the success of Iomab-B and the SIERRA trial and we many not able                                         to complete the necessary clinical development or our development efforts may not result                                         in the data necessary to receive regulatory approval;          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           ●          </td>          <td style="text-align: justify">           Our                                         business could be adversely affected by the effects of health epidemics, including the                                         global COVID-19 pandemic;          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           ●          </td>          <td style="text-align: justify">           We                                         have not demonstrated that any of our products are safe and effective for any indication                                         and will continue to expend substantial time and resources on clinical development before                                         any of our current or future product candidates will be eligible for FDA approval, if                                         ever;          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           ●          </td>          <td style="text-align: justify">           Our                                         clinical trials may fail to demonstrate adequately the efficacy and safety of our product                                         candidates, which would prevent or delay regulatory approval and commercialization;          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           ●          </td>          <td style="text-align: justify">           Healthcare                                         legislative reform measures intended to increase pressure to reduce prices of pharmaceutical                                         products paid for by Medicare or, otherwise, affect the federal regulation of the U.S.                                         healthcare system could have a material adverse effect our business, future revenue,                                         if any, and results of operations;          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           ●          </td>          <td style="text-align: justify">           We                                         rely on third parties to conduct our clinical trials. If these third parties do not successfully                                         carry out their contractual duties or meet expected deadlines or comply with regulatory                                         requirements, we may not be able to obtain regulatory approval for or commercialize our                                         product candidates;          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           ●          </td>          <td style="text-align: justify">           We                                         currently depend on a single third-party manufacturer to produce our pre-clinical and                                         clinical trial drug supplies. Any disruption in the operations of our current third-party                                         manufacturer, or other third-party manufacturers we may engage in the future, could adversely                                         affect our business and results of operations;          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           ●          </td>          <td style="text-align: justify">           Our                                         product candidates may cause undesirable side effects or have other properties that could                                         halt their clinical development, prevent their regulatory approval, limit their commercial                                         potential, or result in significant negative consequences;          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           ●          </td>          <td style="text-align: justify">           Our                                         patent position is highly uncertain and involves complex legal and factual questions.          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           ●          </td>          <td style="text-align: justify">           The                                         use of hazardous materials, including radioactive and biological materials, in our research                                         and development efforts imposes certain compliance costs on us and may subject us to                                         liability for claims arising from the use or misuse of these materials;          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           ●          </td>          <td style="text-align: justify">           We                                         are highly dependent on our key personnel, and if we are not successful in attracting                                         and retaining highly qualified personnel, we may not be able to successfully implement                                         our business strategy;          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           ●          </td>          <td style="text-align: justify">           Certain                                         provisions of our Certificate of Incorporation and Bylaws and Delaware law make it more                                         difficult for a third party to acquire us and make a takeover more difficult to complete,                                         even if such a transaction were in our stockholders’ interest; and          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           ●          </td>          <td style="text-align: justify">           Our                                         ability to utilize our net operating loss carryforwards and certain other tax attributes                                         may be limited.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 15; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         12         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         Risks Related to Our Business        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          We are a clinical-stage company and have generated no revenuefrom commercial sales to date.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        We are a clinical-stagebiopharmaceutical company with a limited operating history. We have no products approved for commercial sale and have not generatedany revenue from product sales to date. We will encounter risks and difficulties frequently experienced by early-stage companiesin rapidly evolving fields. If we do not address these risks successfully, our business will suffer.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          We have incurred net losses in every year since our inceptionand anticipate that we will continue to incur net losses in the future.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        We are not profitable andhave incurred losses in each period since our inception. As of December 31, 2020 and December 31, 2019, we had an accumulated deficitof $231.0 million and $208.8 million, respectively. We reported a net loss of $22.2 million and $21.9 million for the years endedDecember 31, 2020 and 2019, respectively. We expect to continue to operate at a net loss as we continue our research and developmentefforts, continue to conduct clinical trials and develop manufacturing, sales, marketing and distribution capabilities. There canbe no assurance that the products under development by us will be approved for sale in the United States or elsewhere. Furthermore,there can be no assurance that if such products are approved, they will be successfully commercialized, which would have an adverseeffect on our business prospects, financial condition and results of operation.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          If we fail to obtain additional financing,we will be unable to continue or complete our product development and you will likely lose your entire investment.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        On April 24, 2020, we issuedand sold 4.3 million shares of common stock and pre-funded warrants to purchase 2.8 million shares of common stock. Gross proceedsfrom this offering to us were $31.6 million, before deducting underwriting discounts and commissions and other offering expensespayable by us. On June 19, 2020, we issued and sold 1.9 million shares of common stock and 0.7 million pre-funded warrants to purchaseshares of common stock. Gross proceeds from this offering to us were $25.0 million, before deducting underwriting discounts andcommissions and other offering expenses payable us. In August 2020, we entered into the Capital on Demand™ Sales Agreementwith JonesTrading, pursuant to which we may sell, from time to time, through or to JonesTrading Institutional Services LLC (“JonesTrading”),up to an aggregate of $200 million of our common stock. Shares of common stock are offered pursuant to our shelf registration statementfiled with the United States Securities and Exchange Commission (“SEC”) on August 7, 2020. As of December 31, 2020,we sold 2.1 million shares of common stock, resulting in gross proceeds of $22.6 million and net proceeds of $21.7 million. Asof the date of filing this report, we expect that our existing resources will be more than sufficient to fund our planned operationsfor more than 12 months following the date of this report.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 16; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         13         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Our business or operationsmay change in a manner that would consume available funds more rapidly than anticipated and substantial additional funding maybe required to maintain operations, fund expansion, develop new or enhanced products, acquire complementary products, businessor technologies or otherwise respond to competitive pressures and opportunities, such as a change in the regulatory environmentor a change in preferred cancer treatment modalities. However, we may not be able to secure funding when we need it or on favorableterms or indeed on any terms. In addition, from time to time, we may not be able to secure enough capital in a timely enough mannerwhich may cause the generation of a going-concern opinion from our auditors which can and may impair our stock market valuationand also our ability to finance on favorable terms or indeed on any terms.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        To raise additional capital,we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable for our commonstock. We cannot assure you that we will be able to sell shares or other securities in any other offering at a price per sharethat is equal to or greater than the price per share paid by investors, and investors purchasing shares or other securities inthe future could have rights superior to existing stockholders.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        If we cannot raise adequatefunds to satisfy our capital requirements, we will have to delay, scale back or eliminate our research and development activities,clinical studies or future operations. We may also be required to obtain funds through arrangements with collaborators, which arrangementsmay require us to relinquish rights to certain technologies or products that we otherwise would not consider relinquishing, includingrights to future product candidates or certain major geographic markets. We may further have to license our technology to others.This could result in sharing revenues which we might otherwise have retained for ourselves. Any of these actions may harm our business,financial condition and results of operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        The amount of funding wewill need depends on many factors, including the progress, timing and scope of our product development programs; the progress,timing and scope of our preclinical studies and clinical trials; the time and cost necessary to obtain regulatory approvals; thetime and cost necessary to further develop manufacturing processes and arrange for contract manufacturing; our ability to enterinto and maintain collaborative, licensing and other commercial relationships; and our partners’ commitment of time and resourcesto the development and commercialization of our products.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          We have limited access to the capitalmarkets and even if we can raise additional funding, we may be required to do so on terms that are dilutive to you.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        We have limited accessto the capital markets to raise funds. The capital markets have been unpredictable in the recent past for radioisotope and otheroncology companies and unprofitable companies such as ours. In addition, it is generally difficult for development-stage companiesto raise capital under current market conditions. The amount of capital that a company such as ours is able to raise often dependson variables that are beyond our control. As a result, we may not be able to secure financing on terms attractive to us, or atall. If we are able to consummate a financing arrangement, the amount raised may not be sufficient to meet our future needs. Ifadequate funds are not available on acceptable terms, or at all, our business, including our technology licenses, results of operations,financial condition and our continued viability will be materially adversely affected.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 17; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         14         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          We are highly dependent on the successof Iomab-B and the SIERRA trial and we may not able to complete the necessary clinical development or our development efforts maynot result in the data necessary to receive regulatory approval.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Iomab-B, which we licensedfrom the Fred Hutchinson Cancer Research Center (“FHCRC”) in June 2012 is our lead program to which we allocate a significantportion of our resources. We are currently enrolling patients in the pivotal Phase 3 SIERRA trial (Study of Iomab-B in ElderlyRelapsed or Refractory AML), a 150-patient multi-center randomized trial that will compare outcomes of patients who receive Iomab-Band a BMT to those patients receiving physician’s choice of salvage chemotherapy, defined as conventional care, as no standardof care exists for this patient population. The SIERRA trial may be unsuccessful and fail to demonstrate a safety and efficacyprofile that is necessary to receive favorable regulatory approval. The trials DMC may recommend that the trial be stopped earlyfor safety or efficacy concerns, which could prevent us from completing the SIERRA trial. Even if Iomab-B receives favorable regulatoryapproval, we may not be successful in securing adequate reimbursement or establishing successful commercial operations. Any orall of these factors could have a material adverse impact on our business and ability to continue operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          We may be unable to establish sales,marketing and commercial supply capabilities.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        We do not currently have,nor have we ever had, commercial sales and marketing capabilities. If any of our product candidates become approved, we would haveto build and establish these capabilities in order to commercialize our approved product candidates. The process of establishingcommercial capabilities will be expensive and time consuming. Even if we are successful in building sales and marketing capabilities,we may not be successful in commercializing any of our product candidates. Any delays in commercialization or failure to successfullycommercialize any product candidate may have material adverse impacts on our business and ability to continue operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          Our business could be adversely affected by the effects ofhealth epidemics, including the global COVID-19 pandemic.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        In December 2019, a novelstrain of coronavirus was reported in China. Since then, COVID-19 has spread globally. The spread of COVID-19 from China to othercountries resulted in the World Health Organization (WHO) declaring the outbreak of COVID-19 as a “pandemic,” or aworldwide spread of a new disease, on March 11, 2020. Many countries around the world have imposed quarantines and restrictionson travel and mass gatherings to slow the spread of the virus and have closed non-essential businesses, and many domestic jurisdictionscontinue to have such restrictions in place.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        As many domestic jurisdictionscontinue to maintain such restrictions in place, our ability to continue to operate our business may also be limited. These restrictionsmay result in a period of business, supply and drug product manufacturing disruption, and in reduced operations, any of which couldmaterially affect our business, financial condition and results of operations. In response to COVID-19, we implemented remote workingand thus far have not experienced a significant disruption or delay in our operations as it relates to the clinical developmentof our drug candidates. Such government-imposed precautionary measures may have been relaxed in certain countries or states, butthere is no assurance that more strict measures will be put in place again due to a resurgence in COVID-19 cases, including thoseinvolving new variants of the coronavirus, which may be more contagious and deadly than prior strains. Therefore, the COVID-19pandemic may continue to affect our operation, may further divert the attention and efforts of the medical community to copingwith COVID-19 and disrupt the marketplace in which we operate and may have a material adverse effect on our operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        The spread of COVID-19,which has caused a broad impact globally, may materially affect us economically. While the ultimate economic impact brought by,and the duration of, the COVID-19 pandemic may be difficult to assess or predict, including new information which may emerge concerningthe severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among others, the pandemic has resulted in significantdisruptions in the general commercial activity and the global economy and caused financial market volatility and uncertainty insignificant and unforeseen ways in the recent months. A continuation or worsening of the levels of market disruption and volatilityseen in the recent past could have an adverse effect on our ability to access capital, which could in the future negatively affectour liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect ourbusiness and the value of our common stock.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 18; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         15         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Currently, the Phase 3SIERRA trial for our lead program, Iomab-B, continues to remain active at a majority of our clinical trial sites, with investigatorsproviding feedback that recruitment and enrollment will remain active because of the acute nature of the disease, the high unmetneeds of patients with relapsed or refractory AML, the potentially curative nature of BMT and the differentiated profile of Iomab-B.Certain sites that had not been actively enrolling due to COVID-19 at the initial outbreak of the pandemic resumed recruitmentand enrollment in mid-2020, and we currently do not have any sites that are not recruiting and enrolling due to COVID-19. We alsobelieve our earlier stage clinical trials for our CD33 program will also continue to recruit and enroll patients given the acutenature of relapsed or refractory AML. The continuation of the pandemic globally could adversely affect our planned clinical trialoperations, including our ability to conduct the trials on the expected timelines and recruit and retain patients and principalinvestigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 if their geography is impactedby the pandemic. Further, the continuation and/or resurgence of the COVID-19 pandemic could result in delays in our clinical trialsdue to prioritization of hospital resources toward the pandemic, restrictions in travel, potential unwillingness of patients toenroll in trials at this time, or the inability of patients to comply with clinical trial protocols if quarantines or travel restrictionsimpede patient movement or interrupt healthcare services. In addition, we rely on independent clinical investigators, contractresearch organizations and other third-party service providers to assist us in managing, monitoring and otherwise carrying outour preclinical studies and clinical trials, and the pandemic may affect their ability to devote sufficient time and resourcesto our programs or to travel to sites to perform work for us.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Additionally, COVID-19may result in delays in receiving approvals from domestic and foreign regulatory authorities, delays in necessary interactionswith Institutional Review Boards (“IRBs”), domestic and foreign regulators, ethics committees and other important agenciesand contractors due to limitations in employee resources or forced furlough of government employees.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        COVID-19 has caused severedisruptions in transportation and limited access to our facility, resulting in limited support from our staff and professionaladvisors.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        We continue to monitorthe impacts of COVID-19 on the global economy and on our business operations. However, the ultimate impact from COVID-19 on ourbusiness operations and financial results during 2021 will depend on, among other things, the ultimate severity and scope of thepandemic, the pace at which governmental and private travel restrictions and public concerns about public gatherings will ease,the rate at which historically large increases in unemployment rates will decrease, if at all, and whether, and the speed withwhich the economy recovers. We are not able to fully quantify the impact that these factors will have on our financial resultsduring 2021 and beyond, but developments related to COVID-19 may materially affect us in 2021.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          Our business is subject to cybersecurity risks.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Our operations are increasinglydependent on information technologies and services. Threats to information technology systems associated with cybersecurity risksand cyber incidents or attacks continue to grow, and include, among other things, storms and natural disasters, terrorist attacks,utility outages, theft, viruses, phishing, malware, design defects, human error, and complications encountered as existing systemsare maintained, repaired, replaced, or upgraded. Risks associated with these threats include, among other things:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            theft or misappropriation of funds;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            loss, corruption, or misappropriation of intellectual property, or other proprietary, confidential or personally identifiable information (including supplier, clinical data or employee data);           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            disruption or impairment of our and our business operations and safety procedures;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            damage to our reputation with our potential partners, patients and the market;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            exposure to litigation;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            increased costs to prevent, respond to or mitigate cybersecurity events.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 19; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         16         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Although we utilize variousprocedures and controls to mitigate our exposure to such risk, cybersecurity attacks and other cyber events are evolving and unpredictable.Moreover, we have no control over the information technology systems of third parties conducting our clinical trials, our suppliers,and others with which our systems may connect and communicate. As a result, the occurrence of a cyber incident could go unnoticedfor a period time.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        We recently secured cybersecurityinsurance coverage to protect against cybersecurity risks. However, we cannot ensure that it will be sufficient to cover any particularlosses we may experience as a result of such cyberattacks. Any cyber incident could have a material adverse effect on our business,financial condition and results of operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         Risks Related to Regulation        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          The FDA or comparable foreign regulatoryauthorities may disagree with our regulatory plans and we may fail to obtain regulatory approval of our product candidates.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Our products are subjectto rigorous regulation by the FDA and numerous other federal, state and foreign governmental authorities. The process of seekingregulatory approval to market an antibody radiation-conjugate product is expensive and time-consuming, and, notwithstanding theeffort and expense incurred, approval is never guaranteed. If we are not successful in obtaining timely approval of our productsfrom the FDA, we may never be able to generate significant revenue and may be forced to cease operations. In particular, the FDApermits commercial distribution of a new antibody radiation-conjugate product only after a BLA for the product has received FDAapproval. The BLA process is costly, lengthy and inherently uncertain. Any BLA filed by us will have to be supported by extensivedata, including, but not limited to, technical, preclinical, clinical trial, chemistry, manufacturing and controls (“CMC”)and labeling data, to demonstrate to the FDA’s satisfaction the safety and efficacy of the product for its intended use.The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtainregulatory approval to market our product candidates, which would significantly harm our business, results of operations and prospects.In addition, even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer ormore limited indications than we request, may not approve the price we intend to charge for our products, may grant approval contingenton the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not includethe labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoingscenarios could materially harm the commercial prospects for our product candidates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        The approval process inthe United States and in other countries could result in unexpected and significant costs for us and consume management’stime and other resources. The FDA and other foreign regulatory agencies could ask us to supplement our submissions, collect non-clinicaldata, conduct additional clinical trials or engage in other time-consuming actions, or it could simply deny our applications. Inaddition, even if we obtain approval to market our products in the United States or in other countries, the approval could be revoked,or other restrictions imposed if post-market data demonstrates safety issues or lack of effectiveness. We cannot predict with certaintyhow, or when, the FDA or other regulatory authorities will act. If we are unable to obtain the necessary regulatory approvals,our financial condition and cash flow may be materially adversely affected, and our ability to grow domestically and internationallymay be limited. Additionally, even if we obtain approval, regulatory authorities may approve any of our product candidates forfewer or more limited indications that we request. The Company’s products may not be approved for the specific indicationsthat are most necessary or desirable for successful commercialization or profitability.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 20; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         17         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          We have not demonstrated that any ofour products are safe and effective for any indication and will continue to expend substantial time and resources on clinical developmentbefore any of our current or future product candidates will be eligible for FDA approval, if ever.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        We expect that a substantialportion of our efforts and expenditures over the next few years will be devoted to development of our existing and contemplatedbiological product candidates. Accordingly, our business currently depends heavily on the successful development, FDA approval,and commercialization of such candidates, which may never receive FDA approval or be successfully commercialized even if FDA approvalis received. The research, testing, manufacturing, labeling, approval, sale, marketing, and distribution of our biological productcandidates are, and will remain, subject to extensive regulation by the FDA and other regulatory authorities in the United Statesand other countries, as applicable. We are currently not permitted to market any of our current or future product candidates inthe United States until we receive FDA approval (of each) via the BLA process. To date, we have two product candidates in clinicaldevelopment and have not-yet submitted a BLA for any of our candidates and, for many such candidates, do not expect to be in aposition to do so for the foreseeable future, as there are numerous developmental steps that must be completed before we can prepareand submit a BLA.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">        In the United States, the FDA regulates pharmaceuticaland biological product candidates under the FDCA and the Public Health Service Act (“PHSA”), as well as their respectiveimplementing regulations. Such products and product candidates are also subject to other federal, state, and local statutes andregulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local,and foreign statutes and regulations requires the expenditure of substantial time and financial resources. The process requiredby the FDA before a drug or biological product may be marketed in the United States generally involves the following:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            completion of preclinical laboratory tests and animal studies in accordance with FDA’s good laboratory practices (“GLPs”) and applicable requirements for the humane use of laboratory animals or other applicable regulations;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            submission to the FDA of an Investigational New Drug (“IND”), which must become effective before human clinical trials in the United States may begin;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            performance of adequate and well-controlled human clinical trials in accordance with FDA’s IND regulations, GCPs, and any additional requirements for the protection of human research subjects and their health information, to establish the safety and efficacy of the proposed biological product for its intended use;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            submission to the FDA of a BLA for marketing approval that meets applicable requirements to ensure the continued safety, purity, and potency of the product that is the subject of the BLA based on results of preclinical testing and clinical trials;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the biological product is produced, to assess compliance with cGMPs and assure that the facilities, methods and controls are adequate to preserve the biological product’s identity, strength, quality and purity;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            potential FDA audit of the nonclinical study and clinical trial sites that generated the data in support of the BLA; and           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            FDA review and approval, or denial, of the BLA.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 21; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         18         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Before testing any biologicalproduct candidate in humans, the product candidate enters the preclinical testing stage. Preclinical tests include laboratory evaluationsof product chemistry, toxicity and formulation, as well as animal studies to assess the potential safety and activity of the productcandidate. The conduct of the preclinical tests must comply with federal regulations and requirements including GLPs. The clinicaltrial sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any availableclinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. Some preclinical testing may continueeven after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raisesconcerns or questions regarding the proposed clinical trials and places the trial on a clinical hold within that 30-day time period.In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDAmay also impose clinical holds on a biological product candidate at any time before or during clinical trials due to safety concernsor non-compliance. If the FDA imposes a clinical hold, trials may not recommence without FDA authorization and then only underterms authorized by the FDA. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinicaltrials to begin or that, for those that have already commenced under an active IND, that issues will not arise that suspend orterminate such trials.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Clinical trials involvethe administration of the biological product candidate to healthy volunteers or patients under the supervision of qualified investigators,generally physicians not employed by or under the trial sponsor’s control. Clinical trials are conducted under protocolsdetailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria,and the parameters to be used to monitor subject safety, including stopping rules that assure a clinical trial will be stoppedif certain adverse events should occur. Each protocol and any amendments to the protocol must be submitted to the FDA as part ofthe IND. Clinical trials must be conducted and monitored in accordance with the FDA’s regulations composing the GCP requirements,including the requirement that all research subjects provide informed consent. Further, each clinical trial must be reviewed andapproved by an independent institutional review board, or IRB, at or servicing each institution at which the clinical trial willbe conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whetherthe risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits.The IRB also approves the form and content of the informed consent that must be signed by each clinical trial subject or his orher legal representative and must monitor the clinical trial until completed. Human clinical trials are typically conducted inthree sequential phases that may overlap or be combined:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            Phase 1. The biological product is initially introduced into healthy human subjects and tested for safety. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in subjects.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            Phase 2. The biological product is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            Phase 3. Clinical trials are undertaken to further evaluate dosage, clinical efficacy, potency, and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk to benefit ratio of the product and provide an adequate basis for product labeling.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Post-approval clinicaltrials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These clinical trialsare used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly forlong-term safety follow-up.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 22; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         19         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        After the completion ofclinical trials of a biological product, FDA approval of a BLA must be obtained before commercial marketing of the biological product.The BLA must include results of product development, laboratory and animal studies, human trials, information on the manufactureand composition of the product, proposed labeling and other relevant information. The FDA may grant deferrals for submission ofdata, or full or partial waivers. The testing and approval processes require substantial time and effort and there can be no assurancethat the FDA will accept the BLA for filing and, even if filed, that any approval will be granted on a timely basis, if at all.Before approving a BLA, the FDA will inspect the facilities at which the product is manufactured. The FDA will not approve theproduct unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequateto assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA willtypically inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with IND trial requirementsand GCP requirements. To assure cGMP and GCP compliance, an applicant must incur significant expenditure of time, money and effortin the areas of training, record keeping, production, and quality control.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Notwithstanding the submissionof relevant data and information, the FDA may ultimately decide that the BLA does not satisfy its regulatory criteria for approvaland deny approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently thanwe interpret the same data. Our product candidates are in the earliest stages of clinical development and, therefore, a long wayfrom BLA submission. We cannot predict with any certainty if or when we might submit a BLA for regulatory approval for our productcandidates or whether any such BLA will be approved by the FDA. Human clinical trials are very expensive and difficult to designand implement, in part because they are subject to rigorous regulatory requirements. For example, the FDA may not agree with ourproposed endpoints for any clinical trial we propose, which may delay the commencement of our clinical trials. The clinical trialprocess is also lengthy and requires substantial time and effort.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        In December 2015, the FDAcleared our IND filing for Iomab-B (for acute myeloid leukemia or AML), and we are currently enrolling patients in a randomized,controlled, pivotal Phase 3 clinical trial under such IND to study Iomab-B in patients 55 years of age or older with relapsed orrefractory AML. Assuming the Phase 3 trial meets its endpoints and there are no unexpected issues or delays, it will form the basisfor a BLA in the reasonably near future for Iomab-B for use in preparing and conditioning AML patients for BMTs. Additionally,there are physician IND trials at the FHCRC that have been conducted or are currently ongoing at FHCRC with Iomab-B (for othertarget indications) and the BC8 antibody we licensed. And, we have multiple Phase 1 and Phase 2 clinical trials ongoing and othersthat we have planned but not-yet commenced, for our other drug candidates under our own sponsorship and multiple investigator-initiatedtrials ongoing. Except for Iomab-B (for patients with AML), we expect that the clinical trials we need to conduct to be in a positionto submit BLAs for our product candidates currently in-development will take, at least, several years to complete. Moreover, failurecan occur at any stage of the trials, and we could encounter problems that cause us to abandon or repeat clinical trials. Also,the results of early preclinical and clinical testing may not be predictive of the results of subsequent clinical trials. A numberof companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacyor adverse safety profiles, notwithstanding promising results in earlier studies. And, preclinical and clinical data are oftensusceptible to multiple interpretations and analyses. Many companies that have believed their product candidates performed satisfactorilyin preclinical studies and clinical trials have, nonetheless, failed to obtain marketing approval of their products. Success inpreclinical testing and early clinical trials does not ensure that later clinical trials, which involve many more subjects, andthe results of later clinical trials may not replicate the results of prior clinical trials and preclinical testing. Any failureor substantial delay in our product development plans may have a material adverse effect on our business.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 23; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         20         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          We may encounter substantial delays inour clinical trials or may not be able to conduct our trials on the timelines we expect.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        We cannot predict whetherwe will encounter problems with any of our ongoing or planned clinical trials that will cause us or regulatory authorities to delay,suspend, or discontinue clinical trials or to delay the analysis of data from ongoing clinical trials. Any of the following coulddelay or disrupt the clinical development of our product candidates and potentially cause our product candidates to fail to receiveregulatory approval:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 19.95pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify">          </td>          <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            conditions imposed on us by the FDA or comparable foreign authorities regarding the scope or design of our clinical trials;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            delays in receiving, or the inability to obtain, required approvals from IRBs or other reviewing entities at clinical sites selected for participation in our clinical trials;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            delays in enrolling patients into clinical trials;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            a lower than anticipated retention rate of patients in clinical trials;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            the need to repeat or discontinue clinical trials as a result of inconclusive or negative results or unforeseen complications in testing or because the results of later trials may not confirm positive results from earlier preclinical studies or clinical trials;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            inadequate supply, delays in distribution, deficient quality of, or inability to purchase or manufacture drug product, comparator drugs or other materials necessary to conduct our clinical trials;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            unfavorable FDA or other foreign regulatory inspection and review of a clinical trial site or records of any clinical or preclinical investigation;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            serious and unexpected drug-related side effects experienced by participants in our clinical trials, which may occur even if they were not observed in earlier trials or only observed in a limited number of participants;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            a finding that the trial participants are being exposed to unacceptable health risks;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            the placement by the FDA or a foreign regulatory authority of a clinical hold on a trial; or           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            delays in obtaining regulatory agency authorization for the conduct of our clinical trials.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        We may suspend, or theFDA or other applicable regulatory authorities may require us to suspend, clinical trials of a product candidate at any time ifwe or they believe the patients participating in such clinical trials, or in independent third-party clinical trials for drugsbased on similar technologies, are being exposed to unacceptable health risks including but not limited to unacceptable or suboptimalfactors related to toxicity, clinical efficacy, imbalances in safety and efficacy profiles or for other reasons.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Further, individuals involvedwith our clinical trials may serve as consultants to us from time to time and receive stock options or cash compensation in connectionwith such services. If these relationships and any related compensation to the clinical investigator carrying out the study resultin perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected interpretationof the study, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of theclinical trial itself may be jeopardized. The delay, suspension or discontinuation of any of our clinical trials, or a delay inthe analysis of clinical data for our product candidates, for any of the foregoing reasons, could adversely affect our effortsto obtain regulatory approval for and to commercialize our product candidates, increase our operating expenses and have a materialadverse effect on our financial results.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 24; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         21         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Clinical trials may alsobe delayed or terminated as a result of ambiguous or negative interim results. In addition, a clinical trial may be suspended orterminated by us, the FDA, the IRBs at the sites where the IRBs are overseeing a trial, or a data safety monitoring board, or DSMB(Data Safety Monitoring Board)/DMC (Data Monitoring Committee), overseeing the clinical trial at issue, or other regulatory authoritiesdue to a number of factors, including:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 19.95pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify">          </td>          <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            inspection of the clinical trial operations or trial sites by the FDA or other regulatory authorities resulting in the imposition of a clinical hold;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            varying interpretation of data by the FDA or similar foreign regulatory authorities;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            failure to achieve primary or secondary endpoints or other failure to demonstrate efficacy;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            unforeseen safety issues; or           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            lack of adequate funding to continue the clinical trial.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          Modifications to our product candidates may require federalapprovals.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        The BLA application isthe vehicle through which the company may formally propose that the FDA approve a new pharmaceutical for sale and marketing inthe United States. Once a particular product candidate receives FDA approval, expanded uses or uses in new indications of our productsmay require additional human clinical trials and new regulatory approvals, including additional IND and BLA submissions and premarketapprovals before we can begin clinical development, and/or prior to marketing and sales. If the FDA requires new approvals fora particular use or indication, we may be required to conduct additional clinical studies, which would require additional expendituresand harm our operating results. If the products are already being used for these new indications, we may also be subject to significantenforcement actions.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Conducting clinical trialsand obtaining approvals is a time-consuming process, and delays in obtaining required future approvals could adversely affect ourability to introduce new or enhanced products in a timely manner, which in turn would have an adverse effect on our business prospects,financial condition and results of operation.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          The FDA or comparable foreign regulatoryauthorities may disagree with our regulatory plans, and we may fail to obtain regulatory approval of our product candidates.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        In June 2012, we acquiredrights to BC8 (Iomab), a clinical stage monoclonal antibody with safety and efficacy data in more than 300 patients in need ofa BMT. Iomab-B is our product candidate that links I-131 to the BC8 antibody that is being studied in an ongoing Phase 3 pivotaltrial. Product candidates utilizing this antibody would require BLA approval before they can be marketed in the United States.We are also evaluating a lower dose of the BC8 antibody and I-131 for lymphodepletion prior to CAR-T or adoptive cell therapy.We are currently evaluating clinical trials that would use our construct for lymphodepletion. Our lintuzumab-Ac-225 product candidateis also being studied in several Phase 1 trials under our sponsorship and investigator-initiated trials in patients with AML, myelodysplasticsyndrome and multiple myeloma. Product candidates utilizing the lintuzumab antibody would require BLA approval before they canbe marketed in the United States. We are in the early stages of evaluating other product candidates consisting of conjugates ofAc-225 with human or humanized antibodies for pre-clinical and clinical development in other types of cancer. The FDA may not approvethese products for the indications that are necessary or desirable for successful commercialization. The FDA may fail to approveany BLA we submit for new product candidates or for new intended uses or indications for approved products or future product candidates.Failure to obtain FDA approval for our products in the proposed indications would have a material adverse effect on our businessprospects, financial condition and results of operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 25; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         22         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          Clinical trials necessary to supportapproval of our product candidates are time-consuming and expensive.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Initiating and completingclinical trials necessary to support FDA approval of a BLA for Iomab-B, CD33 program candidates, and other product candidates,is a time-consuming and expensive process, and the outcome is inherently uncertain. Moreover, the results of early clinical trialsare not necessarily predictive of future results, and any product candidate we advance into clinical trials may not have favorableresults in later clinical trials. We have worked with the FDA to develop a clinical trial designed to test the safety and efficacyof Iomab-B in patients with relapsed or refractory AML who are age 55 and above prior to a BMT. This trial is designed to supporta BLA filing for marketing approval by the FDA, pending results from the trial. In addition to clinical data, a BLA filing encompassespreclinical, CMC, labeling and other information. Even if the clinical data from the SIERRA trial is positive, there can be noassurances that the BLA filing we produce will meet all of the FDA’s requirements or that they will not request additionalinformation or studies, which may delay the FDA’s review or we may not be able to produce. We have also worked with the FDAto develop a regulatory pathway for our Actimab-MDS trial that consists of a dose-confirming Phase 1 trial that can be followedby a randomized, controlled pivotal trial that could support a BLA filing. There can be no assurance that the data generated duringthe trial will meet our chosen safety and effectiveness endpoints or otherwise produce results that will eventually support thefiling or approval of a BLA. Even if the data from this trial are favorable, the data may not be predictive of the results of anyfuture clinical trials.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          Our clinical trials may fail to demonstrateadequately the efficacy and safety of our product candidates, which would prevent or delay regulatory approval and commercialization.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Even if our clinical trialsare completed as planned, we cannot be certain that their results will support our product candidate claims or that the FDA orforeign authorities will agree with our conclusions regarding them. Success in pre-clinical studies and early clinical trials doesnot ensure that later clinical trials will be successful, and we cannot be sure that the later trials will replicate the resultsof prior trials and pre-clinical studies. The clinical trial process may fail to demonstrate that our product candidates are safeand effective for the proposed indicated uses. If FDA concludes that the clinical trials for Iomab-B, lintzumab-Ac-225, or anyother product candidate for which we might seek approval, have failed to demonstrate safety and effectiveness, we would not receiveFDA approval to market that product candidate in the United States for the indications sought. In addition, such an outcome couldcause us to abandon the product candidate and might delay development of others. Any delay or termination of our clinical trialswill delay or preclude the filing of any submissions with the FDA and, ultimately, our ability to commercialize our product candidatesand generate revenues. It is also possible that patients enrolled in clinical trials will experience adverse side effects thatare not currently part of a product candidate’s profile.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          The intellectual property related toantibodies we have licensed has expired or likely expired.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        The key patents relatedto the humanized antibody, lintuzumab, which we use in our CD33 program product candidates have expired. It is generally possiblethat others may be eventually able to use an antibody with the same sequence, and we will then need to rely on additional patentprotection covering alpha particle drug products comprising Ac-225. Our final drug construct consists of the lintuzumab antibodylabeled with the isotope Ac-225. We have licensed issued patents that relate to the linker technology we use to conjugate the isotopeto the antibody. Further, we own issued and pending patents related to methods for drug conjugation and isotope labeling and formethods of isotope production. In addition, we possess trade secrets and know how related to the manufacturing and use of isotopes.Any competing product based on the lintuzumab antibody is likely to require several years of development before achieving our productcandidate’s current status and may be subject to significant regulatory hurdles but is nevertheless a possibility that couldnegatively impact our business in the future. We own an issued patent in the US relating to composition of the Iomab-B productcandidate. Five related patents are also pending in the US and internationally. We have and may continue to file patents relatedto Iomab-B that can provide barriers to entry but there is no certainty that these patents will be granted or such granting thereofwill adequately prevent others from seeking to replicate and use the BC8 antibody or the construct. We have pending patents relatedto radioimmunoconjugate composition, formulation administration, and methods of use in solid or liquid cancers. This matter includescomposition, administration, and methods of treatment for our products Actimab-A and Iomab-B. Any competing product based on theantibody used in Iomab-B is likely to require several years of development before achieving our product candidate’s currentstatus and may be subject to significant regulatory hurdles but is nevertheless a possibility that could negatively impact ourbusiness in the future.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 26; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         23         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          Our CD33 program clinical trials aretesting the same drug construct.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Our CD33 program is comprisedof several clinical trials including investigator-initiated trials in AML that are studying the same drug construct consistingof lintuzumab-Ac-225. Negative results from any of these trials could negatively impact our ability to enroll or complete our othertrials studying lintzumab-Ac-225. Additionally, negative outcomes including safety concerns, may result in the FDA discontinuingother trials utilizing lintuzumab-Ac-225.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          We may be unable to obtain a sufficientsupply of isotopes to support clinical development or at commercial scale.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Iodine-131 is a key componentof our Iomab-B drug candidate. We currently source medical grade I-131 from three suppliers including two leading global manufacturers.Currently, there is sufficient supply of I-131 to advance our ongoing SIERRA clinical trial, support additional trials we may undertakeutilizing I-131 and for commercialization of Iomab-B. We continually evaluate I-131 manufacturers and suppliers and intend to havemultiple qualified suppliers prior to the commercial launch of Iomab-B. While we consider I-131 to be commoditized and obtainablethrough several suppliers, there can be no guarantee that we will be able to secure I-131 or obtain I-131 on terms that are acceptableto us.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Actinium-225 is a key componentof our CD33 ARC program, AWE platform and other drug candidates that we might consider for development with the Ac-225 payload.There are adequate quantities of Ac-225 available today to meet our current needs via our present supplier, the Department of Energy(“DOE”). The current Ac-225 currently supplied to Actinium’s clinical trials from the DOE is derived from thenatural decay of thorium-229 from so-called ‘thorium-cows’ and is able to produce sufficient quantities that are severalmultiples of the amount of Ac-225 we require to supply our clinical programs through to early commercialization phase. The DOEis also producing Ac-225 from a recently developed alternative route for Ac-225 production via a linear accelerator that is currentlybeing evaluated by Actinium. Initial preclinical and modelling results have indicated that the linear accelerator sourced Ac-225does not impact labelling efficiency and expected distribution. Per representations made by the DOE, the capacity of Ac-225 fromthis route is expected to be sufficient to supply all of Actinium’s pipeline and commercial Ac-225 needs and support newprogram expansion by not just Actinium but also other companies that are developing Ac-225 based products. Additional routes ofAc-225 production are being pursued by the DOE including the generation of new thorium cows and production via a cyclotron. Thecyclotron production method for Ac-225 production leverages Actinium’s proprietary technology and know-how and presents anadditional path towards production of high-quality Ac-225 that would be able to satisfy commercial needs. In addition, we are awareof at least six other government and non-government entities globally including the U.S., Canada, Russia, Belgium, France and Japanthat have, or expect to have ability to supply Ac-225 or equipment for its production within the timeframes relevant to first commercialapproval of our Ac-225 ARC.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Our contract for supplyof this isotope from the DOE must be renewed yearly, and the current contract extends through the end of 2021. While we expectthis contract will be renewed at the end of its term as it has since 2009, there can be no assurance that the DOE will renew thecontract or that change its policies that allow for the sale of isotope to us. Failure to acquire sufficient quantities of medicalgrade Ac-225 would make it impossible to effectively complete clinical trials and to commercialize any Ac-225 based drug candidatesthat we may develop and would materially harm our business.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 27; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         24         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Our ability to conductclinical trials to advance our ARC drug candidates is dependent on our ability to obtain the radioisotopes I-131, Ac-225 and otherisotopes we may choose to utilize in the future. Currently, we are dependent on third party manufacturers and suppliers for ourisotopes. These suppliers may not perform their contracted services or may breach or terminate their agreements with us. Our suppliersare subject to regulations and standards that are overseen by regulatory and government agencies and we have no control over oursuppliers’ compliance to these standards. Failure to comply with regulations and standards may result in their inabilityto supply isotope could result in delays in our clinical trials, which could have a negative impact on our business. We have developedintellectual property, know-how and trade secrets related to the manufacturing process of Ac-225. While we have manufactured medicalgrade Ac-225 of a purity compared to the cyclotron sourced material in the past, this activity was terminated due to operatingcost reasons and we currently do not have experience in manufacturing medical grade Ac-225 and may not obtain the resources necessaryto establish our own manufacturing capabilities in future. Our inability to build out and establish our own manufacturing facilitieswould require us to continue to rely on third party suppliers as we currently do. However, based on our current third-party suppliersand potential future suppliers of Ac-225 we expect to have adequate isotope supply to support our current ongoing clinical trials,current AWE program activities and commercialization should our drug candidates receive approval.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          If we encounter difficulties enrollingpatients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        The timely completion ofclinical trials in accordance with their protocols depends on our ability to enroll a sufficient number of patients who remainin the trial until its conclusion. We may experience difficulties in patient enrollment in our clinical trials for a variety ofreasons, including:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify">          </td>          <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            the size and nature of the patient population;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            the patient eligibility criteria defined in the protocol;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            the size of the study population required for analysis of the trial’s primary endpoints;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            the proximity of patients to trial sites;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            the design of the trial;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            our ability to recruit clinical trial investigators with the appropriate competencies and expertise;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            competing clinical trials for similar or alternate therapeutic treatments;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            clinician’s and patients’ perceptions as to the potential advantages and side effects of the product candidate being studied in relation to other available therapies;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            our ability to obtain and maintain patient consents; and           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            the risk that patients enrolled in clinical trials will not complete a clinical trial.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        In addition, refractorypatients, which several of our trials are enrolling, participating in clinical trials are seriously and often terminally ill andtherefore may not complete the clinical trial due to reasons including comorbid conditions or occurrence of adverse medical eventsrelated or unrelated to the investigational products, or death. Even if we are able to enroll a sufficient number of patients inour clinical trials, delays in patient enrollment will result in increased costs or affect the timing of our planned trials, whichcould adversely affect our ability to advance the development of our product candidates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <!-- Field: Page; Sequence: 28; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         25         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          FDA may take actions that would prolong,delay, suspend, or terminate clinical trials of our product candidates, which may delay or prevent us from commercializing ourproduct candidates on a timely basis.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        There can be no assurancethat the data generated in our clinical trials will be acceptable to FDA or that if future modifications during the trial are necessary,that any such modifications will be acceptable to FDA. Certain modifications to a clinical trial protocol made during the courseof the clinical trial have to be submitted to the FDA. This could result in the delay or halt of a clinical trial while the modificationis evaluated. In addition, depending on the quantity and nature of the changes made, FDA could take the position that some or allof the data generated by the clinical trial is not usable because the same protocol was not used throughout the trial. This mightrequire the enrollment of additional subjects, which could result in the extension of the clinical trial and the FDA delaying approvalof a product candidate. If the FDA believes that its prior approval is required for a particular modification, it can delay orhalt a clinical trial while it evaluates additional information regarding the change.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 19.95pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Any delay or terminationof our current or future clinical trials as a result of the risks summarized above, including delays in obtaining or maintainingrequired approvals from IRBs, delays in patient enrollment, the failure of patients to continue to participate in a clinical trial,and delays or termination of clinical trials as a result of protocol modifications or adverse events during the trials, may causean increase in costs and delays in the filing of any submissions with the FDA, delay the approval and commercialization of ourproduct candidates or result in the failure of the clinical trial, which could adversely affect our business, operating resultsand prospects. Lengthy delays in the completion of our Iomab-B clinical trials would adversely affect our business and prospectsand could cause us to cease operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          We have obtained orphan drug designationfrom FDA for two of our current product candidates and intend to pursue such designation for other candidates and indications inthe future, but we may be unable to obtain such designations or to maintain the benefits associated with any orphan drug designationswe have received or may receive in the future.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        We have received orphandrug designation for Iomab-B and lintuzumab-CD33 ARC for treatment of AML in both the United States and the EU. Under the OrphanDrug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is adisease or condition that affects fewer than 200,000 individuals in the United States, or if it affects more than 200,000 individualsin the United States, there is no reasonable expectation that the cost of developing and making available a drug or biologic forthis type of disease or condition will be recovered from sales in the United States for that drug or biologic. Similarly, the EMAgrants orphan drug designation to promote the development of products that are intended for the diagnosis, prevention, or treatmentof a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the EU.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Orphan drug designationneither shortens the development time or regulatory review time of a drug or biologic nor gives the drug or biologic any advantagein the regulatory review or approval process. In the United States, orphan drug designation entitles a party to financial incentives,such as opportunities for grant funding towards clinical trial costs, tax advantages, and application fee waivers. In addition,if a product candidate receives the first FDA approval for the indication for which it has orphan designation, such product isentitled, upon approval, to seven years of orphan-drug exclusivity, during which the FDA may not approve any other applicationto market the same drug for the same indication, unless a subsequently approved product is clinically superior to orphan drug orwhere the manufacturer is unable to assure sufficient product quantity in the applicable patient population. In the EU, orphandrug designation entitles a party to financial incentives such as reduction of fees or fee waivers and ten years of market exclusivityfollowing drug or biological product approval. This period may be reduced to six years if the orphan drug designation criteriaare no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of marketexclusivity.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Even if we obtain (or haveobtained) orphan drug designation for certain product candidates, we may not be the first to obtain marketing approval for suchcandidates for the applicable indications due to the uncertainties inherent in the development of novel biologic products. And,an orphan drug candidate may not receive orphan-drug exclusivity upon approval if such candidate is approved for a use that isbroader than the indication for which it received orphan designation. In addition, exclusive marketing rights in the United Statesmay be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unableto assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 29; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         26         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Finally, even if we successfullyobtain orphan-drug exclusivity for an orphan drug candidate upon approval, such exclusivity may not effectively protect the productfrom competition because (i) different drugs with different active moieties can be approved for the same condition; and (ii) theFDA or EMA can also subsequently approve a subsequent product with the same active moiety and for the same indication as the orphandrug if the later-approved drug if deemed clinically superior to the orphan drug.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          Even if we receive regulatory approvalof our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Any regulatory approvalsthat we receive for our product candidates will require surveillance to monitor the safety and efficacy of the product candidate.The FDA may also require a REMS in order to approve our product candidates, which could entail requirements for a medication guide,physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registriesand other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates,the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import,export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirementsinclude submissions of safety and other post-marketing information and reports, registration, as well as continued compliance withcGMPs and GCPs for any clinical trials that we conduct post-approval. In addition, the FDA could require us to conduct anotherstudy to obtain additional safety or biomarker information. Later discovery of previously unknown problems with our product candidates,including adverse events of unanticipated severity or frequency, or with our third-party suppliers or manufacturing processes,or failure to comply with regulatory requirements, may result in, among other things:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify">          </td>          <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            restrictions on the marketing or manufacturing of our product candidates, withdrawal of the product from the market, or voluntary or mandatory product recalls;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            fines, warning letters or holds on clinical trials;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            product seizure or detention, or refusal to permit the import or export of our product candidates; and           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            injunctions or the imposition of civil or criminal penalties.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        The FDA’s and otherregulatory authorities’ policies may change, and additional government regulations may be enacted that could prevent, limitor delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulationthat may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unableto adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintainregulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 30; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         27         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          Coverage and reimbursement may be limitedor unavailable in certain market segments for our product candidates which could limit our sales of our product candidates, ifapproved.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        The commercial successof our product candidates in both domestic and international markets will be substantially dependent on whether third-party coverageand reimbursement is available for patients that use our products. However, the availability of insurance coverage and reimbursementfor newly approved cancer therapies is uncertain, and therefore, third-party coverage may be particularly difficult to obtain evenif our products are approved by the FDA as safe and efficacious. Patients using existing approved therapies are generally reimbursedall or part of the product cost by Medicare or other third-party payors. Medicare, Medicaid, health maintenance organizations andother third-party payors are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursementof new drugs, and, as a result, they may not cover or provide adequate payment for these products. Submission of applications forreimbursement approval generally does not occur prior to the filing of a BLA for that product and may not be granted until manymonths after BLA approval. In order to obtain coverage and reimbursement for these products, we or our commercialization partnersmay have to agree to a net sales price lower than the net sales price we might charge in other sales channels. The continuing effortsof government and third-party payors to contain or reduce the costs of healthcare may limit our revenue. Initial dependence onthe commercial success of our products may make our revenues particularly susceptible to any cost containment or reduction efforts.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          Healthcare legislative reform measuresintended to increase pressure to reduce prices of pharmaceutical products paid for by Medicare or, otherwise, affect the federalregulation of the U.S. healthcare system could have a material adverse effect our business, future revenue, if any, and resultsof operations.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        In the United States, therehave been a number of legislative and regulatory initiatives focused on containing the cost of healthcare. The Affordable CareAct, for example, substantially changed the way healthcare is financed by both governmental and private insurers. The AffordableCare Act contains a number of provisions that could impact our business and operations, primarily, once we obtain FDA approvalto commercialize one of our product candidates in the United States, if ever, and may also affect our operations in ways we cannotcurrently predict. Affordable Care Act provisions that may affect our business include, among others, those governing enrollmentin federal healthcare programs, reimbursement changes, rules regarding prescription drug benefits under health insurance exchanges,expansion of the 340B program, expansion of state Medicaid programs, fees and increased discount and rebate obligations, transparencyand reporting requirements, and fraud and abuse enforcement. Such changes may impact existing government healthcare programs, industrycompetition, formulary composition, and may result in the development of new programs, including Medicare payment for performanceinitiatives, health technology assessments, and improvements to the physician quality reporting system and feedback program.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        There have been significantongoing judicial, administrative, executive, and legislative initiatives to modify, limit, replace, or repeal the Affordable CareAct. For example, former President Trump issued several Executive Orders and other directives designed to delay the implementationof certain provisions of the Affordable Care Act or otherwise circumvent some of the requirements for health insurance mandatedby the Affordable Care Act. Concurrently, Congress considered legislation that would repeal or replace all or part of the AffordableCare Act. While Congress has not passed comprehensive repeal legislation, several bills affecting the implementation the AffordableCare Act have been passed. For example, the Tax Cuts and Jobs Act of 2017 eliminated the Affordable Care Act provision requiringindividuals to purchase and maintain health coverage, or the “individual mandate,” by reducing the associated penaltyto zero, beginning in 2019. In December 2018, a district court in Texas held that the individual mandate is unconstitutional andthat the rest of the Affordable Care Act is, therefore, invalid. On appeal, the Fifth Circuit Court of Appeals affirmed the holdingon the individual mandate but remanded the case back to the lower court to reassess whether and how such holding affects the validityof the rest of the Affordable Care Act. The U.S. Supreme Court is currently reviewing the case. Substantial uncertainty remainsas to the future of the Affordable Care Act. There is no way to predict whether, and to what extent, if any, the Affordable CareAct will remain in-effect in the future, and it is unclear how these decisions, subsequent appeals, or other efforts to repealand replace the Affordable Care Act will impact the United States healthcare industry or our business.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 31; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         28         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Furthermore, we cannotpredict what reform measures the Biden administration will implement in connection with the Affordable Care Act or otherwise. Theadoption or implementation of new or amended legislation at the federal or state level could affect our ability to obtain regulatoryapproval for any of our vaccine candidates and the commercial viability of our future approved products, if any. We cannot predictthe ultimate nature, timing, or effect of any changes to the Affordable Care Act or other federal and state reform efforts, andthere is no assurance that such efforts will not adversely affect our future business and financial results.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        In addition to the AffordableCare Act, there have been several recent Congressional inquiries and proposed and enacted federal and state legislation designedto, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patientprograms, and reform government program reimbursement methodologies for drug products. Pharmaceutical product prices have beenthe focus of increased scrutiny by the government, including certain state attorneys general, members of Congress and the UnitedStates Department of Justice. State or federal healthcare reform measures or other social or political pressure to lower the costof pharmaceutical products could have a material adverse impact on our business, results of operations and financial condition.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          Our relationships with customers, healthcare professionals and third-party payors may be subject to applicable healthcare laws, which could expose us to penalties, includingadministrative, civil or criminal penalties, damages, fines, imprisonment, exclusion from participation in federal healthcare programssuch as Medicare and Medicaid, reputational harm, the curtailment or restructuring of our operations and diminished future profitsand earnings.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Healthcare professionalsand third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtainmarketing approval. Our current and future arrangements with customers, healthcare professionals and third-party payors may exposeus to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financialarrangements and relationships through which we conduct research, market, sell and distribute any products for which we obtainmarketing approval. Federal and state healthcare laws and regulations that may affect our operations, directly or indirectly, includethe following, among others:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           ●          </td>          <td style="text-align: justify">           the                                         federal Anti-Kickback Statute, which prohibits persons and entities from, among other                                         things, knowingly and willfully soliciting, offering, receiving or providing remuneration,                                         directly or indirectly, in cash or in kind, to induce or reward either the referral of                                         an individual for, or the purchase, lease, order or recommendation of, any good, facility,                                         item or service, for which payment may be made under federal and state healthcare programs                                         such as Medicare and Medicaid;          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           ●          </td>          <td style="text-align: justify">           the                                         federal false claims laws, including civil whistleblower or qui tam actions under the                                         federal False Claims Act, which impose criminal and civil penalties against individuals                                         or entities for, among other things, knowingly presenting, or causing to be presented,                                         to the federal government, claims for payment that are false or fraudulent or making                                         a false statement to avoid, decrease or conceal an obligation to pay money to the federal                                         government;          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           ●          </td>          <td style="text-align: justify">           the                                         federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended                                         by the Health Information Technology for Economic and Clinical Health Act of 2009, or                                         HITECH, which imposes criminal and civil liability for, among other things, executing                                         a scheme to defraud any healthcare benefit program or making false statements relating                                         to healthcare matters and also imposes obligations, including mandatory contractual terms,                                         on covered entities, including certain healthcare providers, health plans, and healthcare                                         clearinghouses, and their respective business associates that create, receive, maintain                                         or transmit individually identifiable health information for or on behalf of the covered                                         entity as well as their covered subcontractors, with respect to safeguarding the privacy,                                         security and transmission of individually identifiable health information;          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           ●          </td>          <td style="text-align: justify">           the                                         federal Civil Monetary Penalties Law, which prohibits, among other things, the offering                                         or transfer of remuneration to a Medicare or state healthcare program beneficiary if                                         the person knows or should know it is likely to influence the beneficiary’s selection                                         of a particular provider, practitioner, or supplier of services reimbursable by Medicare                                         or a state healthcare program, unless an exception applies;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 32; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         29         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           ●          </td>          <td style="text-align: justify">           the                                         federal Physician Payments Sunshine Act, created under the Affordable Care Act, and its                                         implementing regulations, which requires certain manufacturers of drugs, devices, biologicals                                         and medical supplies for which payment is available under Medicare, Medicaid or the Children’s                                         Health Insurance Program (with certain exceptions) to report annually information related                                         to certain payments or other transfers of value provided to physicians and any ownership                                         and investment interests held by physicians or their immediate family members. Beginning                                         in 2022, applicable manufacturers also will be required to report such information regarding                                         payments and other transfers of value to physician assistants, nurse practitioners, clinical                                         nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists                                         and certified nurse midwives during the previous year; and          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           ●          </td>          <td style="text-align: justify">           analogous                                         state laws and regulations, including (among others) state anti-kickback and false claims                                         laws, which may apply to our business practices, including, but not limited to, research,                                         distribution, sales and marketing arrangements and claims involving healthcare items                                         or services reimbursed by any third-party payor, including private insurers; state laws                                         that require pharmaceutical companies to comply with the pharmaceutical industry’s                                         voluntary compliance guidelines and the relevant compliance guidance promulgated by the                                         United States federal government, or otherwise restrict payments that may be made to                                         healthcare providers and other potential referral sources; state laws and regulations                                         that require drug manufacturers to file reports relating to pricing and marketing information                                         and that require tracking gifts and other remuneration and items of value provided to                                         healthcare professionals and entities; state and local laws that require the registration                                         of pharmaceutical sales representatives; and state laws governing the privacy and security                                         of health information in certain circumstances, many of which differ from each other                                         in significant ways and often are not preempted by federal law, thus complicating compliance                                         efforts.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Efforts to comply withapplicable healthcare laws and regulations will involve substantial costs. Interpretations of standards of compliance under theselaws and regulations are rapidly changing and subject to varying interpretations and it is possible that governmental authoritieswill conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicablefraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws orany other laws that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines,exclusion from government funded healthcare programs, such as Medicare and Medicaid, reputational harm, imprisonment, additionalreporting obligations and oversight (if we become subject to a corporate integrity agreement or other agreement to resolve allegationsof non-compliance with these laws), and the curtailment or restructuring of our operations, any of which could diminish our futureprofits or earnings. If any of the physicians or other providers or entities with whom we expect to do business are found to benot in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusionsfrom government funded healthcare programs.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          Third-party payors may not adequatelyreimburse customers for any of our products that we may commercialize or promote, and may impose coverage restrictions or limitationssuch as prior authorizations and step edits that affect their use.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Our ability to commercializeany product candidates successfully also will depend in part on the extent to which coverage and adequate reimbursement for theseproducts and related treatments will be available from government health programs, private health insurers, integrated deliverynetworks and other third-party payors. Third-party payors decide which medications they will pay for and establish reimbursementlevels. A significant trend in the United States healthcare industry and elsewhere is cost containment. Government authoritiesand third-party payors have attempted to control costs by limiting coverage and the amount of payment for particular medications.Increasingly, third-party payors are requiring that drug companies provide predetermined discounts from list prices and are challengingthe prices charged for medical products. Coverage and reimbursement may not be available for any product that we commercializeand, if reimbursement is available, the level of reimbursement may not be sufficient for commercial success. Coverage and reimbursementmay impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage and reimbursementis not available or is available only to limited levels, we may not be able to successfully commercialize any product candidatefor which we obtain marketing approval.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 33; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         30         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Obtaining reimbursementapproval for any product candidate for which we obtain marketing approval from any government or other third-party payor is a time-consumingand costly process. There may be significant delays in obtaining coverage and adequate reimbursement for newly approved products.Moreover, eligibility for coverage and reimbursement does not imply that any product will be paid for in all cases or at a ratethat covers our costs, including research, development, manufacture, sale and distribution. Even when a payor determines that aproduct that we may commercialize or promote is eligible for reimbursement under its criteria, the payor may impose coverage limitationsthat preclude payment for some uses that are approved by the FDA, or may impose restrictions, such as prior authorization requirements,or may simply deny coverage altogether. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient tocover our costs and may not be made permanent. Coverage and reimbursement rates may vary according to the use of the drug and themedical circumstances under which it is used may be based on reimbursement levels already set for lower cost products or proceduresor may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts orrebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrictimports of drugs from countries where they may be sold at lower prices than in the United States. Furthermore, the Centers forMedicare and Medicaid Services frequently change product descriptors, coverage policies, product and service codes, payment methodologiesand reimbursement values. Commercial third-party payors often rely upon Medicare coverage policies and payment limitations in settingtheir own reimbursement policies. Our inability to promptly obtain and maintain coverage and profitable payment rates from bothgovernment-funded programs and private payors for any approved products that we develop could have a material adverse effect onour operating results, our ability to raise capital needed to commercialize our approved products and our overall financial condition.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         Risks Related to Third Parties        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          We rely on third parties to conduct ourclinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines or complywith regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our product candidates.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        We do not have the abilityto independently conduct our clinical trials for our product candidates and we must rely on third parties, such as contract researchorganizations, medical institutions, clinical investigators and contract laboratories to conduct such trials. Our reliance on thesethird parties for clinical development activities results in reduced control over these activities. Moreover, the FDA requiresus to comply with regulations and standards, commonly referred to as GCPs (good clinical practices), for conducting, recordingand reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the trialparticipants are adequately protected. Our reliance on third parties does not relieve us of these responsibilities and requirements.If we or any of our third-party contractors fail to comply with applicable GCPs, the clinical data generated in our clinical trialsmay be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinicaltrials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority,such regulatory authority will determine that any of our clinical trials complies with GCP regulations. In addition, our clinicaltrials must be conducted with product produced under current good manufacturing practice, or cGMP, regulations. Our failure tocomply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        If our consultants, contractresearch organizations and other similar entities with which we are working do not successfully carry out their contractual duties,meet expected deadlines, or comply with applicable regulations, we may be required to replace them. Although we believe that thereare a number of other third-party contractors, we could engage to continue these activities, we may not be able to enter into arrangementswith alternative third-party contractors or to do so on commercially reasonable terms, which may result in a delay of our plannedclinical trials and delayed development of our product candidates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        In addition, our third-partycontractors are not our employees, and except for remedies available to us under our agreements with such third-party contractors,we cannot control whether or not they devote sufficient time and resources to our programs. If these third parties do not successfullycarry out their contractual duties or regulatory obligations or meet expected deadlines, or if the quality or accuracy of the datathey obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons,our pre-clinical development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not beable to obtain regulatory approval for, or successfully commercialize, our product candidates on a timely basis, if at all, andour business, operating results and prospects would be adversely affected.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 34; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         31         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          The antibodies we use in our antibodyradiation-conjugate product candidates may be subject to generic competition.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        We are not aware of anyexisting or pending regulations or legislation that pertains to generic radiopharmaceutical products such as our antibody radiation-conjugateproduct candidates. Our product candidates are regulated by the FDA as biologic products and we intend to seek approval for theseproducts pursuant to the BLA pathway. The Biologics Price Competition and Innovation Act of 2009, or BPCIA, created an abbreviatedpathway for the approval of biosimilar and interchangeable biologic products. The abbreviated regulatory pathway establishes legalauthority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as “interchangeable”based on its similarity to an existing brand product. Under the BPCIA, an application for a biosimilar product cannot be approvedby the FDA until 12 years after the original branded product was approved under a BLA. The law is complex and is still being interpretedand implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. Even if abiosimilar gets approved for one of the antibodies that we use, the final constructs of our drug candidates consist of an antibody,radioisotope and in some cases a linker. Therefore, we do not believe that the final drug product of our candidates can be subjectto competition from a biosimilar as outlined in BPCIA.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          Our product candidates may never achievemarket acceptance.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Iomab-B, CD33 ARC programcandidates and future product candidates that we may develop may never gain market acceptance among physicians, patients and themedical community. The degree of market acceptance of any of our products will depend on a number of factors, including the actualand perceived effectiveness and reliability of the product; the results of any long-term clinical trials relating to use of theproduct; the availability, relative cost and perceived advantages and disadvantages of alternative technologies; the degree towhich treatments using the product are approved for reimbursement by public and private insurers; the strength of our marketingand distribution infrastructure; and the level of education and awareness among physicians and hospitals concerning the product.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        We believe that oncologistsand other physicians will not widely adopt a product candidate unless they determine, based on experience, clinical data, and publishedpeer-reviewed journal articles, that the use of that product candidate provides an effective alternative to other means of treatingspecific cancers. Patient studies or clinical experience may indicate that treatment with our product candidates does not providepatients with sufficient benefits in extension of life or quality of life. We believe that recommendations and support for theuse of each product candidate from influential physicians will be essential for widespread market acceptance. Our product candidatesare still in the development stage and it is premature to attempt to gain support from physicians at this time. We can provideno assurance that such support will ever be obtained. If our product candidates do not receive such support from these physiciansand from long-term data, physicians may not use or continue to use, and hospitals may not purchase or continue to purchase, them.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Failure of Iomab-B, CD33ARC program candidates or any of our other product candidates to significantly penetrate current or new markets would negativelyimpact our business financial condition and results of operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          We may be subject to claims that ourthird-party service providers, consultants or current or former employees have wrongfully used or disclosed confidential informationof third parties.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        We have received confidentialand proprietary information from third parties. In addition, we employ individuals who were previously employed at other biotechnologyor pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors haveinadvertently or otherwise used or disclosed confidential information of these third parties or our employees’ former employers.Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigationcould result in substantial cost and be a distraction to our management and employees.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">        <b>         <i>         </i>        </b>       </p>       <!-- Field: Page; Sequence: 35; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         32         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          We currently depend on single third-partymanufacturers to produce our pre-clinical and clinical trial drug supplies. Any disruption in the operations of our current third-partymanufacturers, or other third-party manufacturers we may engage in the future, could adversely affect our business and resultsof operations.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        We do not currently operatemanufacturing facilities for pre-clinical or clinical production of any of our product candidates. We rely on third-party manufacturersto supply, store, and distribute pre-clinical and clinical supply of the components of our drug product candidates including monoclonalantibodies, linkers and radioisotopes, as well as the final construct which comprises our drug product candidates. We expect tocontinue to depend on third-party manufacturers for the foreseeable future. Any performance failure on the part of our existingor future manufacturers could delay clinical development, cause us to suspend or terminate development or delay or prohibit regulatoryapproval of our product candidates or commercialization of any approved products. Further avenues of disruption to our clinicalor eventual commercial supply may also occur due to the sale, acquisition, business reprioritization, bankruptcy or other unforeseencircumstances that might occur at any of our suppliers or contract manufacturing partners including an inability to come to termson renewal of existing contracts or new contracts.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        We currently rely on singlemanufacturers to manufacture our pre-clinical and clinical trial drug supplies. With a view to maintaining business continuitywe are evaluating alternatives and second and even third sources of supply or manufacturing for our core suppliers and manufacturingpartners, however there can be no assurances that we will be able to identify such suppliers or partners and assuming we did, thatwe would be able to enter into contracts that are on favorable terms or on terms that will enable sufficient supply to ensure businesscontinuity and support our growth plans.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Our product candidatesrequire precise, high-quality manufacturing. Failure by our current contract manufacturer or other third-party manufacturers wemay engage in the future to achieve and maintain high manufacturing standards could result in patient injury or death, productrecalls or withdrawals, delays or failures in testing or delivery, cost overruns, or other problems that could seriously hurt ourbusiness. Contract manufacturers may encounter difficulties involving production yields, quality control, and quality assurance.These manufacturers are subject to ongoing periodic and unannounced inspections by the FDA and corresponding state and foreignagencies to ensure strict compliance with cGMPs and other applicable government regulations and corresponding foreign standards;we do not have control over third-party manufacturers’ compliance with these regulations and standards.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        We depend on vendors withspecialized operations, equipment and know-how to manufacture the respective components of our drug candidates. We have enteredinto manufacturing and supply agreements with these third-parties, and in some instances, we have agreed that such vendor be theexclusive manufacturer and supplier. If any of the third-parties we depend on encounter difficulties in their operations, failto comply with required regulations or breach their contractual obligations it may be difficult, or we may be unable to identifysuitable alternative third-party manufacturers. While we identify and evaluate third-party manufacturers from time to time, evenif we do identify suitable alternative third-parties, we may fail to reach agreement on contractual terms, it may be prohibitivelyexpensive and there can be no assurance that we can successfully complete technology transfer and development work necessary orcomplete the necessary work in a timely manner. Any of which could prevent us from commencing manufacturing with third-partieswhich could cause delays or suspension of our clinical trials and pre-clinical work that may have a negative impact on our business.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Furthermore, these third-partycontractors, whether foreign or domestic, may experience regulatory compliance difficulty, mechanical shut downs, employee strikes,or any other unforeseeable acts that may delay or limit production. Our inability to adequately establish, supervise and conduct(either ourselves or through third parties) all aspects of the formulation and manufacturing processes, and the inability of third-partymanufacturers to consistently supply quality product when required would have a material adverse effect on our ability to developor commercialize our products. We have faced delays and risks associated with reliance on key third party manufacturers in thepast and may be faced with such delays and risks in the future. Any future manufacturing interruptions or related supply issuescould have an adverse effect on our company, including delays in clinical trials.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 36; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         33         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          If we are successful in obtaining marketingapproval from the FDA and/or other regulatory agencies for any of our product candidates, we anticipate continued reliance on third-partymanufacturers.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        To date, our product candidateshave been manufactured in small quantities for preclinical and clinical testing by third-party manufacturers. If the FDA or otherregulatory agencies approve any of our product candidates for commercial sale, we expect that we would continue to rely, at leastinitially, on third-party specialized manufacturers to produce commercial quantities of approved products. These manufacturersmay not be able to successfully increase the manufacturing capacity for any approved product in a timely or economic manner, orat all. Significant scale-up of manufacturing may require additional validation studies, which the FDA must review and approve.Scale-up for commercial product may require financial commitment or investment by us, which we may not have sufficient capitalfor or may elect not to undertake. If third party manufacturers are unable to successfully increase the manufacturing capacityfor a product candidate, or we are unable to establish our own manufacturing capabilities, the commercial launch of any approvedproducts may be delayed or there may be a shortage in supply, which in turn could have a material adverse effect on our business.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        In addition, the facilitiesused by our contract manufacturers to manufacture our product candidates must be approved by the FDA pursuant to inspections thatwill be conducted after we submit a BLA to the FDA. We do not control the manufacturing process of, and are completely dependenton, our contract manufacturing partners for compliance with cGMPs. If our contract manufacturers cannot successfully manufacturematerial that conforms to our specifications and the strict regulatory requirements of the FDA or other regulatory authorities,they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities. If the FDA or a comparableforeign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdrawsany such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact ourability to develop, obtain regulatory approval for or market our product candidates, if approved.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          We may have conflicts with our partnersthat could delay or prevent the development or commercialization of our product candidates.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        We may have conflicts withour partners, such as conflicts concerning the interpretation of preclinical or clinical data, the achievement of milestones, theinterpretation of contractual obligations, payments for services, development obligations or the ownership of intellectual propertydeveloped during our collaboration. If any conflicts arise with any of our partners, such partner may act in a manner that is averseto our best interests. Any such disagreement could result in one or more of the following, each of which could delay or preventthe development or commercialization of our product candidates, and in turn prevent us from generating revenues: unwillingnesson the part of a partner to pay us milestone payments or royalties we believe are due under a collaboration; uncertainty regardingownership of intellectual property rights arising from our collaborative activities, which could prevent us from entering intoadditional collaborations; unwillingness by the partner to cooperate in the development or manufacture of the product, includingproviding us with product data or materials; unwillingness on the part of a partner to keep us informed regarding the progressof its development and commercialization activities or to permit public disclosure of the results of those activities; initiatinglitigation or alternative dispute resolution options by either party to resolve the dispute; or attempts by either party to terminatethe agreement.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          We face significant competition fromother biotechnology and pharmaceutical companies.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Our product candidatesface, and will continue to face, intense competition from large pharmaceutical and biotechnology companies, as well as academicand research institutions. We compete in an industry that is characterized by (i) rapid technological change, (ii) evolving industrystandards, (iii) emerging competition and (iv) new product introductions. Our competitors have existing products and technologiesthat will compete with our product candidates and technologies and may develop and commercialize additional products and technologiesthat will compete with our product candidates and technologies. Because several competing companies and institutions have greaterfinancial resources than us, they may be able to (i) provide broader services and product lines, (ii) make greater investmentsin research and development, or R&amp;D, and (iii) carry on broader R&amp;D initiatives. Our competitors also have greater developmentcapabilities than we do and have substantially greater experience in undertaking preclinical and clinical testing of product candidates,obtaining regulatory approvals, and manufacturing and marketing pharmaceutical products. They also have greater name recognitionand better access to customers than us.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 37; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         34         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          Our product candidates may cause undesirableside effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit theircommercial potential, or result in significant negative consequences.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Undesirable side effectscaused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and couldresult in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities.The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or resultin potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.Even if any of our product candidates receives marketing approval, as greater numbers of patients use a product following its approval,an increase in the incidence of side effects or the incidence of other post-approval problems that were not seen or anticipatedduring pre-approval clinical trials could result in a number of potentially significant negative consequences, including:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           ●          </td>          <td style="text-align: justify">           regulatory authorities may withdraw their approval of the product;          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           ●          </td>          <td style="text-align: justify">           regulatory authorities may require the addition of labeling statements, such as warnings or    contraindications;          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           ●          </td>          <td style="text-align: justify">           we may be required to change the way the product is administered, conduct additional clinical    trials or change the labeling of the product;          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           ●          </td>          <td style="text-align: justify">           we may elect, or we may be required, to recall or withdraw product from the market;          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           ●          </td>          <td style="text-align: justify">           we could be sued and held liable for harm caused to patients; and          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           ●          </td>          <td style="text-align: justify">           our reputation may suffer.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Any of these events couldsubstantially increase the costs and expenses of developing, commercializing and marketing any such product candidates or couldharm or prevent sales of any approved products.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         Risks Related to Our Intellectual Property        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          We depend upon securing and protecting critical intellectualproperty.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        We are dependent on obtainingand maintaining patents, trade secrets, copyright and trademark protection of our technologies in the United States and other jurisdictions,as well as successfully enforcing this intellectual property and defending this intellectual property against third-party challenges.The degree of future protection of our proprietary rights is uncertain for product candidates that are currently in the early stagesof development because we cannot predict which of these product candidates will ultimately reach the commercial market or whetherthe commercial versions of these product candidates will incorporate proprietary technologies.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          Our patent position is highly uncertainand involves complex legal and factual questions.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Accordingly, we cannotpredict the breadth of claims that may be allowed or enforced under our patents or in third-party patents. For example, we or ourlicensors might not have been the first to make the inventions covered by each of our pending patent applications and issued patents;we or our licensors might not have been the first to file patent applications for these inventions; others may independently developsimilar or alternative technologies or duplicate any of our technologies; it is possible that none of our pending patent applicationsor the pending patent applications of our licensors will result in issued patents; our issued patents and issued patents of ourlicensors may not provide a basis for commercially viable technologies, or may not provide us with any competitive advantages,or may be challenged and invalidated by third parties; and, we may not develop additional proprietary technologies that are patentable.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 38; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         35         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        As a result, our ownedand licensed patents may not be valid, and we may not be able to obtain and enforce patents and to maintain trade secret protectionfor the full commercial extent of our technology. The extent to which we are unable to do so could materially harm our business.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        We or our licensors haveapplied for and will continue to apply for patents for certain products. Such applications may not result in the issuance of anypatents, and any patents now held or that may be issued may not provide us with adequate protection from competition. Furthermore,it is possible that patents issued or licensed to us may be challenged successfully. In that event, if we have a preferred competitiveposition because of such patents, such preferred position would be lost. If we are unable to secure or to continue to maintaina preferred position, we could become subject to competition from the sale of generic products. Failure to receive, inability toprotect, or expiration of our patents for medical use, manufacture, conjugation and labeling of Ac-225, the antibodies that welicense from third parties, or subsequent related filings, would adversely affect our business and operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Patents issued or licensedto us may be infringed by the products or processes of others. The cost of enforcing our patent rights against infringers, if suchenforcement is required, could be significant, and we do not currently have the financial resources to fund such litigation. Further,such litigation can go on for years and the time demands could interfere with our normal operations. There has been substantiallitigation and other proceedings regarding patent and other intellectual property rights in the pharmaceutical industry. We maybecome a party to patent litigation and other proceedings. The cost to us of any patent litigation, even if resolved in our favor,could be substantial. Some of our competitors may be able to sustain the costs of such litigation more effectively than we canbecause of their substantially greater financial resources. Litigation may also absorb significant management time.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Unpatented trade secrets,improvements, confidential know-how and continuing technological innovation are important to our scientific and commercial success.Although we attempt to and will continue to attempt to protect our proprietary information through reliance on trade secret lawsand the use of confidentiality agreements with our partners, collaborators, employees and consultants and other appropriate means,these measures may not effectively prevent disclosure of our proprietary information, and, in any event, others may develop independently,or obtain access to, the same or similar information.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Certain of our patent rightsare licensed to us by third parties. If we fail to comply with the terms of these license agreements, our rights to those patentsmay be terminated, and we will be unable to conduct our business.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          If we are found to be infringing on patentsor trade secrets owned by others, we may be forced to cease or alter our product development efforts, obtain a license to continuethe development or sale of our products, and/or pay damages.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Our manufacturing processesand potential products may violate proprietary rights of patents that have been or may be granted to competitors, universitiesor others, or the trade secrets of those persons and entities. As the pharmaceutical industry expands and more patents are issued,the risk increases that our processes and potential products may give rise to claims that they infringe the patents or trade secretsof others. These other persons could bring legal actions against us claiming damages and seeking to enjoin clinical testing, manufacturingand marketing of the affected product or process. If any of these actions are successful, in addition to any potential liabilityfor damages, we could be required to obtain a license in order to continue to conduct clinical tests, manufacture or market theaffected product or use the affected process. Required licenses may not be available on acceptable terms, if at all, and the resultsof litigation are uncertain. If we become involved in litigation or other proceedings, it could consume a substantial portion ofour financial resources and the efforts of our personnel.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 39; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         36         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          Our ability to protect and enforce ourpatents does not guarantee that we will secure the right to commercialize our patents.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        A patent is a limited monopolyright conferred upon an inventor, and his successors in title, in return for the making and disclosing of a new and non-obviousinvention. This monopoly is of limited duration but, while in force, allows the patent holder to prevent others from making and/orusing its invention. While a patent gives the holder this right to exclude others, it is not a license to commercialize the inventionwhere other permissions may be required for commercialization to occur. For example, a drug cannot be marketed without the appropriateauthorization from the FDA, regardless of the existence of a patent covering the product. Further, the invention, even if patenteditself, cannot be commercialized if it infringes the valid patent rights of another party.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          We rely on confidentiality agreementsto protect our trade secrets. If these agreements are breached by our employees or other parties, our trade secrets may becomeknown to our competitors.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        We rely on trade secretsthat we seek to protect through confidentiality agreements with our employees and other parties. If these agreements are breached,our competitors may obtain and use our trade secrets to gain a competitive advantage over us. We may not have any remedies againstour competitors and any remedies that may be available to us may not be adequate to protect our business or compensate us for thedamaging disclosure. In addition, we may have to expend resources to protect our interests from possible infringement by others.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          The use of hazardous materials, includingradioactive and biological materials, in our research and development efforts imposes certain compliance costs on us and may subjectus to liability for claims arising from the use or misuse of these materials.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Our research, developmentand manufacturing activities involve the controlled use of hazardous materials, including chemicals, radioactive and biologicalmaterials, such as radioactive isotopes. We are subject to federal, state, local and foreign environmental laws and regulationsgoverning, among other matters, the handling, storage, use and disposal of these materials and some waste products. We cannot completelyeliminate the risk of contamination or injury from these materials and we could be held liable for any damages that result, whichcould exceed our financial resources. We currently maintain insurance coverage for injuries resulting from the hazardous materialswe use; however, future claims may exceed the amount of our coverage. Also, we do not have insurance coverage for pollution cleanupand removal. Currently the costs of complying with such federal, state, local and foreign environmental regulations are not significant,and consist primarily of waste disposal expenses. However, they could become expensive, and current or future environmental lawsor regulations may impair our research, development, production and commercialization efforts.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          We may undertake international operations,which will subject us to risks inherent with operations outside of the United States.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Although we do not haveany international operations at this time, we intend to seek market clearances in foreign markets that we believe will generatesignificant opportunities. However, even with the cooperating of a commercialization partner, conducting drug development in foreigncountries involves inherent risks, including, but not limited to difficulties in staffing, funding and managing foreign operations;unexpected changes in regulatory requirements; export restrictions; tariffs and other trade barriers; difficulties in protecting,acquiring, enforcing and litigating intellectual property rights; fluctuations in currency exchange rates; and potentially adversetax consequences.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        If we were to experienceany of the difficulties listed above, or any other difficulties, any international development activities and our overall financialcondition may suffer and cause us to reduce or discontinue our international development and registration efforts.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 40; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         37         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          We are highly dependent on our key personnel,and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implementour business strategy.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Our future operations andsuccesses depend in large part upon the continued service of key members of our senior management team whom we are highly dependentupon to manage our business. If any member of our current senior management terminates his employment with us and we are unableto find a suitable replacement quickly, the departure could have a material adverse effect on our business.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Our future success alsodepends on our ability to identify, attract, hire or engage, retain and motivate other well-qualified managerial, technical, clinicaland regulatory personnel. There can be no assurance that such professionals will be available in the market, or that we will beable to retain existing professionals or meet or continue to meet their compensation requirements. Furthermore, the cost base inrelation to such compensation, which may include equity compensation, may increase significantly, which could have a material adverseeffect on us. Failure to establish and maintain an effective management team and workforce could adversely affect our ability tooperate, grow and manage our business.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          Managing our growth as we expand operationsmay strain our resources.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        We expect to need to growrapidly in order to support additional, larger, and potentially international, pivotal clinical trials of our product candidates,which will place a significant strain on our financial, managerial and operational resources. In order to achieve and manage growtheffectively, we must continue to improve and expand our operational and financial management capabilities. Moreover, we will needto increase staffing and to train, motivate and manage our employees. All of these activities will increase our expenses and mayrequire us to raise additional capital sooner than expected. Failure to manage growth effectively could materially harm our business,financial condition or results of operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          We may expand our business through theacquisition of rights to new product candidates that could disrupt our business, harm our financial condition and may also dilutecurrent stockholders’ ownership interests in our company.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Our business strategy includesexpanding our products and capabilities, and we may seek acquisitions of product candidates, antibodies or technologies to do so.Acquisitions involve numerous risks, including substantial cash expenditures; potentially dilutive issuance of equity securities;incurrence of debt and contingent liabilities, some of which may be difficult or impossible to identify at the time of acquisition;difficulties in assimilating acquired technologies or the operations of the acquired companies; diverting our management’sattention away from other business concerns; risks of entering markets in which we have limited or no direct experience; and thepotential loss of our key employees or key employees of the acquired companies.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        We can make no assurancesthat any acquisition will result in short-term or long-term benefits to us. We may incorrectly judge the value or worth of an acquiredproduct, company or business. In addition, our future success would depend in part on our ability to manage the rapid growth associatedwith some of these acquisitions. We cannot assure that we will be able to make the combination of our business with that of acquiredproducts, businesses or companies work or be successful. Furthermore, the development or expansion of our business or any acquiredproducts, business or companies may require a substantial capital investment by us. We may not have these necessary funds, or theymight not be available to us on acceptable terms or at all. We may also seek to raise funds by selling shares of our preferredor common stock, which could dilute each current stockholder’s ownership interest in the Company.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 41; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         38         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          Risks Related to Ownership of Our CommonStock         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          The sale of securities by us in any equityor debt financing could result in dilution to our existing stockholders and have a material adverse effect on our earnings.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        We have financed our operationsprimarily through sales of stock and warrants. It is likely that during the next twelve months we will seek to raise additionalcapital through the sales of stock and warrants in order to expand our level of operations to continue our research and developmentefforts.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Any sale of common stockby us in a future offering could result in dilution to our existing stockholders as a direct result of our issuance of additionalshares of our capital stock. In addition, our business strategy may include expansion through internal growth or by establishingstrategic relationships with targeted customers and vendors. In order to do so, or to finance the cost of our other activities,we may issue additional equity securities that could dilute our stockholders’ stock ownership. We may also assume additionaldebt and incur impairment losses related to goodwill and other tangible assets if we acquire another company and this could negativelyimpact our earnings and results of operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          Our common stock is subject to pricevolatility which could lead to losses by stockholders and potential costly security litigation.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        The trading volume of ourcommon stock has been and may continue to be extremely limited and sporadic. We expect the market price of our common stock tofluctuate substantially due to a variety of factors, including market perception of our ability to achieve our planned growth,quarterly operating results of other companies in the same industry, trading volume in our common stock, changes in general conditionsin the economy and the financial markets or other developments affecting our competitors or us. This volatility has had a significanteffect on the market price of securities issued by many companies for reasons unrelated to their operating performance and couldhave the same effect on our common stock.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        The trading price of ourcommon stock may be highly volatile and could fluctuate in response to factors such as:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           ●          </td>          <td style="text-align: justify">           actual or anticipated variations in our operating results;          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           ●          </td>          <td style="text-align: justify">           announcements of developments by us or our competitors;          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           ●          </td>          <td style="text-align: justify">           the timing of IND and/or BLA approval, the completion and/or results of our clinical trials;          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           ●          </td>          <td style="text-align: justify">           regulatory actions regarding our products;          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           ●          </td>          <td style="text-align: justify">           announcements by us or our competitors of significant acquisitions, strategic partnerships,    joint ventures or capital commitments;          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           ●          </td>          <td style="text-align: justify">           adoption of new accounting standards affecting our industry;          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           ●          </td>          <td style="text-align: justify">           additions or departures of key personnel;          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           ●          </td>          <td style="text-align: justify">           introduction of new products by us or our competitors;          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           ●          </td>          <td style="text-align: justify">           sales of our common stock or other securities in the open market; and          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           ●          </td>          <td style="text-align: justify">           other events or factors, many of which are beyond our control.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <!-- Field: Page; Sequence: 42; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         39         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        The stock market is subjectto significant price and volume fluctuations. Moreover, the COVID-19 pandemic has resulted in significant financial market volatilityand uncertainty in recent months. In the past, following periods of volatility in the market price of a company’s securities,securities class action litigation has often been initiated against such a company. Litigation initiated against us, whether ornot successful, could result in substantial costs and diversion of our management’s attention and our resources, which couldharm our business and financial condition.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          We do not intend to pay dividends onour common stock, so any returns will be determined by the value of our common stock.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        We have never declaredor paid any cash dividends on our common stock. For the foreseeable future, it is expected that earnings, if any, generated fromour operations will be used to finance the growth of our business, and that no dividends will be paid to holders of our commonstock. As a result, the success of an investment in our common stock will depend upon any future appreciation in its value. Thereis no guarantee that our common stock will appreciate in value.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          Certain provisions of our Certificateof Incorporation and Bylaws and Delaware law make it more difficult for a third party to acquire us and make a takeover more difficultto complete, even if such a transaction were in our stockholders’ interest.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Provisions of our certificateof incorporation and bylaws may delay or discourage transactions involving an actual or potential change in our control or changein our management, including transactions in which stockholders might otherwise receive a premium for their shares, or transactionsthat our stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect theprice of our stock. Among other things, the certificate of incorporation and bylaws:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr>          <td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify">          </td>          <td style="vertical-align: top; width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            provide that the authorized number of directors may be changed by resolution of the board of directors;           </font>          </td>         </tr>         <tr>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          </td>          <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">          </td>          <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">          </td>         </tr>         <tr>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          </td>          <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            provide that all vacancies, including newly-created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;           </font>          </td>         </tr>         <tr>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          </td>          <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">          </td>          <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">          </td>         </tr>         <tr>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          </td>          <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            divide the board of directors into three classes;           </font>          </td>         </tr>         <tr>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          </td>          <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">          </td>          <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">          </td>         </tr>         <tr>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">          </td>          <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-size: 10pt">            provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide notice in writing in a timely manner, and meet specific requirements as to the form and content of a stockholder’s notice;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        In addition, we are governedby Section 203 of the Delaware General Corporation Law. In general, Section 203 prohibits a public Delaware corporation from engagingin a “business combination” with an “interested stockholder” for a period of three years after the dateof the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribedmanner. A “business combination” includes mergers, asset sales or other transactions resulting in a financial benefitto the stockholder. An “interested stockholder” is a person who, together with affiliates and associates, owns, orwithin three years, did own, 15% or more of the corporation’s outstanding voting stock. These provisions may have the effectof delaying, deferring or preventing a change in our control.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          Compliance with the reporting requirementsof federal securities laws can be expensive.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        We are subject to the informationand reporting requirements of the Exchange Act and other federal securities laws, and the compliance obligations of the Sarbanes-OxleyAct. The costs of preparing and filing annual and quarterly reports and other information with the Securities and Exchange Commissionand furnishing audited reports to stockholders are substantial. In addition, we will incur substantial expenses in connection withthe preparation of registration statements and related documents with respect any offerings of our common stock.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 43; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         40         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          Our ability to utilize our net operatingloss carryforwards and certain other tax attributes may be limited.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Our ability to utilizeour federal net operating loss and tax credit carryforwards may be limited under Sections 382 and 383 of the Internal Revenue Codeof 1986, as amended, or the Code. The limitations apply if we experience an “ownership change”, generally definedas a greater than 50 percentage point change in the ownership of our equity by certain stockholders over a rolling three-year period. Similarprovisions of state tax law may also apply. We have not assessed whether such an ownership change has previously occurred. Ifwe have experienced an ownership change at any time since our formation, we may already be subject to limitations on our abilityto utilize our existing net operating losses and other tax attributes to offset taxable income. In addition, future changes inour stock ownership, which may be outside of our control, may trigger an ownership change and, consequently, the limitations underSections 382 and 383 of the Code. As a result, if or when we earn net taxable income, our ability to use our pre-change netoperating loss carryforwards and other tax attributes to offset such taxable income may be subject to limitations, which couldadversely affect our future cash flows.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          Failure to establish and maintain adequatefinance infrastructure and accounting systems and controls could impair our ability to comply with the financial reporting andinternal controls requirements for publicly traded companies.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        As a public company, weoperate in an increasingly demanding regulatory environment, including with respect to more complex accounting rules. Company responsibilitiesrequired by the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act, include establishing and maintaining corporateoversight and adequate internal control over financial reporting and disclosure controls and procedures. Effective internal controlsare necessary for us to produce reliable financial reports and are important to help prevent financial fraud.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Our compliance with Section404 of the Sarbanes-Oxley Act requires that we incur substantial accounting expense and expend significant management efforts.We complied with Section 404 at December 31, 2020 and 2019 and while our testing did not reveal any material weaknesses in ourinternal controls, any material weaknesses in our internal controls in the future would be required us to remediate in a timelymanner so as to be able to comply with the requirements of Section 404 each year. If we are not able to comply with the requirementsof Section 404 in a timely manner each year, we could be subject to sanctions or investigations by the SEC, NYSE American or otherregulatory authorities which would require additional financial and management resources and could adversely affect the marketprice of our common stock. Furthermore, if we cannot provide reliable financial reports or prevent fraud, our business and resultsof operations could be harmed, and investors could lose confidence in our reported financial information.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          If securities or industry analysts donot publish research or publish inaccurate or unfavorable research about our business, the price of our common stock and tradingvolume could decline.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        The trading market forour common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business.Multiple securities and industry analysts currently cover us. If one or more of the analysts downgrade our common stock or publishinaccurate or unfavorable research about our business, the price of our common stock would likely decline. If one or more of theseanalysts cease coverage of us or fail to publish reports on us regularly, demand for our common stock could decrease, which couldcause the price of our common stock and trading volume to decline.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <i>          Our amended and restated bylaws,as amended, designate the U.S. federal district courts as the exclusive forum for the resolution of anycomplaint asserting a cause of action arising under the Securities Act of 1933, as amended.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Our amended and restated bylaws,as amended, provide that, unless we consent in writing to the selection of an alternative forum, the federal district courtsof the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising underthe Securities Act of 1933, as amended. In addition, our amended and restated bylaws, as amended, state that any person purchasingor otherwise acquiring any interest in our security shall be deemed to have notice of and to have consented to such provision.Such choice of forum provision may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorablefor disputes with us or our directors, officers or other employees, which may discourage such lawsuits, if successful, might benefitour stockholders. Stockholders who do bring a claim in the federal district courts of the United States of America could face additionallitigation costs in pursuing any such claim.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 44; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         41         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <a name="aph165213a004">        </a>        <b>         ITEM 1B. UNRESOLVED STAFF COMMENTS.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        None.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <a name="aph165213a005">         </a>         ITEM 2. PROPERTIES.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        We do not own any realproperty. We lease offices at 275 Madison Avenue, New York, NY. The lease is for 5,790 square feet and has a term of seven yearsand three months, with an expiration date of September 6, 2022, with a current annual rate $342 thousand. We are also responsiblefor certain other costs, such as insurance, taxes, utilities and maintenance. We issued a letter of credit of $391 thousand inconnection with the lease and maintained a $391 thousand certified deposit as collateral for the letter of credit.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <a name="aph165213a006">         </a>         ITEM 3. LEGAL PROCEEDINGS.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        From time to time, we maybecome involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. Litigation is subjectto inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm business.We are currently not aware of any such legal proceedings or claims that will have, individually or in the aggregate, a materialadverse effect on our business, financial condition or operating results.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <a name="aph165213a007">         </a>         ITEM 4. MINE SAFETY DISCLOSURES.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Not Applicable.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 45; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         42         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">        <b>         <a name="aph165213a008">         </a>         PART II        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <a name="aph165213a009">         </a>         ITEM 5. MARKET FOR REGISTRANT’S COMMONEQUITY, RELATED STOCKHOLDERS MATTERS, AND ISSUER PURCHASE OF EQUITY SECURITIES.        </b>       </p>       <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         Market Information        </b>       </p>       <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Our common stock is listedfor quotation on the NYSE AMERICAN under the symbol “ATNM”.       </p>       <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <b>         Holders        </b>       </p>       <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        As of March 31, 2021, therewere 19,245,638 shares of common stock issued and outstanding, which were held by approximately 99 holders of record. There areno shares of preferred stock outstanding.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         Securities Authorized for Issuance underEquity Compensation Plans        </b>       </p>       <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        We currently have threeequity compensation plans defined as follows:       </p>       <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        The Company’s 2019Amended and Restated Stock Plan has an expiration date of October 18, 2029 and the number of shares of our common stock availablefor grant to employees, directors and consultants authorized under the plan is 3,083,333 shares.       </p>       <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        The Company’s 2013Amended and Restated Stock Plan has an expiration date of September 9, 2023 and after a number of amendments approved by stockholders,the number of shares of our common stock available for grant to employees, directors and consultants authorized under the planis 758,333 shares.       </p>       <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        The Company’s 2013Equity Incentive Plan has an expiration date of September 9, 2023 and the number of shares of our common stock available for grantto employees, directors and consultants under the plan is 33,333 shares.       </p>       <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        The following table indicatesshares of common stock authorized for issuance under our equity compensation plans as of December 31, 2020:       </p>       <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-weight: bold; padding-bottom: 1.5pt; border-bottom: Black 1.5pt solid">           Plan category          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Number of           <br/>           securities to           <br/>           be issued           <br/>           upon exercise           <br/>           of outstanding           <br/>           options          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Weighted-           <br/>           average           <br/>           exercise           <br/>           price of           <br/>           outstanding           <br/>           options          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Number of           <br/>           securities           <br/>           remaining           <br/>           available           <br/>           for future           <br/>           issuance          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="width: 64%; text-align: left">           Equity compensation plans approved by security holders          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           815,112          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           21.53          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           3,874,999          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="text-align: left; padding-bottom: 1.5pt">           Equity compensation plans not approved by security holders          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 4pt">           Total          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           815,112          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           21.53          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           3,874,999          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        <b>        </b>       </p>       <!-- Field: Page; Sequence: 46; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         43         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <a name="aph165213a010">         </a>         ITEM 6. SELECTED FINANCIAL DATA.        </b>       </p>       <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        The following selectedfinancial data should be read in conjunction with our consolidated financial statements and related notes and the “Management’sDiscussion and Analysis of Financial Condition and Results of Operations” and other financial data included elsewherein this Form 10-K. The selected statements of operations and the selected balance sheet data are derived from our consolidatedaudited financial statements.       </p>       <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="padding-bottom: 1.5pt">           (in thousands, except for number of shares and per share data)          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Year ended December 31,          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-weight: bold">           Statements of Operations Data:          </td>          <td>          </td>          <td colspan="2">          </td>          <td>          </td>          <td>          </td>          <td colspan="2">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="text-align: justify">           Revenues          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="width: 76%; text-align: justify">           Loss from operations          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           (22,393          </td>          <td style="width: 1%; text-align: left">           )          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           (22,072          </td>          <td style="width: 1%; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="text-align: justify">           Net loss          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           (22,215          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           (21,900          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="text-align: justify">           Net loss per common share:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="text-align: justify">           Basic and diluted          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           (1.83          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           (4.40          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="text-align: justify">           Weighted-average common shares outstanding:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="text-align: justify">           Basic and diluted          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           12,134,259          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           4,975,721          </td>          <td style="text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="padding-bottom: 1.5pt">           (in thousands)          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           As of December 31,          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-weight: bold; text-align: justify">           Balance Sheet Data:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="width: 76%; text-align: justify">           Cash and cash equivalents          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           63,560          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           9,254          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="text-align: justify">           Total assets          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           66,397          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           11,670          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="text-align: justify">           Total liabilities          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           5,078          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           6,026          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="text-align: left">           Stockholders’ equity          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">            61,319           </p>          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           5,644          </td>          <td style="text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 47; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         44         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <a name="aph165213a011">         </a>         ITEM 7. MANAGEMENT’S DISCUSSION ANDANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0; text-align: justify">        <i>         The information and financial data discussedbelow is derived from the audited consolidated financial statements of Actinium Pharmaceuticals, Inc. for its fiscal years endedDecember 31, 2020 and 2019.   The consolidated financial statements of Actinium Pharmaceuticals, Inc. were preparedand presented in accordance with generally accepted accounting principles in the United States. The information and financial datadiscussed below is only a summary and should be read in conjunction with the historical financial statements and related notesof Actinium Pharmaceuticals, Inc. contained elsewhere in this Report. The financial statements contained elsewhere in thisReport fully represent Actinium Pharmaceuticals, Inc.’s financial condition and operations; however, they are not indicativeof the Company’s future performance. See “Cautionary Note Regarding Forward-Looking Statements” above for a discussionof forward-looking statements and the significance of such statements in the context of this Report.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Actinium Pharmaceuticals,Inc. is a clinical-stage, biopharmaceutical company applying its proprietary platform technology and deep understanding of radiobiologyto the development of novel targeted therapies known as Antibody Radiation-Conjugates, or ARCs. Radiation is an effective therapeuticmodality that is used in the treatment of over fifty percent of all cancer patients and is often combined with chemotherapy, immunotherapyand other treatments for greater therapeutic effect. Radiation is typically administered via an external beam source from outsidethe body, leading to off-target exposure to normal healthy tissue and organs, which can constrain the amount of radiation thatcan be administered to patients due to associated dose-limiting toxicities. In addition, use of external beam radiation is largelylimited to solid tumors and cannot be used in blood cancers, which are diffuse throughout the body of a patient. ARCs combine thecell-killing ability of radiation via a radioisotope payload with a targeting agent, such as a monoclonal antibody to deliver radiationin a precise manner inside the body to specific, targeted cells, to potentially achieve greater efficacy with lower toxicity thanwith external beam radiation. ARCs enable a broader usage of radiation than external beam radiation as they can be used in thetreatment of both solid tumors and blood cancers. Blood or hematologic cancers are known to be highly sensitive to radiation. Ourclinical pipeline is focused on ARCs targeting the antigens CD45 and CD33, both of which are expressed in multiple hematologiccancers. Our clinical programs are focused on two primary areas: (1) targeted conditioning prior to a bone marrow transplant, orBMT, adoptive cell therapy, or ACT, such as CAR-T or gene therapy and (2) ARC therapeutic combinations with other agents. Our productdevelopment strategy is actively informed by clinical data with our ARCs in over 500 patients, including our ongoing Pivotal Phase3 SIERRA trial. Our clinical pipeline has emanated from our Antibody Warhead Enabling, or AWE technology platform, which is protectedby over 140 issued and pending patents, trade secrets and know-how and is being utilized in a collaborative research partnershipwith Astellas Pharma, Inc.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         Recent Developments        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <i>         Impact of COVID–19 Pandemic        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In December 2019, anovel strain of COVID-19 was reported in China. Since then, COVID-19 has spread globally. The spread of COVID-19 from China toother countries has resulted in the World Health Organization (WHO) declaring the outbreak of COVID-19 as a “pandemic,”or a worldwide spread of a new disease, on March 11, 2020. Many countries around the world have imposed quarantines and restrictionson travel and mass gatherings to slow the spread of the virus and have closed non-essential businesses, and as of the date of thisreport, many local jurisdictions continue to have such restrictions in place.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        As many local jurisdictionscontinue to have such restrictions in place, our ability to continue to operate our business may also be limited. Such events mayresult in a period of business, supply and drug product manufacturing disruption, and in reduced operations, any of which couldmaterially affect our business, financial condition and results of operations. In response to COVID-19, we implemented remote workingand thus far have not experienced a significant disruption or delay in our operations as it relates to the clinical developmentof our drug candidates. Such government-imposed precautionary measures may have been relaxed in certain countries or states, butthere is no assurance that more strict measures will be put in place again due to a resurgence in COVID-19 cases, including thoseinvolving new variants of the coronavirus, which may be more contagious and deadly than prior strains. Therefore, the COVID-19pandemic may continue to affect our operation, may further divert the attention and efforts of the medical community to coping with COVID-19 anddisrupt the marketplace in which we operate and may have a material adverse effect on our operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 48; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         45         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        The spread of COVID-19,which has caused a broad impact globally, may materially affect us economically. While the ultimate economic impact brought by,and the duration of, the COVID-19 pandemic may be difficult to assess or predict, including new information which may emerge concerningthe severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among others, the pandemic has resulted in significantdisruptions in the general commercial activity and the global economy and caused financial market volatility and uncertainty insignificant and unforeseen ways in the recent months. A continuation or worsening of the levels of market disruption and volatilityseen in the recent past could have an adverse effect on our ability to access capital, which could in the future negatively affectour liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect ourbusiness and the value of our common stock.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Currently, the Phase 3SIERRA trial for our lead program, Iomab-B, continues to remain active at a majority of our clinical trial sites, with investigatorsproviding feedback that recruitment and enrollment will remain active because of the acute nature of the disease, the high unmetneeds of patients with relapsed or refractory AML, the potentially curative nature of BMT and the differentiated profile of Iomab-B.Certain sites that had not been actively enrolling due to COVID-19 at the initial outbreak of the pandemic resumed recruitmentand enrollment in mid-2020, and we currently do not have any sites that are not recruiting and enrolling patients due to COVID-19.We also believe our earlier stage clinical trials for our CD33 program will also continue to recruit and enroll patients giventhe acute nature of relapsed or refractory AML. The continuation of the pandemic could adversely affect our planned clinical trialoperations, including our ability to conduct the trials on the expected timelines and recruit and retain patients and principalinvestigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 if their geography is impactedby the pandemic. Further, the continuation and/or resurgence of the COVID-19 pandemic could result in delays in our clinical trialsdue to prioritization of hospital resources toward the pandemic, restrictions in travel, potential unwillingness of patients toenroll in trials at this time, or the inability of patients to comply with clinical trial protocols if quarantines or travel restrictionsimpede patient movement or interrupt healthcare services. In addition, we rely on independent clinical investigators, contractresearch organizations and other third-party service providers to assist us in managing, monitoring and otherwise carrying outour preclinical studies and clinical trials, and the pandemic may affect their ability to devote sufficient time and resourcesto our programs or to travel to sites to perform work for us.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Additionally, COVID-19may result in delays in receiving approvals from local and foreign regulatory authorities, delays in necessary interactions withIRB’s or Institutional Review Boards, local and foreign regulators, ethics committees and other important agencies and contractorsdue to limitations in employee resources or forced furlough of government employees.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        To date, COVID-19 has nothad a financial impact on our company. However, COVID-19 has caused severe disruptions in transportation and limited access toour facility, resulting in limited support from our staff and professional advisors.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        We continue to monitorthe impacts of COVID-19 on the global economy and on our business operations. However, the ultimate impact from COVID-19 on ourbusiness operations and financial results during 2021 will depend on, among other things, the ultimate severity and scope of thepandemic, the pace at which governmental and private travel restrictions and public concerns about public gatherings will ease,the rate at which historically large increases in unemployment rates will decrease, if at all, and whether, and the speed withwhich the economy recovers. We are not able to fully quantify the impact that these factors will have on our financial resultsduring 2021 and beyond, but developments related to COVID-19 may materially affect us in 2021.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 49; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         46         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         Results of Operations – Year EndedDecember 31, 2020 Compared to the Year Ended December 31, 2019        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        The following table setsforth, for the periods indicated, data derived from our statements of operations:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           For the year ended           <br/>           December 31,          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center">           Increase          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="padding-bottom: 1.5pt">           (in thousands)          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           (Decrease)          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td colspan="2">          </td>          <td>          </td>          <td>          </td>          <td colspan="2">          </td>          <td>          </td>          <td>          </td>          <td colspan="2">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           Revenues          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="text-align: left">           Operating expenses:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="width: 64%; text-align: left; padding-left: 10pt">           Research and development, net of reimbursements          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           16,085          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           16,550          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           (465          </td>          <td style="width: 1%; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">           General and administrative          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           6,308          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           5,522          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           786          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">           Total operating expenses          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           22,393          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           22,072          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           321          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="text-align: left">           Other income          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">           Interest income – net          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           178          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           172          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           6          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">           Total other income          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           178          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           172          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           6          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="text-align: left; padding-bottom: 4pt">           Net loss          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           (22,215          </td>          <td style="padding-bottom: 2pt; text-align: left">           )          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           (21,900          </td>          <td style="padding-bottom: 2pt; text-align: left">           )          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           (315          </td>          <td style="padding-bottom: 2pt; text-align: left">           )          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <b>         Revenues        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        We recorded no commercialrevenues for the years ended December 31, 2020 and 2019, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         Research and Development Expense        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Research and developmentexpenses declined by $0.5 million to $16.1 million for the year ended December 31, 2020 compared to $16.6 million for the yearended December 31, 2019. The decrease was primarily attributable to lower expenses related to our CD33 program, mostly offset byhigher expenses on our CD45 program.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         General and Administrative Expenses        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        General and administrativeexpenses increased by $0.8 million to $6.3 million for the year ended December 31, 2020 compared to $5.5 million for the year endedDecember 31, 2019, primarily attributable to higher third-party professional fees, including consultants, investor relations andrecruiters.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         Other Income        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Other income of $0.2 millionfor both time periods was attributable to interest income - net.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         Net Loss        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Net loss increased by $0.3million to $22.2 million for the year ended December 31, 2020 compared to $21.9 million for the year ended December 31, 2019, primarilydue to higher general and administrative expenses.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 50; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         47         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         Liquidity and Capital Resources        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        We have financed our operationsprimarily through sales of our stock, pre-funded warrants and warrants.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        The following tables setsforth selected cash flow information for the periods indicated:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           For the year ended           <br/>           December 31,          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="padding-bottom: 1.5pt">           (in thousands)          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td colspan="2">          </td>          <td>          </td>          <td>          </td>          <td colspan="2">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="width: 76%; text-align: left">           Cash used in operating activities          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           (21,618          </td>          <td style="width: 1%; text-align: left">           )          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           (21,462          </td>          <td style="width: 1%; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="text-align: left">           Cash used in investing activities          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (253          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (64          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="text-align: left; padding-bottom: 1.5pt">           Cash provided by financing activities          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           76,177          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           17,114          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="text-align: left; padding-bottom: 4pt">           Net change in cash, cash equivalents and restricted cash          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           54,306          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           (4,412          </td>          <td style="padding-bottom: 2pt; text-align: left">           )          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Net cash used in operatingactivities for the year ended December 31, 2020 of $21.6 million increased by $0.1 million from $21.5 million used in operationsfor the prior year, primarily due to the timing of payments to vendors.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Net cash used in investingactivities of $253 thousand and $64 thousand for the years ended December 31, 2020 and December 31, 2019, respectively, was forthe purchase of equipment.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Net cash provided by financingactivities was mainly generated by the sale of shares of common stock, pre-funded warrants and warrants. Net cash provided by financingactivities was $76.2 million for the year ended December 31, 2020, reflecting $76.6 million in proceeds from the sales of commonstock and pre-funded warrants in April and June 2020 and sales of common stock throughout 2020. During 2019, net cash providedby financing activities was $17.1 million, reflecting $15.9 million in proceeds from the sale of common stock and warrants, plus$1.5 million in proceeds from the exercise of warrants.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        On April 24, 2020, we issuedand sold 4.3 million shares of common stock and pre-funded warrants to purchase 2.8 million shares of common stock. The price tothe public for each share of common stock sold in the offering was $4.50, and the price to the public for each pre-funded warrantsold in the offering was $4.497. The pre-funded warrants were exercisable at an exercise price of $0.003 per share and were exercisableimmediately upon issuance. Gross proceeds from this offering were $31.6 million, before deducting underwriting discounts and commissionsand other offering expenses payable by us. Net proceeds from the offering were approximately $29.1 million       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        On June 19, 2020, we issuedand sold 1.9 million shares of common stock and pre-funded warrants to purchase 0.7 million shares of common stock. The price tothe public in this offering for each share of common stock was $9.75 and for each pre-funded warrant was $9.747. Each pre-fundedwarrant had an exercise price of $0.003 per share and were exercisable immediately upon issuance. Gross proceeds from this offeringto us were $25.0 million, before deducting underwriting discounts and commissions and other offering expenses payable us. Net proceedsfrom this offering were approximately $23.0 million.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        During the year ended December31, 2020, holders of all 2.8 million pre-funded April 2020 warrants and 0.7 million pre-funded June 2020 warrants exercised theirpre-funded warrants at $0.003 per share and received 2.8 million shares of common stock and 0.7 million shares of common stock,respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        In August 2020, we entereda Capital on Demand™ Sales Agreement with JonesTrading, pursuant to which we may sell, from time to time, through or to JonesTrading,up to an aggregate of $200 million of our common stock. Shares of common stock are offered pursuant to our shelf registration statementfiled with the SEC on August 7, 2020. As of December 31, 2020, we sold 2.1 million shares of common stock, resulting in gross proceedsof $22.6 million and net proceeds of $21.7 million.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 51; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         48         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        In December 2018, we enteredinto the Amended and Restated At Market Issuance Sales Agreement with B. Riley FBR, Inc. and JonesTrading pursuant to which weconducted our at-the market program. In early 2020, we sold 0.3 million shares of common stock through our at-the-market program,resulting in net proceeds of $2.5 million.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        In October 2018,we and Lincoln Park Capital Fund, LLC, or Lincoln Park entered into a purchase agreement and a registration rights agreement, pursuantto which we have the right to sell to Lincoln Park shares of our common stock having an aggregate value of up to $32.5 million,subject to certain limitations and conditions set forth in the agreement. In early 2020, we elected to sell to Lincoln Park 27thousand shares and received $0.2 million.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        In April 2019, we sold1.4 million shares of common stock at an offering price of $11.55 per share and warrants to purchase 1.4 million shares of commonstock at an exercise price of $15.00 per share and with a term of 5 years, resulting in gross proceeds of $16.5 million and netproceeds of $15.1 million after deducting underwriting and other offering expenses.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        As of the date of filingthis report, we expect that our existing resources will be more than sufficient to fund our planned operations for more than 12months following the date of this report.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         Off-Balance Sheet Arrangements        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        We do not have any off-balancesheet arrangements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         Critical Accounting Policies        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Our management’sdiscussion and analysis of financial condition and results of operations is based on our consolidated financial statements, whichhave been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. The preparation ofthese financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilitiesand expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements during the reportingperiods. These items are monitored and analyzed by us for changes in facts and circumstances, and material changes in these estimatescould occur in the future. We base our estimates on historical experience, known trends and events, and on various other factorsthat we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carryingvalue of assets and liabilities that are not readily apparent from other sources. Changes in estimates are reflected in reportedresults for the period in which they become known. Actual results may differ materially from these estimates under different assumptionsor conditions       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         Fair Value of Financial Instruments        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Fair value is defined asthe price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants.A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active marketsfor identical assets or liabilities and the lowest priority to unobservable inputs.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         Research and Development Costs        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Research and developmentcosts are expensed as incurred. These costs include the costs of manufacturing drug components and final drug product, the costsof clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to facilities andequipment. Research and development reimbursements are recorded by us as a reduction of research and development costs.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         Share-Based Payments        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        We estimate the fair valueof each stock option award at the grant date by using the Black-Scholes option pricing model. The fair value determined representsthe cost for the award and is recognized over the vesting period during which an employee is required to provide service in exchangefor the award. We account for forfeitures of stock options as they occur.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 52; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         49         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <b>         Income Taxes        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        We use the asset and liabilitymethod to calculate deferred taxes. Deferred taxes are recognized based on the differences between the financial reporting andincome tax bases of assets and liabilities using the enacted tax rates and laws that will be in effect when the differences areexpected to reverse. We review deferred tax assets for a valuation allowance based upon whether it is more likely than not thatthe deferred tax asset will be fully realized. A valuation allowance, if necessary, is provided against deferred tax assets, basedupon our assessment as to their realization.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        We recognize tax when thepositions meet a “more-likely-than-not” recognition threshold. There were no tax positions for which it is consideredreasonably possible that the total amounts of unrecognized tax benefits will significantly increase or decrease within the nextyear. We recognize interest related to unrecognized tax benefits in interest expense and penalties in operating expenses.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         Accounting Standards Recently Adopted        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        In August 2018, FASB issuedASU 2018-13,        <i>         Fair Value Measurement - Disclosure Framework (Topic 820).        </i>        The updated guidance improves the disclosure requirementson fair value measurements, primarily associated with Level 3 fair value measurements and is effective for fiscal years, and interimperiods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted upon issuance of the standardfor disclosures modified or removed with a delay of adoption of the additional disclosures until their effective date. We adoptedthis standard effective January 1, 2020 and the standard did not have a significant impact to our financial statements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        In November 2018, FASBissued ASU 2018-18, C        <i>         ollaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606,        </i>        which, among other things, provides guidance on how to assess whether certain collaborative arrangement transactions should beaccounted for under Topic 606. The amendments in this ASU are effective for fiscal years, and interim periods within those fiscalyears, beginning after December 15, 2019, with early adoption permitted. We adopted this standard effective January 1, 2020 andthe standard did not have a significant impact to our financial statements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <b>         Recent Accounting Standards        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        In August 2020, FASB issuedASU 2020-06,        <i>         Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contractsin Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity        </i>        ,which, among other things, provides guidance on how to account for contracts on an entity’s own equity. This ASU simplifiesthe accounting for certain financial instruments with characteristics of liabilities and equity. Specifically, the ASU eliminatesthe need for us to assess whether a contract on the entity’s own equity (1) permits settlement in unregistered shares, (2)whether counterparty rights rank higher shareholder’s rights, and (3) whether collateral is required. In addition, the ASUrequires incremental disclosure related to contracts on the entity’s own equity and clarifies the treatment of certain financialinstruments accounted for under this ASU on earnings per share. This ASU may be applied on a full retrospective of modified retrospectivebasis. This ASU is effective January 1, 2022 and interim periods presented. Early adoption of the ASU is permitted by us effectiveJanuary 1, 2021. We are in the process of assessing the adoption of the ASU on our financial statements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         Subsequent Events        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Since December 31, 2020we have sold 1.7 million shares of common stock under our Capital on Demand™ Sales Agreement with JonesTrading, resultingin net proceeds of $14.4 million.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        In January 2021, we announceda collaborative research agreement with Astellas Pharma, Inc. and began work on this project that will utilize our AWE technologyplatform with select targeting agents owned by Astellas in the development of theranostics for solid tumor indications, which combinethe ability of radioisotopes to be used for both diagnostic and therapeutic purposes.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         <a name="aph165213a012">         </a>         ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURESABOUT MARKET RISK.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Not Applicable       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 53; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         50         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 7pt">        <a name="aph165213a013">        </a>        <b>         ITEM 8. FINANCIAL STATEMENTSAND SUPPLEMENTARY DATA.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">        <b>         REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTINGFIRM        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        To the Shareholders and Board of Directors of       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        Actinium Pharmaceuticals, Inc.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0">        <b>         Opinion on the FinancialStatements        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0">        We have audited the accompanyingconsolidated balance sheets of Actinium Pharmaceuticals, Inc. (the “Company”) as of December 31, 2020 and 2019, the relatedconsolidated statements of operations, stockholders’ equity and cash flows for each of the years ended December 31, 2020 and 2019,and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements presentfairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operationsand its cash flows for each of years then ended, in conformity with accounting principles generally accepted in the United States of America.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <b>         Basis for Opinion        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        These financial statements are the responsibilityof the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. Weare a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and arerequired to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules andregulations of the Securities and Exchange Commission and the PCAOB.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        We conducted our audits in accordance with the standardsof the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statementsare free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform,an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internalcontrol over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal controlover financial reporting. Accordingly, we express no such opinion.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        Our audits included performing procedures to assessthe risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respondto those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluatingthe overall presentation of the financial statements. We believe that our audits provides a reasonable basis for our opinion.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         Critical Audit Matters        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        Critical audit matters are matters arising fromthe current period audit of the financial statements that were communicated or required to be communicated to the audit committee andthat: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging,subjective, or complex judgments. We determined that there are no critical audit matters.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-variant: small-caps">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        /s/ Marcum        <font style="font-variant: small-caps">         llp        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-variant: small-caps">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        Marcum        <font style="font-variant: small-caps">         llp        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <font style="font-variant: small-caps">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        We have served as the Company’s auditor since 2012        <b>         .        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        Houston, Texas        <br/>        March 31, 2021       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 7pt; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 7pt">       </p>       <!-- Field: Page; Sequence: 54; Options: NewSection; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         1         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         Actinium Pharmaceuticals, Inc.         <br/>         Consolidated Balance Sheets        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">        <tbody>         <tr style="vertical-align: bottom">          <td style="padding-left: 0.125in; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold; text-indent: -0.125in">           (amounts in thousands, except share and per share data)          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           December 31,           <br/>           2020          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           December 31,           <br/>           2019          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="padding-left: 0.125in; text-indent: -0.125in">          </td>          <td>          </td>          <td colspan="2">          </td>          <td>          </td>          <td>          </td>          <td colspan="2">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="padding-left: 0.125in; font-size: 10pt; font-weight: bold; text-align: center; text-indent: -0.125in">           Assets          </td>          <td>          </td>          <td colspan="2">          </td>          <td>          </td>          <td>          </td>          <td colspan="2">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="padding-left: 0.125in; font-size: 10pt; font-weight: bold; text-indent: -0.125in">           Current Assets:          </td>          <td>          </td>          <td colspan="2">          </td>          <td>          </td>          <td>          </td>          <td colspan="2">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-indent: -0.125in; padding-left: 0.25in; width: 76%; font-size: 10pt; text-align: left">           Cash and cash equivalents          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 9%; font-size: 10pt; text-align: right">           63,560          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 9%; font-size: 10pt; text-align: right">           9,254          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-indent: -0.125in; padding-left: 0.25in; font-size: 10pt; text-align: left">           Restricted cash – current          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           48          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           48          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-indent: -0.125in; padding-left: 0.25in; font-size: 10pt; text-align: left; padding-bottom: 1.5pt">           Prepaid expenses and other current assets          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           1,317          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           786          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-indent: -0.125in; padding-left: 0.375in; font-size: 10pt; font-weight: bold; text-align: left">           Total Current Assets          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           64,925          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           10,088          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; text-indent: -0.125in">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left; text-indent: -0.125in">           Property and equipment, net of accumulated depreciation of $291 and $237          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           312          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           113          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left; text-indent: -0.125in">           Operating lease right-of-use assets          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           579          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           807          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left; text-indent: -0.125in">           Finance leases right-of-use assets          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           140          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           221          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left; text-indent: -0.125in">           Security deposit          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           50          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           50          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in">           Restricted cash          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           391          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           391          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -0.125in">           Total Assets          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; font-weight: bold; text-align: right">           66,397          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; font-weight: bold; text-align: left">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; font-weight: bold; text-align: right">           11,670          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; font-weight: bold; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; text-indent: -0.125in">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font-size: 10pt; font-weight: bold; text-align: center; text-indent: -0.125in">           Liabilities and Stockholders’ Equity          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; text-indent: -0.125in">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font-size: 10pt; font-weight: bold; text-align: left; text-indent: -0.125in">           Current Liabilities:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-indent: -0.125in; padding-left: 0.25in; font-size: 10pt; text-align: left">           Accounts payable and accrued expenses          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">           $          </td>          <td style="font-size: 10pt; text-align: right">           4,340          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">           $          </td>          <td style="font-size: 10pt; text-align: right">           4,598          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-indent: -0.125in; padding-left: 0.25in; font-size: 10pt; text-align: left">           Note payable          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           381          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-indent: -0.125in; padding-left: 0.25in; font-size: 10pt; text-align: left">           Operating leases current liability          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           342          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           286          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-indent: -0.125in; padding-left: 0.25in; font-size: 10pt; text-align: left; padding-bottom: 1.5pt">           Finance leases current liability          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           85          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           79          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-indent: -0.125in; padding-left: 0.375in; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">           Total Current Liabilities          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           4,767          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           5,344          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; text-indent: -0.125in">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-indent: -0.125in; padding-left: 0.25in; font-size: 10pt; text-align: left">           Long-term operating lease obligations          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           245          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           531          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-indent: -0.125in; padding-left: 0.25in; font-size: 10pt; text-align: left; padding-bottom: 1.5pt">           Long-term finance lease obligations          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           66          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           151          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in">           Total Liabilities          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           5,078          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           6,026          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; text-indent: -0.125in">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt; font-weight: bold; text-align: left; text-indent: -0.125in">           Commitments and contingencies          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; text-indent: -0.125in">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt; font-weight: bold; text-align: left; text-indent: -0.125in">           Stockholders’ Equity:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-indent: -0.125in; padding-left: 0.25in; font-size: 10pt; text-align: left">           Preferred stock, $0.001 par value; 50,000,000 shares authorized, 0 shares issued and outstanding          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.25in; font-size: 10pt; text-align: left; text-indent: -0.125in">           Common stock, $0.001 par value; 1,000,000,000 and 600,000,000 shares authorized; 17,532,893 and 5,490,038 shares issued and outstanding          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           18          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           5          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.25in; font-size: 10pt; text-align: left; text-indent: -0.125in">           Additional paid-in capital          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           292,275          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           214,397          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.25in; font-size: 10pt; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in">           Accumulated deficit          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           (230,974          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           (208,758          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.375in; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in">           Total Stockholders’ Equity          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           61,319          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           5,644          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; text-indent: -0.125in">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -0.125in">           Total Liabilities and Stockholders’ Equity          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; font-weight: bold; text-align: right">           66,397          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; font-weight: bold; text-align: left">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; font-weight: bold; text-align: right">           11,670          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; font-weight: bold; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        See accompanying notes to the consolidatedfinancial statements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <!-- Field: Page; Sequence: 55; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         2         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         Actinium Pharmaceuticals, Inc.         <br/>         Consolidated Statements of Operations        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">        <tbody>         <tr style="vertical-align: bottom">          <td style="padding-left: 0.125in; text-align: center; text-indent: -0.125in">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           For the Year ended           <br/>           December 31,          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="padding-left: 0.125in; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold; text-indent: -0.125in">           (amounts in thousands, except share and per share data)          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="padding-left: 0.125in; text-indent: -0.125in">          </td>          <td>          </td>          <td colspan="2">          </td>          <td>          </td>          <td>          </td>          <td colspan="2">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font-size: 10pt; font-weight: bold; text-indent: -0.125in">           Revenue          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">           $          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">           $          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; text-indent: -0.125in">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font-size: 10pt; font-weight: bold; text-align: left; text-indent: -0.125in">           Operating expenses:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.375in; width: 76%; font-size: 10pt; text-align: left; text-indent: -0.125in">           Research and development, net of reimbursements          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 9%; font-size: 10pt; text-align: right">           16,085          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 9%; font-size: 10pt; text-align: right">           16,550          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.375in; font-size: 10pt; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in">           General and administrative          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           6,308          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           5,522          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.25in; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in">           Total operating expenses          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           22,393          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           22,072          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; text-indent: -0.125in">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in">           Loss from operations          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           (22,393          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           (22,072          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; text-indent: -0.125in">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt; font-weight: bold; text-align: left; text-indent: -0.125in">           Other income:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.375in; font-size: 10pt; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in">           Interest income - net          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           178          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           172          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.25in; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in">           Total other income          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           178          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           172          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; text-indent: -0.125in">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -0.125in">           Net loss          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; font-weight: bold; text-align: right">           (22,215          </td>          <td style="padding-bottom: 2pt; font-size: 10pt; font-weight: bold; text-align: left">           )          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; font-weight: bold; text-align: right">           (21,900          </td>          <td style="padding-bottom: 2pt; font-size: 10pt; font-weight: bold; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; text-indent: -0.125in">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in">           Deemed dividend for warrant down-round protection provision          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           (1          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           (1          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -0.125in">           Net loss applicable to common stockholders          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; font-weight: bold; text-align: right">           (22,216          </td>          <td style="padding-bottom: 2pt; font-size: 10pt; font-weight: bold; text-align: left">           )          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; font-weight: bold; text-align: right">           (21,901          </td>          <td style="padding-bottom: 2pt; font-size: 10pt; font-weight: bold; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -0.125in">           Loss per common share - basic and diluted          </td>          <td style="font-size: 10pt; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">           (1.83          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">           (4.40          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; text-indent: -0.125in">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -0.125in">           Weighted average common shares outstanding - basic and diluted          </td>          <td style="font-size: 10pt; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">           12,134,259          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">           4,975,721          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        See accompanying notes to the consolidatedfinancial statements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <!-- Field: Page; Sequence: 56; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         3         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         Actinium Pharmaceuticals, Inc.         <br/>         Consolidated Statement of Changes in Stockholders’ Equity         <br/>         For the Years Ended December 31, 2020 and 2019         <br/>         (amounts in thousands, except share amounts)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">        <tbody>         <tr style="vertical-align: bottom">          <td style="padding-left: 0.125in; text-align: center; text-indent: -0.125in">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Common Stock          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold; text-align: center">           Additional Paid-In          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold; text-align: center">           Accumulated          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold; text-align: center">           Stockholders’          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="padding-left: 0.125in; text-align: center; text-indent: -0.125in">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Shares          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Amount          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Capital          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Deficit          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Equity          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; width: 40%; font-size: 10pt; font-weight: bold; text-indent: -0.125in">           Balance, January 1, 2019          </td>          <td style="width: 1%; font-size: 10pt; font-weight: bold">          </td>          <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">          </td>          <td style="width: 9%; font-size: 10pt; font-weight: bold; text-align: right">           3,856,768          </td>          <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt; font-weight: bold">          </td>          <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">           $          </td>          <td style="width: 9%; font-size: 10pt; font-weight: bold; text-align: right">           4          </td>          <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt; font-weight: bold">          </td>          <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">           $          </td>          <td style="width: 9%; font-size: 10pt; font-weight: bold; text-align: right">           195,666          </td>          <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt; font-weight: bold">          </td>          <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">           $          </td>          <td style="width: 9%; font-size: 10pt; font-weight: bold; text-align: right">           (186,857          </td>          <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">           )          </td>          <td style="width: 1%; font-size: 10pt; font-weight: bold">          </td>          <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">           $          </td>          <td style="width: 9%; font-size: 10pt; font-weight: bold; text-align: right">           8,813          </td>          <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left; text-indent: -0.125in">           Stock-based compensation          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           13,143          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           1,295          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           1,295          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left; text-indent: -0.125in">           Sale of common stock and warrants, net of offering costs          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           1,535,334          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           1          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           15,931          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           15,932          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left; text-indent: -0.125in">           Issuance of common stock from exercise of warrants          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           84,793          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           1,504          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           1,504          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left; text-indent: -0.125in">           Deemed dividend for warrant down-round protection provision          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           1          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           (1          </td>          <td style="font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in">           Net loss          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           (21,900          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           (21,900          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt; text-indent: -0.125in">           Balance, December 31, 2019          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: right">           5,490,038          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold; text-align: left">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: right">           5          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold; text-align: left">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: right">           214,397          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold; text-align: left">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: right">           (208,758          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold; text-align: left">           )          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: right">           5,644          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left; text-indent: -0.125in">           Stock-based compensation          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           6,262          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           1,254          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           1,254          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left; text-indent: -0.125in">           Sale of common stock and warrants, net of offering costs          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           8,575,051          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           9          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           76,580          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           76,589          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left; text-indent: -0.125in">           Issuance of common stock from exercise of pre-funded warrants          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           3,458,929          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           4          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           6          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           10          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left; text-indent: -0.125in">           Issuance of common stock from exercise of warrants          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           2,613          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           37          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           37          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left; text-indent: -0.125in">           Deemed dividend for warrant down-round protection provision          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           1          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           (1          </td>          <td style="font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in">           Net loss          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           (22,215          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           (22,215          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt; font-weight: bold; padding-bottom: 4pt; text-indent: -0.125in">           Balance, December 31, 2020          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; font-weight: bold; text-align: right">           17,532,893          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; font-weight: bold; text-align: left">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; font-weight: bold; text-align: right">           18          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; font-weight: bold; text-align: left">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; font-weight: bold; text-align: right">           292,275          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; font-weight: bold; text-align: left">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; font-weight: bold; text-align: right">           (230,974          </td>          <td style="padding-bottom: 2pt; font-size: 10pt; font-weight: bold; text-align: left">           )          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; font-weight: bold; text-align: right">           61,319          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; font-weight: bold; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        See accompanying notes to the consolidatedfinancial statements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <!-- Field: Page; Sequence: 57; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         4         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         Actinium Pharmaceuticals, Inc.         <br/>         Consolidated Statements of Cash Flows        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: center">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           For the Year ended           <br/>           December 31,          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="padding-bottom: 1.5pt; font-weight: bold">           (amounts in thousands)          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-weight: bold">           Cash Flows from Operating Activities:          </td>          <td>          </td>          <td colspan="2" style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 0.25in">           Net loss          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           (22,215          </td>          <td style="width: 1%; text-align: left">           )          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           (21,900          </td>          <td style="width: 1%; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">           Adjustments to reconcile net loss to net cash used in operating activities:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">           Stock-based compensation expense          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1,254          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1,295          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">           Depreciation and amortization expense          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           447          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           420          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">           Changes in operating assets and liabilities:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">           Decrease in:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; text-indent: -9pt; padding-left: 0.5in">           Prepaid expenses and other current assets          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (531          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           253          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">           Increase (decrease) in:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; text-indent: -9pt; padding-left: 0.5in">           Accounts payable and accrued expenses          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (257          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (1,255          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.5in">           Operating lease liabilities          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (315          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (275          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">           Net Cash Used In Operating Activities          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (21,617          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (21,462          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-indent: -9pt; padding-left: 9pt">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">           Cash Flows from Investing Activities:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">           Purchase of property and equipment          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (253          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (64          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">           Net Cash Used In Investing Activities          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (253          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (64          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-indent: -9pt; padding-left: 9pt">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">           Cash Flows from Financing Activities:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">           Payments on note payable          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (381          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (249          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">           Payments on finance leases          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (79          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (73          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">           Proceeds from sales of shares of common stock and warrants, net of offering costs          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           76,589          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           15,932          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">           Proceeds from the exercise of warrants          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           47          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           1,504          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">           Net Cash Provided By Financing Activities          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           76,176          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           17,114          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-indent: -9pt; padding-left: 9pt">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">           Net change in cash, cash equivalents and restricted cash          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           54,306          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (4,412          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">           Cash, cash equivalents and restricted cash at beginning of year          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           9,693          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           14,105          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">           Cash, cash equivalents and restricted cash at end of year          </td>          <td style="font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">           63,999          </td>          <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">           9,693          </td>          <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-indent: -9pt; padding-left: 9pt">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">           Supplemental disclosures of cash flow information:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">           Cash paid for interest          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           8          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           26          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">           Cash paid for taxes          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           -          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           -          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-indent: -9pt; padding-left: 9pt">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">           Supplemental disclosure of non-cash investing and financing activities:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">           Prepaid expenses financed by accounts payable          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           753          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           423          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">           Deemed dividend for warrant down-round protection provision          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           1          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           1          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        See accompanying notes to the consolidatedfinancial statements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <!-- Field: Page; Sequence: 58; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         5         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         Actinium Pharmaceuticals, Inc.         <br/>         Notes to Consolidated Financial Statements        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Note 1 - Description of Business andSummary of Significant Accounting Policies        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <b>         Nature of Business-        </b>        Actinium Pharmaceuticals, Inc. (the “Company”, “Actinium”, or “We”) is a clinical-stage,biopharmaceutical company focused on developing and potentially commercializing therapies for targeted conditioning prior to celltherapies such as a BMT or Bone Marrow Transplant or CAR-T,        <font style="background-color: white">         a type of cellular therapy thatgenetically alters a patient’s own T cells to target and kill their cancer cells,        </font>        and for other adoptive cell therapies.In addition, the Company is also developing potential therapies for targeting and killing of cancer cells either as single agentsor in combination with other drugs.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <b>         Principles of Consolidation-        </b>        The consolidated financial statements include the Company’s accounts and those of the Company’s wholly ownedsubsidiaries. All significant intercompany accounts and transactions have been eliminated.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <b>         Use of Estimatesin Financial Statement Presentation -        </b>        The preparation of these consolidated financial statements in conformity with accountingprinciples generally accepted in the United States of America requires management to make estimates and assumptions that affectthe reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts ofexpenses during the reporting period. Actual results could differ from those estimates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <b>         Reverse Stock Split        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In August 2020, theCompany effected a reverse stock split of its outstanding common stock by combining outstanding shares of common stock into a lessernumber of outstanding shares of common stock by a ratio of 1-for-30. Accordingly, all common share and per common share data inthese consolidated financial statements and related notes hereto have been retroactively adjusted to account for the effect ofthis reverse stock split for all periods presented.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <b>         Impact of COVID–19Pandemic on Financial Statements        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In December 2019, anovel strain of COVID-19 was reported in China. Since then, COVID-19 has spread globally. The spread of COVID-19 from China toother countries has resulted in the World Health Organization (“WHO”) declaring the outbreak of COVID-19 as a “pandemic,”or a worldwide spread of a new disease, on March 11, 2020. Many countries around the world have imposed quarantines and restrictionson travel and mass gatherings to slow the spread of the virus and have closed non-essential businesses, and many local jurisdictionscontinue to have such restrictions in place.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        As local jurisdictionscontinue to put restrictions in place, the Company’s ability to continue to operate its business may also be limited. Suchevents may result in a period of business, supply and drug product manufacturing disruption, and in reduced operations, any ofwhich could materially affect the Company’s business, financial condition and results of operations. In response to COVID-19,the Company implemented remote working and thus far, has not experienced a significant disruption or delay in its operations asit relates to the clinical development or drug production of our drug candidates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 59; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         6         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The spread of COVID-19,which has caused a broad impact globally, may materially affect the Company economically. While the ultimate economic impact broughtby, and the duration of, the COVID-19 pandemic may be difficult to assess or predict, including new information which may emergeconcerning the severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among others, the pandemic has resultedin significant disruptions in the general commercial activity and the global economy and caused financial market volatility anduncertainty in significant and unforeseen ways in the recent months. A continuation or worsening of the levels of market disruptionand volatility seen in the recent past could have an adverse effect on the Company’s ability to access capital, which couldin the future negatively affect the Company’s liquidity. In addition, a recession or market correction resulting from thespread of COVID-19 could materially affect the Company’s business and the value of the Company’s common stock.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Additionally, COVID-19may result in delays in receiving approvals from local and foreign regulatory authorities, delays in necessary interactions withIRB’s or Institutional Review Boards, local and foreign regulators, ethics committees and other important agencies and contractorsdue to limitations in employee resources or forced furlough of government employees.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        To date, COVID-19 hasnot had a financial impact on the Company. However, COVID-19 has caused severe disruptions in transportation and limited accessto the Company’s facility, resulting in limited support from its staff and professional advisors. The Company continues tomonitor the impacts of COVID-19 on the global economy and on its business operations. However, at this time, it is difficult topredict how long the potential operational impacts of COVID-19 will last or to what degree further disruption might impact theCompany’s operations and financial results.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <b>         Cash and Cash Equivalents-        </b>        The Company considers all highly liquid accounts with original maturities of three months or less to be cash equivalents.Balances held by the Company are typically in excess of Federal Deposit Insurance Corporation insured limits.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Following is a summaryof cash, cash equivalents and restricted cash at December 31, 2020 and December 31, 2019:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">        <tbody>         <tr style="vertical-align: bottom">          <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold; text-align: justify">           (in thousands)          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           December 31,           <br/>           2020          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           December 31,           <br/>           2019          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%; font-size: 10pt; text-align: justify">           Cash and cash equivalents          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 9%; font-size: 10pt; text-align: right">           63,560          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 9%; font-size: 10pt; text-align: right">           9,254          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: justify">           Restricted cash – current          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           48          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           48          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: justify; padding-bottom: 1.5pt">           Restricted cash – long-term          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           391          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           391          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: justify; padding-bottom: 4pt">           Cash, cash equivalents and restricted cash          </td>          <td style="font-size: 10pt; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">           63,999          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">           9,693          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Current restrictedcash relates to credit card accounts, while long-term restricted cash relates to a certificate of deposit held as collateral fora letter of credit issued in connection with the Company’s lease for corporate office space.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <b>         Property and Equipment-        </b>        Machinery and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives of threeto five years. Furniture and fixtures are recorded at cost and depreciated on a straight-line basis over estimated useful livesof seven years. When assets are retired, the cost and related accumulated depreciation are removed from the accounts, and any relatedgain or loss is reflected in operations. Repairs and maintenance expenditures are charged to operations. Capitalized lease assetsare recorded at the lesser of the present value of minimum lease payments or fair value and amortized over the estimated usefullife of the related property or term of the lease.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <b>         Leases        </b>        –The Company has operating and finance leases for corporate office space, office equipment and furniture located at the corporateoffice space. Leases with an initial term of 12 months or less are not recorded on the balance sheet; lease expense for these leasesis recognized on a straight-line basis over the lease term.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 60; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         7         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <b>         Fair Value of FinancialInstruments -        </b>        Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability,in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that givesthe highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservableinputs.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <b>         Income Taxes -        </b>        The Company accounts for income taxes in accordance with FASB ASC 740 Income Taxes, which requires the asset and liability methodto calculate deferred taxes. Deferred taxes are recognized based on the differences between the financial reporting and incometax bases of assets and liabilities using the enacted tax rates and laws that will be in effect when the differences are expectedto reverse. The Company reviews deferred tax assets for a valuation allowance based upon whether it is more likely than not thatthe deferred tax asset will be fully realized.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        FASB ASC 740 prescribesguidance for the financial statement recognition, measurement and disclosure of uncertain tax positions. Tax positions must meeta “more-likely-than-not” recognition threshold to be recognized. There were no tax positions for which it is consideredreasonably possible that the total amounts of unrecognized tax benefits will significantly increase or decrease within the nextyear. The Company recognizes interest related to unrecognized tax benefits in interest expense and penalties in operating expenses       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <b>         Revenue Recognition        </b>        - Revenue will be recognized when control of the promised goods or services is transferred to customers in an amount that reflectsthe consideration expected to be entitled to in exchange for those goods or services        <b>         .        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <b>         Research and DevelopmentCosts -        </b>        Research and development costs are expensed as incurred. These costs include the costs of manufacturing drug product,the costs of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to facilitiesand equipment. Research and development reimbursements are recorded by the Company as a reduction of research and development costs.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <b>         Share-Based Payments-        </b>        The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricingmodel. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employeeis required to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <b>         Loss Per CommonShare        </b>        - Basic loss per common share is computed by dividing the net loss available to common stockholders by the weighted averagenumber of common shares outstanding during the reporting period. For periods of net income, and when the effects are not anti-dilutive,diluted earnings per share is computed by dividing net income available to common stockholders by the weighted-average number ofshares outstanding plus the impact of all potential dilutive common shares, consisting primarily of common shares underlying commonstock options and warrants using the treasury stock method. For periods of net loss, diluted loss per share is calculated similarlyto basic loss per share because the impact of all potential dilutive common shares is anti-dilutive. For the years ended December31, 2020 and 2019, the Company’s potentially dilutive shares, which include outstanding common stock options and warrantshave not been included in the computation of diluted net loss per share as the result would have been anti-dilutive.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">        <tbody>         <tr style="vertical-align: bottom">          <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold; text-align: justify">           (in thousands)          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           December 31,           <br/>           2020          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           December 31,           <br/>           2019          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%; font-size: 10pt; text-align: justify">           Options          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 9%; font-size: 10pt; text-align: right">           815          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 9%; font-size: 10pt; text-align: right">           380          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: justify; padding-bottom: 1.5pt">           Warrants          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           2,113          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           2,871          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: justify; padding-bottom: 4pt">           Total          </td>          <td style="font-size: 10pt; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">           2,928          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">           3,251          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <b>         Subsequent Events        </b>        - The Company’s management reviewed all material events through the date the consolidated financial statements were issuedfor subsequent event disclosure consideration.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 61; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         8         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <b>         Accounting StandardsRecently Adopted        </b>        -       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In August 2018, FASBissued ASU 2018-13,        <i>         Fair Value Measurement - Disclosure Framework (Topic 820).        </i>        The updated guidance improves the disclosurerequirements on fair value measurements, primarily associated with Level 3 fair value measurements and is effective for fiscalyears, and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted upon issuanceof the standard for disclosures modified or removed with a delay of adoption of the additional disclosures until their effectivedate. The Company adopted this standard effective January 1, 2020 and the standard did not have a significant impact to the Company’sfinancial statements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In November 2018, FASBissued ASU 2018-18, C        <i>         ollaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606,        </i>        which,among other things, provides guidance on how to assess whether certain collaborative arrangement transactions should be accountedfor under Topic 606. The amendments in this ASU are effective for fiscal years, and interim periods within those fiscal years,beginning after December 15, 2019, with early adoption permitted. The Company adopted this standard effective January 1, 2020and the standard did not have a significant impact to the Company’s financial statements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <b>         Recent Accounting Standards –        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In August 2018, FASBissued ASU 2018-13,        <i>         Fair Value Measurement - Disclosure Framework (Topic 820).        </i>        The updated guidance improves the disclosurerequirements on fair value measurements and is effective for fiscal years, and interim periods within those fiscal years, beginningafter December 15, 2019. Early adoption is permitted upon issuance of the standard for disclosures modified or removed with a delayof adoption of the additional disclosures until their effective date. The Company is in the process of evaluating the impact thestandard will have on its financial statements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In November 2018, FASBissued ASU 2018-18, C        <i>         ollaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606,        </i>        which, among other things, provides guidance on how to assess whether certain collaborative arrangement transactions should beaccounted for under Topic 606. The amendments in this ASU are effective for fiscal years, and interim periods within those fiscalyears, beginning after December 15, 2019, with early adoption permitted. The Company is in the process of evaluating the impactthe standard will have on its financial statements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <b>         Accounting StandardsRecently Issued-        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In August 2020, FASBissued ASU 2020-06,        <i>         Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contractsin Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity        </i>        ,which, among other things, provides guidance on how to account for contracts on an entity’s own equity. This ASU simplifiesthe accounting for certain financial instruments with characteristics of liabilities and equity. Specifically, the ASU eliminatedthe need for the Company to assess whether a contract on the entity’s own equity (1) permits settlement in unregistered shares,(2) whether counterparty rights rank higher shareholder’s rights, and (3) whether collateral is required. In addition, theASU requires incremental disclosure related to contracts on the entity’s own equity and clarifies the treatment of certainfinancial instruments accounted for under this ASU on earnings per share. This ASU may be applied on a full retrospective of modifiedretrospective basis. This ASU is effective January 1, 2022 and interim periods presented. Early adoption of the ASU is permittedby the Company effective January 1, 2021. The Company is in the process of assessing the adoption of the ASU on the Company’sfinancial statements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Note 2 - Prepaid Expenses and OtherCurrent Assets        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Prepaid expenses andother current assets consisted of the following at December 31, 2020 and 2019:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">        <tbody>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="font-size: 10pt; font-weight: bold">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center">           December 31,          </td>          <td style="font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center">           December 31,          </td>          <td style="font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%; font-size: 10pt; text-align: left">           Prepaid insurance          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 9%; font-size: 10pt; text-align: right">           792          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 9%; font-size: 10pt; text-align: right">           480          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">           Prepaid clinical trial expenses          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           457          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           236          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt">           Other prepaid expenses and other current assets          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           68          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           70          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left; padding-bottom: 4pt">           Total prepaid expenses and other current assets          </td>          <td style="font-size: 10pt; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">           1,317          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">           786          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 62; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         9         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Note 3 - Property and Equipment        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Property and equipmentconsisted of the following at December 31, 2020 and 2019:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">        <tbody>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td style="font-size: 10pt; font-weight: bold">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center">           December 31,          </td>          <td style="font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center">           December 31,          </td>          <td style="font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="padding-bottom: 1.5pt; font-size: 10pt">           <font style="font-size: 10pt">            <b>             (in thousands)            </b>           </font>          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Lives          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 64%; font-size: 10pt; text-align: left">           Lab equipment          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 11%; font-size: 10pt; text-align: center">           5 years          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 9%; font-size: 10pt; text-align: right">           378          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 9%; font-size: 10pt; text-align: right">           148          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">           Office equipment &amp; furniture          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: center">           3 - 7 years          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           225          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           202          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt">           Less: accumulated depreciation          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="text-align: right; padding-bottom: 1.5pt">          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           (291          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           (237          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 4pt">           Property and equipment, net          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="text-align: right; padding-bottom: 4pt">          </td>          <td style="font-size: 10pt; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">           312          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">           113          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Depreciation expenseconsisted of the following for the years ended December 31, 2020 and 2019, respectively:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">        <tbody>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="font-size: 10pt; font-weight: bold">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center">           December 31,          </td>          <td style="font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center">           December 31,          </td>          <td style="font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">           (in thousands)          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%; font-size: 10pt; text-align: left">           Research &amp; development          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 9%; font-size: 10pt; text-align: right">           36          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 9%; font-size: 10pt; text-align: right">           32          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt">           General administrative          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           18          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           22          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-bottom: 4pt">           Total Depreciation expense          </td>          <td style="font-size: 10pt; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">           54          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">           54          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Note 4 - Leases        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company adoptedASC 842 as of January 1, 2019, using a modified retrospective approach and applying the standard’s transition provisionsat January 1, 2019, the effective date. The Company made an accounting policy election to exclude from balance sheet reportingthose leases with initial terms of 12 months or less.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company determinesif an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Companythe right to control the use of a fixed asset for a period of time in exchange for consideration. Control of an underlying assetis conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economicbenefits from using the underlying asset. The Company has lease agreements which include lease and non-lease components, whichthe Company has elected to account for as a single lease component for all classes of underlying assets. Lease expense for variablelease components are recognized when the obligation is probable.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Right-of-use assetsand liabilities are recognized at commencement date based on the present value of lease payments over the lease term. ASC 842 requiresa lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readilydetermined, its incremental borrowing rate. As an implicit interest rate was not readily determinable in the Company’s leases,the incremental borrowing rate was used based on the information available at commencement date in determining the present valueof lease payments.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The lease term forall of the Company’s leases includes the non-cancellable period of the lease plus any additional periods covered by eithera Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option toextend (or not to terminate) the lease controlled by the lessor. Options for lease renewals have been excluded from the lease term(and lease liability) for the majority of the Company’s leases as the reasonably certain threshold is not met.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        At December 31, 2020,the Company has an operating lease for corporate office space and two finance leases for office equipment and furniture locatedin the corporate office space. In addition, the Company has auxiliary corporate office space that it rents on a month-to-monthbasis; this rental is accounted for as an operating lease with the same term as the Company’s main office in the same building.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 63; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         10         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        The components of lease expense are as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">        <tbody>         <tr style="vertical-align: bottom">          <td style="padding-bottom: 1.5pt; font-weight: bold">           (in thousands)          </td>          <td style="font-weight: bold">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           Year ended           <br/>           December 31,           <br/>           2020          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           Year ended           <br/>           December 31,           <br/>           2019          </td>          <td style="font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-bottom: 4pt; width: 76%; text-align: left">           Operating lease expense          </td>          <td style="padding-bottom: 4pt; width: 1%">          </td>          <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; width: 9%; text-align: right">           372          </td>          <td style="padding-bottom: 4pt; width: 1%; text-align: left">          </td>          <td style="padding-bottom: 4pt; width: 1%">          </td>          <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; width: 9%; text-align: right">           369          </td>          <td style="padding-bottom: 4pt; width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left">           Finance lease cost          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; text-align: left">           Amortization of right-to-use assets          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           81          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           81          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-bottom: 1.5pt; padding-left: 0.125in; text-align: left">           Interest on lease liabilities          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           16          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           22          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-bottom: 4pt; text-align: left">           Total finance lease cost          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           97          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           103          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Supplemental cash flow informationrelated to leases are as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           Year ended          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="padding-bottom: 1.5pt; font-weight: bold">           (in thousands)          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-weight: bold">           <b>            December 31,            <br/>            2020           </b>          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           <b>            December 31,            <br/>            2019           </b>          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-weight: bold">           Cash flow information:          </td>          <td>          </td>          <td colspan="2">          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="text-align: center">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td colspan="2">          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="text-align: center">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           Cash paid for amounts included in the measurement of lease liabilities:          </td>          <td>          </td>          <td colspan="2">          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%; text-align: left">           Operating cash flow use from operating leases          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           375          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           356          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left">           Operating cash flow use from finance leases          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           16          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           22          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left">           Financing cash flow use from finance leases          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           78          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           73          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-weight: bold; text-align: left">           Non-cash activity:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left">           Right-of-use assets obtained in exchange for lease obligations:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left">           Operating leases          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           83          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           807          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left">           Finance Leases          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           221          </td>          <td style="text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0">        Weighted average remaining lease terms are as follows at December31, 2020:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">        <tbody>         <tr style="vertical-align: bottom; background-color: White">          <td>           Weighted average remaining lease term:          </td>          <td>          </td>          <td style="text-align: right">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 88%; text-align: left">           Operating leases          </td>          <td style="width: 1%">          </td>          <td style="width: 11%; text-align: right">           1.8 years          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left">           Finance Leases          </td>          <td>          </td>          <td style="text-align: right">           1.7 years          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        As the Company’sleases did not provide an implicit rate, the Company used its incremental borrowing rate based on the information available indetermining the present value of lease payments. The Company’s incremental borrowing rate was based on the term of the lease,the economic environment of the lease and reflect the rate the Company would have had to pay to borrow on a secured basis. Belowis information on the weighted average discount rates used at the time that the leases were evaluated:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">        <tbody>         <tr style="vertical-align: bottom">          <td>           Weighted average discount rates:          </td>          <td>          </td>          <td colspan="2" style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 88%; text-align: left">           Operating leases          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           8          </td>          <td style="width: 1%; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left">           Finance Leases          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           8          </td>          <td style="text-align: left">           %          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Maturities of leaseliabilities are as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">        <tbody>         <tr style="vertical-align: bottom">          <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: left; font-size: 10pt; font-weight: bold">           Year ending December 31,          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Operating           <br/>           Leases          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Finance           <br/>           Leases          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 70%; font-size: 10pt; text-align: left">           2021          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 12%; font-size: 10pt; text-align: right">           377          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 12%; font-size: 10pt; text-align: right">           94          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">           2022          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           252          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           64          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt">           2023          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           4          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left">           Total lease payments          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">           $          </td>          <td style="font-size: 10pt; text-align: right">           629          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">           $          </td>          <td style="font-size: 10pt; text-align: right">           162          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt">           Less imputed interest          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           (42          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           (11          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; text-align: left; font-size: 10pt; padding-bottom: 4pt">           Present value of lease liabilities          </td>          <td style="font-size: 10pt; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">           587          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">           151          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 64; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         11         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Note 5 - Commitments and Contingencies        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Agreements        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company has enteredinto agreements with third parties for the rights to certain intellectual property, manufacturing and clinical trial services underwhich the Company may incur obligations to make payments, including upfront payments, as well as milestone and royalty payments.Notable inclusions in this category are:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.25in">           <font style="font-size: 10pt">            a.           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            Oak Ridge National Laboratory (“ORNL”) – The Company is contracted to purchase radioactive material to be used for research and development, with a renewal option at the contract end. During the years ended December 31, 2020 and 2019, the Company purchased material from ORNL of $0.2 million and $0.2 million, respectively. In December 2020, the Company signed a contract with ORNL to purchase $0.3 million of radioactive material during calendar year 2021.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-size: 10pt">            b.           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            On June 15, 2012, the Company entered into a license and sponsored research agreement with Fred Hutchinson Cancer Research Center (“FHCRC”) to build upon previous and ongoing clinical trials with BC8 (licensed antibody). FHCRC has completed both a Phase 1 and Phase 2 clinical trial with BC8. The Company has been granted exclusive rights to the BC8 antibody and related master cell bank developed by FHCRC. A milestone payment of $1 million will be due to FHCRC upon FDA approval of the first drug utilizing the licensed BC 8 antibody. Upon commercial sale of the drug, royalty payments of 2% of net sales will be due to FHCRC.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Collaborative Agreement        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">        In March 2018, the Company entered intoa research and option agreement with Astellas Pharma Inc. (“Astellas”) to develop ARCs using the Company’s AWETechnology Platform. Under this collaboration, the Company will utilize its AWE Platform to conjugate and label selected Astellastargeting agents with an Actinium-225 payload. The Company is also responsible for conducting preclinical validation studies onany ARCs generated. Payments from Astellas under this agreement are accounted for as a reduction to research and development expense       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Note 6 - Equity        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        On April 24, 2020,the Company issued and sold 4.3 million shares of common stock and 2.8 million pre-funded warrants to purchase shares of commonstock. The price to the public in this offering for each share of common stock was $4.50 and for each pre-funded warrant was $4.497.Each pre-funded warrant had an exercise price of $0.003 per share and was exercisable immediately upon issuance. Gross proceedsfrom this offering were $31.6 million, before deducting underwriting discounts and commissions and other offering expenses payableby the Company. Net proceeds from this offering were $29.1 million.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        During the year endedDecember 31, 2020, holders of all of the 2.8 million pre-funded April 2020 warrants exercised their warrants at $0.003 per shareand received 2.8 million shares of common stock.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        On June 19, 2020, theCompany issued and sold 1.9 million shares of common stock and 0.7 million pre-funded warrants to purchase shares of common stock.The price to the public in this offering for each share of common stock was $9.75 and for each pre-funded warrant was $9.747. Eachpre-funded warrant had an exercise price of $0.003 per share and was exercisable immediately upon issuance. Gross proceeds fromthis offering were $25.0 million, before deducting underwriting discounts and commissions and other offering expenses payable bythe Company. Net proceeds from this offering were $23.0 million.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        During the year endedDecember 31, 2020, holders of all of the 0.7 million pre-funded June 2020 warrants exercised their warrants at $0.003 per shareand received 0.7 million shares of common stock.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 65; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         12         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In August 2020, theCompany entered into the Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC (“JonesTrading”),pursuant to which the Company may sell, from time to time, through or to JonesTrading, up to an aggregate of $200 million of itscommon stock. Shares of common stock are offered pursuant to the Company’s shelf registration statement on Form S-3 filedwith the SEC on August 7, 2020. As of December 31, 2020, the Company has sold 2.1 million shares of common stock, resulting ingross proceeds of $22.6 million and net proceeds of $21.7 million.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In December 2018, theCompany entered into the Amended and Restated At Market Issuance Sales Agreement with B. Riley FBR, Inc. and JonesTrading, pursuantto which the Company conducted its at-the market program. During the year ended December 31, 2020, the Company sold 0.3 millionshares of common stock through its at-the-market program, resulting in net proceeds of $2.5 million.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In October 2018, theCompany and Lincoln Park Capital Fund, LLC (“Lincoln Park”) entered into a purchase agreement and a registration rightsagreement, pursuant to which the Company has the right to sell to Lincoln Park shares of the Company’s common stock havingan aggregate value of up to $32.5 million, subject to certain limitations and conditions set forth in the agreement. During theyear ended December 31, 2020, the Company elected to sell to Lincoln Park 27 thousand shares and received $0.2 million.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In April 2019,the Company sold 1.4 million shares of common stock at an offering price of $11.55 per share and warrants to purchase 1.4 millionshares of common stock at an exercise price of $15.00 per share and with a term of 5 years, resulting in gross proceeds of $16.5million and net proceeds of $15.1 million after deducting underwriting and other offering expenses.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        For the yearended December 31, 2019, the Company sold 93 thousand shares of common stock through its at-the-market program with Jones Trading,resulting in net proceeds of $0.7 million. The Company elected to sell to Lincoln Park 13 thousand shares and received $0.1 million.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In March 2018, theCompany sold an aggregate of 1.0 million units consisting of an aggregate of 1.0 million shares of common stock, 0.3 million seriesA warrants and 0.8 million series B warrants, with each series A warrant exercisable for one share of common stock at an exerciseprice of $18.00 per share and each series B warrant exercisable for one share of common stock at an exercise price of $21.00 pershare. During the year ended December 31, 2019, holders of March 2018 series A warrants exercised 84 thousand shares, resultingin the Company receiving $1.5 million. The remaining March 2018 series A warrants expired in March 2019. The March 2018 SeriesB warrants expired in September 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         2019 Amended and Restated Stock Plan        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In December 2019, theCompany’s 2019 Stock Plan was established. The expiration date of the plan is October 18, 2029 and the total number of sharesof the Company’s common stock available for grant to employees, directors and consultants of the Company was 333,333 shares.At the Company’s Annual Meeting of Stockholders held on November 18, 2020, its stockholders authorized an increase in thenumber of shares authorized under the plan, resulting in the number of shares authorized in the plan to be 3,083,333 shares       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         2013 Amended and Restated Stock Plan        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In September 2013,the Company’s 2013 Stock Plan was established. The expiration date of the plan is September 9, 2023 and at the time of approval,the total number of shares of the Company’s common stock available for grant to employees, directors and consultants of theCompany under the plan was 91,666 shares. After a number of amendments approved by stockholders, the number of shares authorizedunder the plan is 758,333 shares.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 66; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         13         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         2013 Equity Incentive Plan        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In September 2013,the Company’s 2013 Equity Incentive Plan was established. The expiration date of the plan is September 9, 2023 and the totalnumber of shares of the Company’s common stock available for grant to employees, directors and consultants of the Companyunder the plan was 15,000 shares. In December 2013, the shareholders of the Company approved the plan and increased the numberof shares authorized under the plan to 33,333 shares.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Stock Options        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Following is a summaryof stock option activity for the years ended December 31, 2020 and 2019:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">        <tbody>         <tr style="vertical-align: bottom">          <td style="padding-bottom: 1.5pt; font-size: 10pt">           <b>            (in thousands, except for per-share amount)           </b>          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Number of           <br/>           Options          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Weighted           <br/>           Average           <br/>           Exercise           <br/>           Price          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Weighted           <br/>           Average           <br/>           Remaining           <br/>           Contractual           <br/>           Term           <br/>           (in years)          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Aggregate           <br/>           Intrinsic           <br/>           Value          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 52%; font-size: 10pt">           Outstanding, January 1, 2019          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 9%; font-size: 10pt; text-align: right">           241          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 9%; font-size: 10pt; text-align: right">           52.20          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 9%; font-size: 10pt; text-align: right">           7.97          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 9%; font-size: 10pt; text-align: right">           6,400          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt">           Granted          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           195          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           8.10          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font-size: 10pt; padding-bottom: 1.5pt">           Cancelled          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           (56          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: right">           14.40          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt; text-align: right">          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt; text-align: right">          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">           Outstanding, December 31, 2019          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           380          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           35.10          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           7.88          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           155          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font-size: 10pt">           Granted          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           458          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           9.99          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt; padding-bottom: 1.5pt">           Cancelled          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           (23          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: right">           16.84          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt; text-align: right">          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt; text-align: right">          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; padding-bottom: 4pt">           Outstanding, December 31, 2020          </td>          <td style="font-size: 10pt; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">           815          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: right">           21.53          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: right">           8.51          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: right">           120          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; padding-bottom: 4pt">           Exercisable, December 31, 2020          </td>          <td style="font-size: 10pt; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">           254          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: right">           45.98          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: right">           6.74          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: right">           41          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        During 2020, the Companygranted its employees and members of the Board of Directors options to purchase 458 thousand shares of common stock with an exerciseprice ranging from $6.63 to $12.41 per share, a term of 10 years, and a vesting period from 4 to 4.2 years. The options havean aggregated fair value of $3.2 million that was calculated using the Black-Scholes option-pricing model. Variables used in theBlack-Scholes option-pricing model include: (1) discount rate range from 0.34% to 0.56% (2) expected life of 6 years, (3) expectedvolatility range from 83.6% to 85.5%, and (4) zero expected dividends.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        During 2019, the Companygranted its employees and members of the Board of Directors options to purchase 195 thousand shares of common stock with an exerciseprice ranging from $6.44 to $17.40 per share, a term of 10 years, and a vesting period from 4 to 4.2 years. The options havean aggregated fair value of $1.1 million that was calculated using the Black-Scholes option-pricing model. Variables used in theBlack-Scholes option-pricing model include: (1) discount rate range from 1.38% to 2.6% (2) expected life of 6 years, (3) expectedvolatility range from 78.5% to 81.8%, and (4) zero expected dividends.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        During the years endedDecember 31, 2020 and 2019, options to purchase 23 thousand and 56 thousand common shares were cancelled, respectively, upon thetermination of employment. There were no exercises of options during 2020 and 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The fair values ofall options issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expenseat December 31, 2020 was $4.0 million related to unvested options, which is expected to be expensed over a weighted average of3.3 years. During 2020 and 2019, the Company recorded total option expense of $1.2 million and $1.2 million, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 67; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         14         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Pre-funded Warrants        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        As part of the financingsin April 2020 and June 2020, the Company issued pre-funded warrants. Each pre-funded warrant had an exercise price of $0.003 pershare and was exercisable immediately upon issuance. The pre-funded warrants did not have an expiration date. During 2020 all thepre-funded warrants were exercised for shares of common stock.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Following is a summaryof pre-funded warrant activity for the year ended December 31, 2020:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">           (in thousands, except for per-share amounts)          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Number of Shares          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Weighted           <br/>           Average           <br/>           Exercise           <br/>           Price          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Aggregate           <br/>           Intrinsic           <br/>           Value          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">           Outstanding, December 31, 2019          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">           $          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">           $          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="width: 64%; font-size: 10pt">           Granted          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 9%; font-size: 10pt; text-align: right">           3,459          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 9%; font-size: 10pt; text-align: right">           0.003          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font-size: 10pt; padding-bottom: 1.5pt">           Exercised          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           (3,459          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: right">           0.003          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt; text-align: right">          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt; padding-bottom: 4pt">           Outstanding, December 31, 2020          </td>          <td style="font-size: 10pt; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">           $          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">           $          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Warrants        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Following is a summaryof warrant activities for the years ended December 31, 2020 and 2019:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td style="white-space: nowrap">           <font style="font-size: 10pt">            <b>             (in thousands, except for per-share amounts)            </b>           </font>          </td>          <td style="white-space: nowrap">          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: black 1.5pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             Number of             <br/>             Warrants            </b>           </font>          </td>          <td style="white-space: nowrap">          </td>          <td style="white-space: nowrap">          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: black 1.5pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             Weighted             <br/>             Average             <br/>             Exercise             <br/>             Price            </b>           </font>          </td>          <td style="white-space: nowrap">          </td>          <td style="white-space: nowrap">          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: black 1.5pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             Weighted             <br/>             Average             <br/>             Remaining             <br/>             Contractual             <br/>             Term             <br/>             (in years)            </b>           </font>          </td>          <td style="white-space: nowrap">          </td>          <td style="white-space: nowrap">          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: black 1.5pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             Aggregate             <br/>             Intrinsic             <br/>             Value            </b>           </font>          </td>          <td style="white-space: nowrap">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="width: 52%">           <font style="font-size: 10pt">            Outstanding, January 1, 2019           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 9%; text-align: right">           <font style="font-size: 10pt">            1,861           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 9%; text-align: right">           <font style="font-size: 10pt">            36.00           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 9%; text-align: right">           <font style="font-size: 10pt">            2.04           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 9%; text-align: right">           <font style="font-size: 10pt">            569           </font>          </td>          <td style="width: 1%">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 0.125in">           <font style="font-size: 10pt">            Granted           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            1,430           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            15.00           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 0.125in">           <font style="font-size: 10pt">            Exercised           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            (85           </font>          </td>          <td>           <font style="font-size: 10pt">            )           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            17.70           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 0.125in">           <font style="font-size: 10pt">            Cancelled           </font>          </td>          <td>          </td>          <td style="border-bottom: black 1.5pt solid">          </td>          <td style="border-bottom: black 1.5pt solid; text-align: right">           <font style="font-size: 10pt">            (335           </font>          </td>          <td>           <font style="font-size: 10pt">            )           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            82.80           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-size: 10pt">            Outstanding, December 31, 2019           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            2,871           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            20.71           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            2.95           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            301           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 0.125in">           <font style="font-size: 10pt">            Granted           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 0.125in">           <font style="font-size: 10pt">            Exercised           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            (2           </font>          </td>          <td>           <font style="font-size: 10pt">            )           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            15.00           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 0.125in">           <font style="font-size: 10pt">            Cancelled           </font>          </td>          <td>          </td>          <td style="border-bottom: black 1.5pt solid">          </td>          <td style="border-bottom: black 1.5pt solid; text-align: right">           <font style="font-size: 10pt">            (756           </font>          </td>          <td>           <font style="font-size: 10pt">            )           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            20.99           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-size: 10pt">            Outstanding, December 31, 2020           </font>          </td>          <td>          </td>          <td style="border-bottom: black 4.5pt double">          </td>          <td style="border-bottom: black 4.5pt double; text-align: right">           <font style="font-size: 10pt">            2,113           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            20.55           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            2.76           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            362           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-size: 10pt">            Exercisable, December 31, 2020           </font>          </td>          <td>          </td>          <td style="border-bottom: black 4.5pt double">          </td>          <td style="border-bottom: black 4.5pt double; text-align: right">           <font style="font-size: 10pt">            2,111           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            20.56           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            2.76           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            362           </font>          </td>          <td>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In April 2019, theCompany sold 1.4 million shares of common stock at an offering price of $11.55 per share and warrants to purchase 1.4 million sharesof common stock at an exercise price of $15.00 per share and with a term of 5 years. The transaction date relative fair value ofthe April 2019 warrants of $5.3 million was determined utilizing the Black-Scholes option pricing model and variables of (1) adiscount rate of 2.35%, (2) expected term of 5 years, (3) expected volatility of 78% and (4) zero expected dividends.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In March 2018, theCompany sold an aggregate of 1.0 million units consisting of an aggregate of 1.0 million shares of common stock, 0.3 million seriesA warrants and 0.8 million series B warrants, with each series A warrant exercisable for one share of common stock at an exerciseprice of $18.00 per share and each series B warrant exercisable for one share of common stock at an exercise price of $21.00 pershare. During the year ended December 31, 2019, holders of March 2018 series A warrants exercised 84 thousand shares, resultingin the Company receiving $1.5 million. The remaining March 2018 series A warrants expired in March 2019. The March 2018 SeriesB warrants expired in September 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 68; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         15         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company has anoutstanding warrant to purchase 1,907 shares of common stock, issued on March 14, 2017 to Sandesh Seth, the Company’s Chairmanand Chief Executive Officer. The warrant included down-round protection up until it was amended on August 11, 2020. For warrantswith down-round protection, a deemed dividend is recorded for the change in fair value of the warrants when the down-round provisionis triggered. As a result of the April 2019 offering, the exercise price of the warrant was reset from $37.50 per share to $26.40per share. As a result of the April 2020 offering and June 2020 offering, the exercise price of the warrant was reset from $26.40per share to $15.61515 per share. The down-round protection provision in the above warrants created a deemed dividend to commonstockholders of $1 thousand in the years ended December 31, 2020 and 2019, which are reflected in the accompanying consolidatedstatement of operations and consolidated statement of changes in stockholders’ equity. On August 11, 2020, the Company andMr. Seth agreed to amend the warrant to remove the anti-dilution provision that had been in the warrant. Accordingly, pursuantto the amendment, as of August 11, 2020, the exercise price of the warrant will no longer be subject to a proportional adjustmentif and when the Company issues any shares of its common stock for a consideration less than the exercise price of the warrant.All other terms of the warrant remained the same.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        During the years endedDecember 31, 2020 and 2019, the Company recorded stock-based compensation expense related to warrants of $13 thousand and $8 thousand,respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">        <b>         Note 7 - Income Taxes        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Deferred income taxesreflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reportingpurposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets and liabilitiesat December 31, 2020 and 2019 are as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">        <tbody>         <tr style="vertical-align: bottom">          <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">           (in thousands)          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">           Deferred tax assets:          </td>          <td>          </td>          <td colspan="2" style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; width: 76%; font-size: 10pt; text-align: left">           Net operating losses carry forward          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 9%; font-size: 10pt; text-align: right">           33,955          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 9%; font-size: 10pt; text-align: right">           31,688          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left">           Share-based compensation          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           1,689          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           1,422          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left">           Research and development/orphan drug credits          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           12,638          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           10,872          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt">           Intangibles          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           7,873          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           5,942          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font-size: 10pt">           Others          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           19          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           13          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt">           Less: valuation allowance          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           (56,174          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           (49,937          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt">           Deferred tax assets, net          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company has recordeda valuation allowance of $56.2 million and $49.9 million against its deferred tax assets at December 31, 2020 and 2019, respectively,because management determined that it is not more-likely-than not that those assets will be realized.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        For federal incometax purposes, the Company has $152.0 million of unused net operating losses (“NOLs”) at December 31, 2020 availablefor carry forward to future years. NOLs generated prior to 2018 will begin to expire if unused in 2021. The NOLs generated in 2018and later years have an indefinite life, but will be limited to 80% of their value if used in a tax year ending after January 1,2021.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        For state income taxpurposes, the Company has $81.7 million of unused NOLs at December 31, 2020 available for carry forward to future years. TheseNOLs will begin to expire in 2034 if unused.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company has federalresearch and development tax credits of $2.2 million at December 31, 2020 which will begin to expire in 2034 if unused and orphandrug credits of $10.4 million which will begin to expire in 2028 if unused.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 69; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         16         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Federal and state taxlaws impose limitations on the utilization of net operating losses and credit carryforwards in the event of an ownership changefor tax purposes, as defined in Section 382 of the Internal Revenue Code. Accordingly, the Company’s ability to utilize thesecarryforwards may be limited as a result of an ownership change which may have already happened or may happen in the future. Suchan ownership change could result in a limitation in the use of the net operating losses in future years and possibly a reductionof the net operating losses available.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">        Thedifference between the income tax provision and the amount that would result if the U.S. Federal statutory rates were applied topre-tax losses for the year ended December 31, 2020 and 2019 are as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">        <tbody>         <tr style="vertical-align: bottom">          <td style="padding-bottom: 1.5pt; font-size: 10pt">           <b>            (in thousands)           </b>          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           December 31,           <br/>           2020          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           December 31,           <br/>           2019          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td colspan="2" style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 52%; font-size: 10pt; text-align: left">           Federal statutory income taxes          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 9%; font-size: 10pt; text-align: right">           (4,665          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           )          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 9%; font-size: 10pt; text-align: right">           (21.0          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           )%          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 9%; font-size: 10pt; text-align: right">           (4,599          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           )          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 9%; font-size: 10pt; text-align: right">           (21.0          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           )%          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">           State income taxes          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           56          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           0.3          </td>          <td style="font-size: 10pt; text-align: left">           %          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           1,077          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           4.9          </td>          <td style="font-size: 10pt; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left">           Deferred true-up          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           (64          </td>          <td style="font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           (0.3          </td>          <td style="font-size: 10pt; text-align: left">           )%          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           1,810          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           8.3          </td>          <td style="font-size: 10pt; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">           Research and Development/Orphan Drug Tax Credit          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           (1,766          </td>          <td style="font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           (8.0          </td>          <td style="font-size: 10pt; text-align: left">           )%          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           (1,975          </td>          <td style="font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           (9.0          </td>          <td style="font-size: 10pt; text-align: left">           )%          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">           Other          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           202          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           0.9          </td>          <td style="font-size: 10pt; text-align: left">           %          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           145          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           0.6          </td>          <td style="font-size: 10pt; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt">           Change in valuation allowance          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           6,237          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           28.1          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">           %          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           3,542          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">           16.2          </td>          <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 4pt">           Provision for income tax          </td>          <td style="font-size: 10pt; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Note 9 - Subsequent Events        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">        Since December 31, 2020,the Company has sold 1.7 million shares of common stock under its Capital on Demand™ Sales Agreement with JonesTrading, resultingin net proceeds of $14.4 million.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 70; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         17         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <a name="aph165213a014">        </a>        <b>         ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ONACCOUNTING AND FINANCIAL DISCLOSURE.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        None.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <a name="aph165213a015">        </a>        <b>         ITEM 9A. CONTROLS AND PROCEDURES.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <b>         <i>          Disclosure controlsand procedures.         </i>        </b>        The Company, under the supervision and with the participation of its management, including the Company’sprincipal executive officer and principal financial and accounting officer, evaluated the effectiveness of the Company’s“disclosure controls and procedures,” as such term is defined in Rule 13a-15(e) and 15d-15(e) under the SecuritiesAct of 1934, as amended (the “Exchange Act”), as of the end of the period covered by this Annual Report on Form 10-K.Based on that evaluation, the Company’s principal executive officer and principal financial and accounting officer have concludedthat the Company’s disclosure controls and procedures are effective as of December 31, 2020 to ensure that information requiredto be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized andreported within the time periods specified in Securities and Exchange Commission rules and forms, and includes controls and proceduresdesigned to ensure that information required to be disclosed by the Company in such reports is accumulated and communicated tothe Company’s management, including the Company’s principal executive officer and principal financial and accountingofficer, as appropriate, to allow timely decisions regarding required disclosure.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <b>         <i>          Management’sAnnual Report on Internal Control Over Financial Reporting.         </i>        </b>        The Company’s management is responsible for establishingand maintaining adequate internal control over financial reporting. The Company’s internal control over financial reportingis a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financialstatements for external purposes in accordance with generally accepted accounting principles.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company’sinternal control over financial reporting includes policies and procedures that (1) pertain to the maintenance of recordsthat, in reasonable detail, accurately and fairly reflect transactions and dispositions of assets; (2) provide reasonableassurances that transactions are recorded as necessary to permit preparation of financial statements in accordance with generallyaccepted accounting principles, and that receipts and expenditures are being made only in accordance with authorizations of managementand the directors of the Company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorizedacquisition, use or disposition of the Company’s assets that could have a material effect on our financial statements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Because of its inherentlimitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluationof effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions,or that the degree of compliance with the policies or procedures may deteriorate.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Management assessedthe effectiveness of the Company’s internal control over financial reporting as of December 31, 2020. In making this assessment,management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in InternalControl-Integrated Framework (2013). Based on our assessment and those criteria, management concluded that as of December 31, 2020,the Company’s internal control over financial reporting was effective.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        This Annual Reporton Form 10-K does not include an attestation report from our registered public accounting firm regarding internal control overfinancial reporting. Our internal control over financial reporting was not subject to such attestation as we are a non-acceleratedfiler.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <b>         <i>          Changes in internalcontrols over financial reporting         </i>         .        </b>        There were no changes in the Company’s internal controls over financial reportingthat occurred during the fourth quarter of the fiscal year covered by this Annual Report on Form 10-K that have materially affected,or are reasonably likely to materially affect, the Company’s internal control over financial reporting.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <a name="aph165213a016">         </a>         ITEM 9B. OTHER INFORMATION.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Item 5.03 Amendments to Articles of Incorporation orBylaws; Change in Fiscal Year.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        None.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 71; Options: NewSection; Value: 51 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         51         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <a name="aph165213a017">        </a>        <b>         PART III        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <a name="aph165213a018">        </a>        <b>         ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Directors and Executive Officers        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        The names, positions and ages of our directorsand executive officers as of March 31, 2021, are as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td style="border-bottom: black 1.5pt solid; width: 23%">           <font style="font-size: 10pt">            <b>             Name            </b>           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 8%; border-bottom: black 1.5pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             Age            </b>           </font>          </td>          <td style="width: 1%">          </td>          <td style="border-bottom: black 1.5pt solid; width: 67%">           <font style="font-size: 10pt">            <b>             Position            </b>           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-size: 10pt">            Sandesh Seth           </font>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-size: 10pt">            56           </font>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            Chairman and Chief Executive Officer           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-size: 10pt">            Mark S. Berger, M.D.           </font>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-size: 10pt">            66           </font>          </td>          <td>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            Chief Medical Officer           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-size: 10pt">            Dale L. Ludwig, Ph.D.           </font>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-size: 10pt">            59           </font>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            Chief Scientific and Technology Officer           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-size: 10pt">            Steve O’Loughlin           </font>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-size: 10pt">            36           </font>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            Chief Financial Officer (Principal Financial and Accounting Officer)           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-size: 10pt">            Jeffrey W. Chell M.D.           </font>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-size: 10pt">            66           </font>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            Director           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-size: 10pt">            David Nicholson, Ph.D.           </font>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-size: 10pt">            65           </font>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            Lead Independent Director           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-size: 10pt">            Richard I. Steinhart           </font>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-size: 10pt">            63           </font>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            Director           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-size: 10pt">            Ajit S. Shetty, Ph.D.           </font>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-size: 10pt">            74           </font>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            Director           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        Subject to the classified board provisionsof our Charter, all directors hold office until the next annual meeting of stockholders and the election and qualification of theirsuccessors. Officers are elected annually by the Board of Directors and serve at the discretion of the Board of Directors.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        There are no other arrangements orunderstanding between any of our directors and any other persons pursuant to which they were selected as a director.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Background of Executive Officers and Directors        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The principal occupationsfor the past five years (and, in some instances, for prior years) of each of our directors and executive officers are as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Sandesh Seth, Chairman and Chief Executive Officer        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        Mr. Sandesh Seth has been our Chief ExecutiveOfficer since June 2017. Mr. Seth has been a Director since March 2012, our Chairman of the Board since October 2013, and servedas Executive Chairman from August 2014 to June 2017.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        Mr. Seth has 25+ years of experience ininvestment banking (Laidlaw&amp; Co (UK) Ltd., Cowen &amp; Co.), equity research (Bear Stearns, Commonwealth Associates) and inthe pharma industry (Pfizer, Warner-Lambert, SmithKline in strategic planning, business development and R&amp;D project management).Mr. Seth was chairman of Relmada Therapeutics Inc., a specialty pharma company focused on CNS therapeutics, which he helped co-found.Mr. Seth has an MBA in Finance from New York University; an M.S. in the Pharmaceutical Sciences from the University of OklahomaHealth Center and a B.Sc. in Chemistry from Bombay University. He has published several scientific articles and was awarded theUniversity Regents Award for Research Excellence at the University of Oklahoma. Mr. Seth was designated as Regulatory Affairs Certifiedby the Regulatory Affairs Professionals Society which signifies proficiency with U.S. FDA regulations. He has several patents relatedto use of radiopharmaceuticals as conditioning agents for adoptive cell therapies and as therapeutic combinations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 72; Value: 51 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         52         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        That Mr. Seth has servedin various business executive-level positions over the course of his career, has significant investment banking experience, hasdeveloped significant management, operational and leadership skills and is well accustomed to interfacing with investors, analysts,auditors, C-level executives, and outside advisors, led us to conclude that Mr. Seth should serve as a director.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Mark S. Berger, MD., Chief Medical Officer        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        Dr. Berger has been our Chief Medical Officersince January 2017. From September 2013 to January 2017, Dr. Berger worked for Kadmon Corporation where he was senior vice president,clinical research. In this role he was responsible for all clinical aspects of new drug development including designing and managingclinical trials in oncology indications (non-small cell lung cancer and glioblastoma) and non-oncology indications (chronic graftversus host disease and polycystic kidney disease). Dr. Berger joined Kadmon after serving as chief medical officer of DecipheraPharmaceuticals (“Deciphera”) from June 2011 to September 2013. Prior to Deciphera, Dr. Berger was vice president forclinical development at Gemin X Pharmaceuticals (“Gemin X”) where he led the clinical strategy, design and managementof clinical trials for two novel oncology agents including obatoclax, a pan Bcl-2 inhibitor. Based on the results of a randomizedPhase 2 clinical trial of obatoclax, Gemin X was acquired by Cephalon in March of 2011 for a total consideration of $525 millionincluding $225 million in an upfront cash payment.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        Before his work with biotechnology companies,Dr. Berger held key positions in two global pharmaceutical companies. Dr. Berger previously served as group director, medicinedevelopment centre-oncology for GlaxoSmithKline. In this position Dr. Berger managed the development of Tykerb (lapatinib) in lungand breast cancer where he designed and led two Phase 2 clinical trials before planning and leading a 399 patient pivotal Phase3 trial that resulted in the FDA approval of Tykerb in breast cancer. In addition, he managed the Lapatinib Expanded Access Programthat enrolled over 4000 patients on a global basis. Dr. Berger began his career in drug development at Wyeth Research where heled the planning and execution of the pivotal Phase 2 trial for Mylotarg, which was the first antibody targeted chemotherapy agentand targeted CD33, similar to Actimab-A. He presented the Mylotarg clinical data at the FDA’s Oncology Drug Advisory Committeemeeting, after which Mylotarg received accelerated FDA approval for patients with relapsed AML.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        Dr. Berger has a B.A. in biology from WesleyanUniversity and received his M.D. from the University of Virginia School of Medicine. He did his Hematology-Oncology fellowshipat the University of Pennsylvania where he was an Assistant Professor of Medicine, and also was a Research Fellow at the LudwigInstitute for Cancer Research and the Imperial Cancer Research Fund, both in London. Dr. Berger is board certified in internalmedicine, hematology and medical oncology.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Dale L. Ludwig, Ph.D., Chief Scientific and Technology Officer        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        Dr. Ludwig joined Actinium in January 2018.Dr. Ludwig has worked for 20 years in oncology antibody drug discovery and development at Eli Lilly and Company (“Eli Lilly”)and at ImClone Systems, Inc., until its acquisition by Eli Lilly where he supported the development and successful launch of severalbiologic oncology drugs including Erbitux®, CyramzaTM, Portrazza®, and LartruvoTM as well as the clinical advancement of10 additional therapeutic antibodies. Most recently, Dr. Ludwig served as chief scientific officer/vice president of Oncology DiscoveryResearch - Biologics Technology. In this role he was responsible for directing antibody discovery and development for oncologybiologics and contributed to key strategic and project advancement efforts. Dr. Ludwig was a member of the Oncology Research SeniorLeadership Team and directed the empowered antibody drug discovery programs that included collaborations with Immunogen and Zymeworks.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        Prior to the acquisition of Imclone by EliLilly, Dr. Ludwig served as head of molecular &amp; cellular engineering at IMClone Systems Inc. In this capacity, Dr. Ludwig servedas core team leader for several IND filings and Phase 1 advancements for novel antibodies. In addition, he directed and oversawthe full spectrum of drug development including antibody discovery, screening, selection, engineering, optimization, cloning andexpression. He was also tasked with establishing meaningful preclinical collaborations with key academic investigators and industryleaders. Post-acquisition he was the research representative to the ImClone-Lilly Transition Team.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 73; Value: 51 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         53         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        Before his work in the biotechnology industry,Dr. Ludwig trained as a postdoctoral associate in the DNA Damage and Repair Group of the Los Alamos National Laboratory and asa postdoctoral fellow in the Department of Molecular Genetics, Biochemistry and Microbiology at the University of Cincinnati Collegeof Medicine. Dr. Ludwig has a B.S. in biology with a concentration in microbiology from James Madison University and received hisPh.D. in Microbiology from East Carolina University.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Steve O’Loughlin, Chief Financial Officer        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        Steve O’Loughlin has been our ChiefFinancial Officer since August 2020. Mr. O’Loughlin served as our Principal Financial Officer from May 2017 to August 2020.Mr. O’Loughlin joined Actinium in October 2015 as Vice President, Finance and Corporate Development, with almost a decadeof life sciences industry experience gained from previous positions in investment banking and publicly traded life sciences companies.Prior to Actinium, from June 2015 to October 2015, Mr. O’Loughlin worked at J. Streicher LLC as an investment banker, fromAugust 2012 to June 2015 Mr. O’Loughlin held the position of vice president, corporate finance and development and was acorporate officer at Protea Biosciences, Inc., a publicly traded life sciences tools company. Previously, From June 2010 to June2012, Mr. O’Loughlin held corporate development positions with Caliber I.D., a publicly traded diagnostics company. Mr. O’Loughlinpreviously worked in investment banking at Jesup &amp; Lamont where he focused on the biotechnology and life sciences industries.Mr. O’Loughlin has a B.S. in Business Administration with a concentration in finance from Ramapo College of New Jersey.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Jeffrey W. Chell, M.D., Director        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        Dr. Chell has been a Director of the Companysince April 2018. Dr. Chell is also a member of our Audit Committee and Compensation Committee. He has been the chief executiveofficer emeritus of the National Marrow Donor Program (“NMDP”) since 2017 having served as its chief executive officersince 2000. Dr. Chell has led the NMDP through transformational growth as its Be The Match Registry tripled to more than 12 milliondonors, the number of transplants facilitated has grown fivefold to over 6,400 annually, and revenue more than tripled to nearly$400 million per year. He is also the co-founder and has served as executive director of the Center For International Blood &amp;Marrow Transplant Research since 2004, a leading research program in the field contributing over 70 research publications per yearin peer-reviewed journals. Dr. Chell also currently serves as chair of CLR Insurance, a captive insurance company domiciled inthe Cayman Islands. From 2014 to 2016, Dr. Chell served as co-chair of Bone Marrow Donors Worldwide during its IT transformationproject, improving revenues and reducing costs.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        Prior to joining the NMDP, he served aspresident, Allina Medical Clinics, a 450 physician multi-specialty medical group from 1994 to 1999. Prior to that he practicedInternal Medicine in Minneapolis and in the U.S. Air Force Medical Corps.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        Dr. Chell received his M.D. from the Universityof Minnesota and his training in Internal Medicine at the University of Wisconsin, Madison. Dr. Chell is a diplomate of the AmericanBoard of Internal Medicine, a member of the American Society of Hematology and a member of the American Society of Blood and MarrowTransplantation.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        He has received multiple honors includingthe 2018 Public Service award of the American Society For Blood and Marrow Transplantation, 2017 Most Admired CEO by the Minneapolis/St.Paul Business Journal, 2010 Healthcare Executive of the Year by the Minneapolis/St, Paul Business Journal, and the 2017 Bone MarrowFoundation Service Award.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        That Dr. Chell brings many years of experiencewith patient donor programs, knowledge of challenges related to bone marrow transplants, leadership of organizations and experienceworking in medical groups to our Board, led us to conclude that Dr. Chell should serve as a director.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 74; Value: 51 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         54         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         David Nicholson, Ph.D., Director        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        David Nicholson has been a Director of theCompany since 2008. Dr. Nicholson is also a member of our Compensation Committee and Corporate Governance Committee. Since March2015, Dr. Nicholson served as Executive Vice President and Chief R&amp;D Officer of Allergan, which was acquired by Abbvie in May2020. In August 2014, Dr. Nicholson joined Allergan (previously known as Actavis plc and Forest Laboratories, Inc.) as senior vicepresident, Actavis Global Brands R&amp;D. From March 2012 to August 2014, Dr. Nicholson was on the executive committee of BayerCropScience as head of research &amp; development responsible for the integration of the company’s R&amp;D activities intoone global organization. Dr. Nicholson graduated in pharmacology, earning his B.Sc. from the University of Manchester (1975) andhis Ph.D. from the University of Wales (1980). Between 1978 and 1988, Dr. Nicholson worked in the pharmaceutical industry for theBritish company Beecham-Wülfing in Gronau, Germany. The main emphasis of his activities as group leader in a multidisciplinaryproject group was the development of cardiovascular drugs.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        From 1988-2007, Dr. Nicholson held variouspositions of increasing seniority in the UK, the Netherlands and the U.S. with Organon, a business unit of Akzo Nobel. Ultimately,he became executive vice president, research &amp; development, and member of the Organon Executive Management Committee. He implementedchange programs, leading to maximizing effectiveness in research &amp; development, ensuring customer focus and the establishmentof a competitive pipeline of innovative drugs. In 2007, Dr. Nicholson transferred to Schering-Plough, Kenilworth, New Jersey assenior vice president, responsible for Global Project Management and Drug Safety. From 2009 to December 2011, he was vice presidentlicensing and knowledge management at Merck in Rahway, New Jersey, reporting to the president of Merck R&amp;D. As an integrationteam member, Dr. Nicholson played a role in the strategic mergers of Organon BioSciences, the human and animal health businessof Dutch chemical giant Akzo-Nobel, and Schering-Plough in 2007 as well as of Schering-Plough and Merck in 2009.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        That Dr. Nicholson brings over 25 yearsof pharmaceutical experience to our Board, having served in various pharmaceutical research and development executive-level positionsover the course of his career, and that Dr. Nicholson has developed significant management and leadership skills relating to thepharmaceutical industry. and is well accustomed to interfacing with investors, analysts, auditors, outside advisors and governmentalofficials, led us to conclude that Dr. Nicholson should serve as a director.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Ajit S. Shetty, Ph.D., Director        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        Dr. Shetty has been a Director of the Companysince March 2017. Dr. Shetty is also a member of our Audit Committee, Compensation Committee, and Chairman of our Corporate GovernanceCommittee. Dr. Shetty joined Janssen Pharmaceutical, Inc. (“Janssen”) in 1976 ultimately rising to the position ofpresident in 1986 where he led the establishment of Janssen’s business in the U.S. From 1999 to 2008 he was managing directorof Janssen, during this time the Janssen Group of companies’ global sales grew from $1 billion to $8 billion, and from 2004until 2012 he was chairman of the board of directors. In Dr. Shetty’s most recent role at Johnson &amp; Johnson he was headof Enterprise Supply Chain, where he reported to the chief executive officer and was responsible for the transformation and optimizationof Johnson &amp; Johnson’s supply chain. Dr. Shetty earned a Ph.D. in Metallurgy and B.A. Natural Sciences from Trinity College,Cambridge University and a Master of Business Administration from Carnegie Mellon University. Dr. Shetty has served as a memberof Agile Therapeutics, Inc.’s board of directors since February 2016. In 2007, Dr. Shetty was bestowed the title of Baronby King Albert II of Belgium for his exceptional merits. He is a member of the Board of Trustees of Carnegie Mellon University,serves on the Board of Governors for GS1 (Global Standards) in Belgium and formerly served on the Corporate Advisory Board of theJohn Hopkins Carey Business School. In 2016, Dr. Shetty was named as chairperson of the Vlaams Instituut voor Biotechnologie (VIB),a Belgium based life sciences research institute focused on translating scientific results into pharmaceutical, agricultural andindustrial applications. In addition, he was elected Manager of the Year in 2004 in Flanders and received a Life-Time AchievementAward in India in 2010. We believe Dr. Shetty’s qualifications to sit on our Board include his extensive pharmaceutical experienceleading commercial and supply chain operations and his significant education background.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        That Dr. Shetty has 37 years of leadershipand executive experience in the pharmaceutical industry, that he has significant supply chain knowledge and that he has experienceconducting business in the U.S. and Europe, led us to conclude that Dr. Shetty should serve as a director.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 75; Value: 51 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         55         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Richard I. Steinhart, Director        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        Mr. Steinhart has served as our Directorand Chairman of the Audit Committee since November 2013. Mr. Steinhart is also a member of our Corporate Governance Committee.Since October 2017 Mr. Steinhart has been the senior vice president and chief financial officer of BioXcel Therapeutics, Inc. SinceMarch 2014, Mr. Steinhart has been a member of the board of directors of Atossa Genetics, Inc. where he is chairman of the auditcommittee and a member of the compensation committee. From October 2015 to April 2017, Mr. Steinhart was vice president and chieffinancial officer at Remedy Pharmaceuticals, a privately-held, clinical stage pharmaceutical company. From January 2014 throughSeptember 2015 Mr. Steinhart worked as a financial and strategic consultant to the biotechnology and medical device industries.From April 2006 through December 2013, Mr. Steinhart was employed by MELA Sciences, Inc., as its vice president, finance and chieffinancial officer, treasurer and secretary. In April 2012, Mr. Steinhart received a promotion to senior vice president, financeand chief financial officer. From May 1992 until joining MELA Sciences, Mr. Steinhart was a managing director of Forest StreetCapital/SAE Ventures, a boutique investment banking, venture capital, and management consulting firm focused on healthcare andtechnology companies. Prior to Forest Street Capital/SAE Ventures, he was vice president and chief financial officer of EmisphereTechnologies, Inc. Mr. Steinhart’s other experience includes seven years at CW Group, Inc., a venture capital firm focusedon medical technology and biopharmaceutical companies, where he was a general partner and chief financial officer. Mr. Steinhartbegan his career at Price Waterhouse, now known as PricewaterhouseCoopers. He holds BBA and MBA degrees from Pace University andis a Certified Public Accountant (inactive).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        That Mr. Steinhartbrings more than 30 years of financial experience to our Board, having served in various executive-level financial positions overthe course of his career, and that Mr. Steinhart is a certified public accountant, led us to conclude that Mr. Steinhart shouldserve as a director and chair the Audit Committee.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Corporate Governance        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Our Board of Directorsoversees our business affairs and monitors the performance of management. In accordance with our corporate governance principles,our Board of Directors does not involve itself in day-to-day operations. The Directors keep themselves informed through discussionswith the Chairman and Chief Executive Officer and other key executives and by reading the reports and other materials that we sendthem and by participating in Board of Directors and committee meetings.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Term of Office         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Our directors are dividedinto three classes, designated Class I, Class II and Class III. Class I shall consists of two directors, Class II shall consistof one director, and Class III consists of one director. The term of office for each Class I director expires at 2023 Annual Meetingof Stockholders; the term of office for each Class II director expires at the 2021 annual meeting of stockholders; and the termof office for each Class III director expires at the 2022 annual meeting of stockholders.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The term of each directoris set forth below or until their successors are duly elected:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="border-bottom: black 1.5pt solid; width: 34%; text-align: left">           <font style="font-size: 10pt">            <b>             Director            </b>           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             Class            </b>           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             Term (from 2020 Annual Meeting)            </b>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: white">          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top; background-color: #CCEEFF">          <td>           <font style="font-size: 10pt">            David Nicholson           </font>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-size: 10pt">            Class I           </font>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-size: 10pt">            3 years           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: white">          <td>           <font style="font-size: 10pt">            Richard Steinhart           </font>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-size: 10pt">            Class I           </font>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-size: 10pt">            3 years           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: #CCEEFF">          <td>           <font style="font-size: 10pt">            Sandesh Seth           </font>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-size: 10pt">            Class II           </font>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-size: 10pt">            1 year           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: white">          <td>           <font style="font-size: 10pt">            Jeffrey W. Chell           </font>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-size: 10pt">            Class II           </font>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-size: 10pt">            1 year           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: #CCEEFF">          <td>           <font style="font-size: 10pt">            Ajit Shetty           </font>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-size: 10pt">            Class III           </font>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-size: 10pt">            2 years           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Notwithstanding theforegoing, each director shall serve until his successor is duly elected and qualified, or until his or her retirement, death,resignation or removal.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 76; Value: 51 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         56         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Director Independence         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We use the definitionof “independence” of the NYSE American stock exchange to make this determination. We are listed on the NYSE Americanunder the symbol “ATNM”. NYSE MKT corporate governance rule Sec. 803(A)(2) provides that an “independent director”means a person other than an executive officer or employee of the company. No director qualifies as independent unless the issuer’sboard of directors affirmatively determines that the director does not have a relationship that would interfere with the exerciseof independent judgment in carrying out the responsibilities of a director. Under the NYSE American director independence rules,Jeffrey W. Chell, David Nicholson, Ajit S. Shetty, and Richard I. Steinhart are independent directors of the Company.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Chief Executive Officer’s Compensation        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        In August 2018, we amended and restatedMr. Seth’s, our Chairman and Chief Executive Officer, August 6, 2015 Executive Chairman Agreement (as amended and restated,the “2018 Agreement”). The 2018 Agreement set forth the terms related to his position as Chief Executive Officer andChairman of the Board of the Company while retaining and adapting material provisions of the prior agreement to that of his roleof Chief Executive Officer. Under the 2018 Agreement, Mr. Seth was paid an annual base salary of $561,350 in 2019. Pursuant tothe 2018 Agreement, the Board reviewed the amount of his base salary and performance bonus and determined the appropriate adjustmentsto each component of his compensation each calendar year, and he was entitled to a cash bonus in an amount determined by the Boardwith a target of 50% of the base salary. In addition, the Chairman and Chief Executive Officer was awarded stock options at ourBoard’s discretion.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        On August 12, 2020, we and Mr. Seth enteredinto a new employment agreement, which replaced the 2018 Agreement. Pursuant to the employment agreement, Mr. Seth will serve asChairman and Chief Executive Officer until February 24, 2024 unless terminated earlier as set forth in the employment agreement.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        Under the terms of the employment agreement,Mr. Seth is entitled to (i) a base salary, which will be determined by the Board and adjusted to be competitively aligned to arange between the 25th and 75th percentile of the relevant market data of chief executive officer positions of similarly situatedpublicly companies, (ii) a performance bonus with a target of 50% of his annual base salary as well as other multipliers as determinedby the Board and (iii) options to purchase shares of common stock of the Company as the Board may grant. For 2020, Mr. Seth’sannual base salary was set at $578,191.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        When and if granted, the options will havean exercise price equal to the closing price of the Company’s common stock on the date of the approval, and 2% of the grantwill vest each month from the grant date until fully vested, in accordance with the 2013 Stock Plan and 2019 Plan. The optionswill expire 10 years from the grant date, subject to Mr. Seth’s continuing service with the Company. Mr. Seth also receivesthe standard benefits available to other similarly situated employees.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        If Mr. Seth’s employment as ChiefExecutive Officer or Chairman is terminated due to death or disability, Mr. Seth will be entitled to earned, but unpaid, salary,benefits and the Pro-Rated Bonus (as defined herein) for the year of termination. Upon termination of his employment for Cause(as defined in the employment agreement), or his resignation without Good Reason (as defined in the employment agreement), Mr.Seth will receive any accrued and unpaid base salary, the Pro-Rated Bonus and benefits through the date of termination.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        If we terminate Mr. Seth’s employmentwithout Cause, or if Mr. Seth resigns for Good Reason, Mr. Seth will be entitled to (i) a single lump sum payment equal to the24 months of his compensation, (ii) continued health benefits for 24 months, (iii) immediate vesting of all outstanding equityawards granted to Mr. Seth, and (iv) a single lump sum payment equal to his annual bonus subject to the achievement of the applicablegoals, pro-rated based on the number of days in the Company’s fiscal year through the date of termination (the “Pro-RatedBonus”).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 77; Value: 51 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         57         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        In addition, if we terminate Mr. Seth’semployment without Cause or if Mr. Seth resigns for Good Reason, or if we fail to renew his position as Chief Executive Officerand Chairman on February 21, 2024, in any case, within the 12-month period beginning on the date of a Change in Control (as definedin the 2013 Stock Plan and 2019 Plan), Mr. Seth will be entitled to (i) a single lump sum payment equal to 30 months of his compensation,(ii) continued health benefits for 30 months, (iii) immediate vesting of all outstanding equity awards granted to Mr. Seth, and(iv) a single lump sum payment equal to the Pro-Rated Bonus.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Chief Medical Officer Compensation        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        In December 2016, we and Dr. Mark S. Bergerentered into an agreement (the “2016 Berger Employment Agreement”), to employ Dr. Berger as our Chief Medical Officer.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        Pursuant to the 2016 Berger Employment Agreement,Dr. Berger was entitled to the following compensation and benefits:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            Dr. Berger’s annual base salary was $405,000 in 2019. Dr. Berger was also entitled to a cash bonus in an amount to be determined by the Board with a target of 30% of the base salary.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>        </tbody>       </table>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            Dr. Berger was eligible to participate in the Company’s benefit plans that are generally provided for executive employees.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            From time to time, the Board granted him options to purchase shares of common stock of the Company.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        On August 12, 2020, we entered into a newemployment agreement with Dr. Berger, pursuant to which he serves as Chief Medical Officer of the Company. Under the terms of theemployment agreement, Dr. Berger is entitled to (i) a base salary, which shall be determined by the Board, (ii) a performance bonus,which may be up to 30% of the annual base salary based upon the achievement of certain objectives such as the Board shall determineand (iii) options to purchase shares of common stock of the Company as the Board may grant. For 2020, Dr. Berger’s annualbase salary was set at $415,000.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        When and if granted, the options will havean exercise price equal to the closing price of the Company’s common stock on the date of the approval, and 2% of the grantwill vest each month from the grant date until fully vested, in accordance with the 2013 Stock Plan and 2019 Plan. The optionswill expire 10 years from the grant date, subject to Dr. Berger’s continuing service with the Company. Mr. Berger will alsoreceive the standard benefits available to other similarly situated employees.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        In addition, if we terminate Dr. Berger’semployment without Cause (as defined in the employment agreement) within the 12-month period beginning on the date of a Changein Control, Dr. Berger will be entitled to (i) a single lump sum payment equal to his annual base salary, (ii) continued healthbenefits for 12 months, and (iii) immediate vesting of all outstanding equity awards granted to Dr. Berger.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 78; Value: 51 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         58         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Chief Financial Officer/Principal Financial Officer Compensation        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        In August 2018, we amended and restatedMr. O’Loughlin’s, our former Principal Financial Officer, September 17, 2015 Employment Agreement, as amended (as amendedand restated, the “PFO Agreement”). The PFO Agreement set forth the terms related to his position as Principal FinancialOfficer of the Company while retaining and adapting material provisions of the prior agreement to that of his role of PrincipalFinancial Officer.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        Pursuant to the PFO Agreement, Mr. O’Loughlinwas entitled to the following compensation and benefits:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            Mr. O’Loughlin’s annual base salary was $293,550 in 2019, and Mr. O’Loughlin was entitled to a cash bonus in an amount to be determined by the Board with a target of 30% of the base salary.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>        </tbody>       </table>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            From time to time, the Board granted him options to purchase shares of common stock of the Company.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>        </tbody>       </table>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            Mr. O’Loughlin was eligible to receive all standard benefits that Company employees are eligible to receive.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        On August 12, 2020, we entered into a newemployment agreement with Mr. O’Loughlin, pursuant to which he serves as Chief Financial Officer of the Company. Under theterms of the employment agreement, Mr. O’Loughlin is entitled to (i) a base salary, which shall be determined by the Board,(ii) a performance bonus, which may be up to 30% of the annual base salary based upon the achievement of certain objectives suchas the Board shall determine and (iii) options to purchase shares of common stock of the Company as the Board may grant. For 2020,Mr. O’Loughlin’s annual base salary was set at $330,000.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        When and if granted, the options will havean exercise price equal to the closing price of the Company’s common stock on the date of the approval, and 2% of the grantwill vest each month from the grant date until fully vested, in accordance with the 2013 Stock Plan and 2019 Plan. The optionswill expire 10 years from the grant date, subject to Mr. O’Loughlin’s continuing service with the Company. Mr. Loughlinwill also receive the standard benefits available to other similarly situated employees.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        In addition, if we terminate Mr. O’Loughlin’semployment without Cause (as defined in the employment agreement) or if Mr. O’Loughlin resigns for Good Reason (as definedin the employment agreement), in either case, within the 12-month period beginning on the date of a Change in Control, Mr. O’Loughlinwill be entitled to (i) a single lump sum payment equal to his annual base salary, (ii) continued health benefits for 12 months,and (iii) immediate vesting of all outstanding equity awards granted to Mr. O’Loughlin.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         Chief Scientific and Technology Officer Compensation        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        We and Dr. Dale Ludwig, effective January2018, entered into an Offer Letter pursuant to which Dr. Ludwig served as the Company’s Chief Scientific Officer (the “OfferLetter”). Pursuant to the Offer Letter. Dr. Ludwig was entitled to the following compensation and benefits:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            Dr. Ludwig’s annual base salary was $334,750 in 2019 and Dr. Ludwig was entitled to a cash bonus in an amount to be determined by the Board with a target of 30% of the base salary.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>        </tbody>       </table>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            From time to time, the Board granted him options to purchase shares of common stock of the Company.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>        </tbody>       </table>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            Dr. Ludwig was eligible to receive all standard benefits that Company employees are eligible to receive.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <!-- Field: Page; Sequence: 79; Value: 51 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         59         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        On August 12, 2020, we entered into a newemployment agreement with Dr. Ludwig, pursuant to which he serves as Chief Scientific and Technology Officer of the Company. Underthe terms of the employment agreement, Dr. Ludwig is entitled to (i) a base salary, which shall be determined by the Board, (ii)a performance bonus, which may be up to 30% of the annual base salary based upon the achievement of certain objectives such asthe Board shall determine and (iii) options to purchase shares of common stock of the Company as the Board may grant. For 2020,Dr. Ludwig’s annual base salary was set at $375,000.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        When and if granted, the options will havean exercise price equal to the closing price of the Company’s common stock on the date of the approval, and 2% of the grantwill vest each month from the grant date until fully vested, in accordance with the 2013 Stock Plan and 2019 Plan. The optionswill expire 10 years from the grant date, subject to Mr. Ludwig’s continuing service with the Company. Dr. Ludwig will alsoreceive the standard benefits available to other similarly situated employees.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        In addition, if we terminate Dr. Ludwig’semployment without Cause (as defined in the employment agreement) within the 12-month period beginning on the date of a Changein Control, Dr. Ludwig will be entitled to (i) a single lump sum payment equal to his annual base salary, (ii) continued healthbenefits for 12 months, and (iii) immediate vesting of all outstanding equity awards granted to Mr. Ludwig.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Board of Directors Meetings and Attendance        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        During 2020, our Boardof Directors held fourteen meetings and did not act by unanimous written consent. Each director attended all of the meetings ofour Board and of any committees of which he was a member during the year ended December 31, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Committees of the Board of Directors        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Our Board of Directorshas formed three standing committees: audit, compensation and corporate governance. Actions taken by our committees are reportedto the full board. Each of our committees has a charter and each charter is posted on our website.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 34%; border-bottom: black 1.5pt solid">           <font style="font-size: 10pt">            <b>             Audit Committee            </b>           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             Compensation Committee            </b>           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             Corporate Governance Committee            </b>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: #CCEEFF">          <td>           <font style="font-size: 10pt">            Richard I. Steinhart*           </font>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            David Nicholson*           </font>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            Ajit S. Shetty*           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: white">          <td>           <font style="font-size: 10pt">            Jeffrey W. Chell           </font>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            Jeffrey W. Chell           </font>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            David Nicholson           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: #CCEEFF">          <td>           <font style="font-size: 10pt">            Ajit S. Shetty           </font>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            Ajit S. Shetty           </font>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            Richard I. Steinhart           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0px">          </td>          <td style="width: 0.25in">           <font style="font-size: 10pt">            <b>             *            </b>           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            Indicates committee chair           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Audit Committee         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        Our Audit Committee, which currently consistsof three directors, provides assistance to our Board in fulfilling its legal and fiduciary obligations with respect to mattersinvolving the accounting, financial reporting, internal control and compliance functions of the Company. The Board has determinedthat Mr. Steinhart is an “audit committee financial expert” as defined in Item 407(d)(5)(ii) of RegulationS-K. Our Audit Committee employs an independent registered public accounting firm to audit the financial statements of the Companyand perform other assigned duties. Further, our Audit Committee provides general oversight with respect to the accounting principlesemployed in financial reporting and the adequacy of our internal controls. In discharging its responsibilities, our Audit Committeemay rely on the reports, findings and representations of the Company’s auditors, legal counsel, and responsible officers.Our Board has determined that all members of the Audit Committee are financially literate within the meaning of SEC rules and underthe current listing standards of the NYSE American. The Audit Committee met four times during 2020. Each member of the Audit Committeewas present at all of the Audit Committee meetings held during 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 80; Value: 51 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         60         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Compensation Committee         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        Our Compensation Committee, which currentlyconsists of three directors, establishes executive compensation policies consistent with the Company’s objectives and stockholderinterests. The Compensation Committee met one time during 2020. Each member of the Compensation Committee was present at the meetingheld in 2020. Our Compensation Committee also reviews the performance of our executive officers and establishes, adjusts and awardscompensation, including incentive-based compensation, as more fully discussed below. In addition, our Compensation Committee generallyis responsible for:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.25in">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            establishing and periodically reviewing our compensation philosophy and the adequacy of compensation plans and programs for our directors, executive officers and other employees;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td style="text-align: justify">          </td>         </tr>        </tbody>       </table>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            overseeing our compensation plans, including the establishment of performance goals under the Company’s incentive compensation arrangements and the review of performance against those goals in determining incentive award payouts;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>        </tbody>       </table>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            overseeing our executive employment contracts, special retirement benefits, severance, change in control arrangements and/or similar plans;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>        </tbody>       </table>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            acting as administrator of any company stock option plans; and           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>        </tbody>       </table>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            overseeing outside compensation consultants when engaged.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        Our Compensation Committee periodicallyreviews the compensation paid to our non-employee directors and the principles upon which their compensation is determined. TheCompensation Committee also periodically reports to the Board on how our non-employee director compensation practices compare withthose of other similarly situated public corporations and, if the Compensation Committee deems it appropriate, recommends changesto our director compensation practices to our Board for approval.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Outside consultingfirms retained by our compensation committee and management also will, if requested, provide assistance to the Compensation Committeein making its compensation-related decisions. We paid consultant fees to StreeterWyatt of $20,000 during the year ended December31, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Corporate Governance Committee         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        Our Corporate Governance Committee, whichcurrently consists of three directors, monitors our corporate governance system. The Corporate Governance Committee met one timeduring 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Nominating Committee         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        We do not have a nominating committee ora committee performing similar functions. Our Board does not believe a nominating committee is necessary because Board nominationsare selected, or recommended for the Board’s selection, by a majority of the independent directors. Our independent directorsinclude Jeffrey W. Chell, David Nicholson, Richard I. Steinhart and Ajit S. Shetty. These directors are charged with the responsibilityof proposing potential director nominees to the Board for consideration. Our independent directors use criteria by which it willseek to evaluate candidates to serve on our Board. The evaluation methodology includes items such as experience in the biotechnologysector, experience with public companies, executive managerial experience, operations and commercial experience, fundraising experienceand contacts in the investment banking industry, personal and skill set compatibility with current Board members, industry reputation,knowledge of our company generally, and independence.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        Our Board considers all qualified candidatesidentified by members of the Board, by senior management and by stockholders. The Board follows the same process and uses the samecriteria for evaluating candidates proposed by stockholders, members of the Board and members of senior management. We did notpay fees to any third party to assist in the process of identifying or evaluating director candidates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <!-- Field: Page; Sequence: 81; Value: 51 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         61         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        Our Amended and Restated Bylaws, as amended(the “Bylaws”) contains provisions that address the process by which a stockholder may nominate an individual to standfor election to the Board at our annual meetings. To recommend a nominee for election to the Board, a stockholder must submit hisor her recommendation to our Secretary at our corporate offices at 275 Madison Avenue, 7        <sup>         th        </sup>        Floor, New York, New York10016. Such nomination must satisfy the notice, information and consent requirements set forth in our Bylaws and must be receivedby us prior to the date set forth under “Submission of Future Stockholder Proposals” below. A stockholder’s recommendationmust be accompanied by the information with respect to stockholder nominees as specified in our Bylaws, including among other things,the name, age, address and occupation of the recommended person, the proposing stockholder’s name and address, the ownershipinterests of the proposing stockholder and any beneficial owner on whose behalf the nomination is being made (including the numberof shares beneficially owned, any hedging, derivative, short or other economic interests and any rights to vote any shares) andany material monetary or other relationships between the recommended person and the proposing stockholder and/or the beneficialowners, if any, on whose behalf the nomination is being made.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        We have no formal policy regarding Boarddiversity. We take into consideration the overall composition and diversity of the Board and areas of expertise that director nomineesmay be able to offer, including business experience, knowledge, abilities and customer relationships. Generally, we will striveto assemble a Board that brings to us a variety of perspectives and skills derived from business and professional experience aswe may deem are in our and our stockholders’ best interests. In doing so, we will also consider candidates with appropriatenon-business backgrounds.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-align: justify">        <b>         <i>          Lead Director         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">        InSeptember 2017, our board of directors created the position of Lead Director. Our board of directors designated David Nicholson,an existing independent director, as our Lead Director. Pursuant to the charter of the Lead Director, the Lead Director shall bean independent, non-employee director designated by our board of directors who shall serve in a lead capacity to coordinatethe activities of the other non-employee directors, interface with and advise management, and perform such other dutiesas are specified in the charter or as our board of directors may determine.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Family Relationships        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        There are no familyrelationships among any of our officers or directors.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Involvement in Certain Legal Proceedings        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        To our knowledge, noneof our current directors or executive officers has, during the past ten years:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            been convicted in a criminal proceeding or been subject to a pending criminal proceeding (excluding traffic violations and other minor offenses);           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>        </tbody>       </table>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            had any bankruptcy petition filed by or against the business or property of the person, or of any partnership, corporation or business association of which he was a general partner or executive officer, either at the time of the bankruptcy filing or within two years prior to that time;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>        </tbody>       </table>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            been subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction or federal or state authority, permanently or temporarily enjoining, barring, suspending or otherwise limiting, his involvement in any type of business, securities, futures, commodities, investment, banking, savings and loan, or insurance activities, or to be associated with persons engaged in any such activity;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>        </tbody>       </table>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            been found by a court of competent jurisdiction in a civil action or by the SEC or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>        </tbody>       </table>       <!-- Field: Page; Sequence: 82; Value: 51 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         62         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.25in">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            been the subject of, or a party to, any federal or state judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated (not including any settlement of a civil proceeding among private litigants), relating to an alleged violation of any federal or state securities or commodities law or regulation, any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order, or any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td style="text-align: justify">          </td>         </tr>        </tbody>       </table>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            been the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Exchange Act), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Except as set forthin our discussion below in “Certain Relationships and Related Transactions,” none of our directors or executive officershas been involved in any transactions with us or any of our directors, executive officers, affiliates or associates which are requiredto be disclosed pursuant to the rules and regulations of the SEC.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Code of Ethics        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company has adopteda code of ethics, a copy of which is attached as Exhibit 14.1 to the Form 8-K filed on January 2, 2013.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Compliance with Section 16 (a) of the Exchange Act        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Under Section 16(a)of the Exchange Act, our directors and certain of our officers, and persons holding more than 10 percent of our common stock arerequired to file forms reporting their beneficial ownership of our common stock and subsequent changes in that ownership with theUnited States Securities and Exchange Commission.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Based solely upon areview of copies of such forms filed on Forms 3, 4, and 5, and amendments thereto furnished to us, we believe that as of December31, 2020, our executive officers and directors have complied on a timely basis with all Section 16(a) filing requirements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Compensation Discussion and Analysis        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Our Compensation Committeeof our Board of Directors has the responsibility to review, determine and approve the compensation for our executive officers.Further, our Compensation Committee oversees our overall compensation strategy, including compensation policies, plans and programsthat cover all employees. At our 2019 Annual Meeting of Stockholders, our Stockholders voted on an advisory basis with respectto our compensation program during 2018 for named executive officers. Of the votes cast (excluding abstentions and broker non-votes),72.1% were cast in support of the program. In light of this, in reviewing the executive compensation program for 2019 and 2020,our Compensation Committee decided to retain the general overall program design, which ties a significant portion of the executives’pay closely with our performance. In the future, our Compensation Committee will continue to consider the executive compensationprogram in light of changing circumstances and stockholder feedback.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We currently employfour executive officers, each of whom serves as a “Named Executive Officer” (or NEO) for purposes of SEC reporting:(1) Sandesh Seth, our Chairman and Chief Executive Officer (who we refer to in this Compensation Discussion and Analysis as ourCEO); (2) Steve O’Loughlin, our Chief Financial Officer, (3) Mark Berger, our Chief Medical Officer and (4) Dale Ludwig,our Chief Scientific and Technology Officer.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        This Compensation Discussionand Analysis sets forth a discussion of the compensation for our NEOs as well as a discussion of our philosophies underlying thecompensation for our NEOs and our employees generally.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 83; Value: 51 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         63         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Objectives of Our Compensation Program        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Compensation Committee’sphilosophy seeks to align the interests of our stockholders, officers and employees by tying compensation to individual and companyperformance, both directly in the form of salary or annual cash incentive payments, and indirectly in the form of equity awards.The objectives of our compensation program enhance our ability to:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            attract and retain qualified and talented individuals; and           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>        </tbody>       </table>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in; text-align: justify">          </td>          <td style="width: 0.25in; text-align: justify">           <font style="font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            provide reasonable and appropriate incentives and rewards to our team for building long-term value within our company, in each case in a manner comparable to companies similar to ours.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In addition, we striveto be competitive with other similarly situated companies in our industry. The process of developing pharmaceutical products andbringing those products to market is a long-term proposition and outcomes may not be measurable for several years. Therefore, inorder to build long-term value for our company and its stockholders, and in order to achieve our business objectives, we believethat we must compensate our officers and employees in a competitive and fair manner that reflects current company activities butalso reflects contributions to building long-term value.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We utilize the servicesof StreeterWyatt Governance LLC to review compensation programs of peer companies in order to assist the Compensation Committeein determining the compensation levels for our NEOs, as well as for other employees of our company. StreeterWyatt is a recognizedindependent consulting company and services clients throughout the United States.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Elements of Our Compensation Program and Why We Chose Each        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <i>         Main CompensationComponents        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Our company-wide compensationprogram, including for our NEOs, is broken down into three main components: base salary, performance cash bonuses and potentiallong-term compensation in the form of stock options or restricted stock awards. We believe these three components constitute theminimum essential elements of a competitive compensation package in our industry.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <i>         Salary        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Base salary is usedto recognize the experience, skills, knowledge and responsibilities required of our NEOs as well as recognizing the competitivenature of the biopharmaceutical industry. This is determined partially by evaluating our peer companies as well as the degree ofresponsibility and experience levels of our NEOs and their overall contributions to our company. Base salary is one component ofthe compensation package for NEOs; the other components being cash bonuses, annual equity grants, and company benefit programs.Base salary is determined in advance whereas the other components of compensation are awarded in varying degrees following an assessmentof the performance of a NEO. This approach to compensation reflects the philosophy of our board of directors and its CompensationCommittee to emphasize and reward, on an annual basis, performance levels achieved by our NEOs.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <i>         Performance BonusPlan        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We have a performancebonus plan under which bonuses are paid to our NEOs based on achievement of company performance goals and objectives establishedby the Compensation Committee and/or our board of directors as well as on individual performance. The bonus program is discretionaryand is intended to: (i) strengthen the connection between individual compensation and our company’s achievements; (ii) encourageteamwork among all disciplines within our company; (iii) reinforce our pay-for-performance philosophy by awarding higher bonusesto higher performing employees; and (iv) help ensure that our cash compensation is competitive. Depending on the cash positionof the company, the Compensation Committee and our board of directors have the discretion to not pay cash bonuses in order thatwe may conserve cash and support ongoing development programs and commercialization efforts. Regardless of our cash position, weconsistently grant annual merit-based stock options to continue incentivizing both our senior management and our employees.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 84; Value: 51 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         64         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Based on their employmentagreements, each NEO is assigned a target payout under the performance bonus plan, expressed as a percentage of base salary forthe year. Actual payouts under the performance bonus plan are based on the achievement of corporate performance goals and an assessmentof individual performance, each of which is separately weighted as a component of such officer’s target payout. For the NEOs,the corporate goals receive the highest weighting in order to ensure that the bonus system for our management team is closely tiedto our corporate performance. Each employee also has specific individual goals and objectives as well that are tied to the overallcorporate goals. For employees, mid-year and end-of-year progress is reviewed with the employees’ managers.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <i>         Equity IncentiveCompensation        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We view long-term compensation,currently in the form of stock options and restricted stock generally vesting in annual increments over four years, as a tool toalign the interests of our NEOs and employees generally with the creation of stockholder value, to motivate our employees to achieveand exceed corporate and individual objectives and to encourage them to remain employed by the company. While cash compensationis a significant component of employees’ overall compensation, the Compensation Committee and our board of directors (aswell as our NEOs) believe that the driving force of any employee working in a small biotechnology company should be strong equityparticipation. We believe that this not only creates the potential for substantial longer-term corporate value but also servesto motivate employees and retain their loyalty and commitment with appropriate personal compensation.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <i>         Other Compensation        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In addition to themain components of compensation outlined above, we also have provided contractual severance and/or change in control benefits toseveral employees including our CEO. The change in control benefits for all applicable persons have a “double trigger.”A double-trigger means that the executive officers will receive the change in control benefits described in the agreements onlyif there is both (1) a Change in Control of our company (as defined in the agreements) and (2) a termination by us of the applicableperson’s employment “without cause” or a resignation by the applicable persons for “good reason”(as defined in the agreements) within a specified time period prior to or following the Change in Control. We believe this doubletrigger requirement creates the potential to maximize stockholder value because it prevents an unintended windfall to managementas no benefits are triggered solely in the event of a Change in Control while providing appropriate incentives to act in furtheranceof a change in control that may be in the best interests of the stockholders. We believe these severances or change in controlbenefits are important elements of our compensation program that assist us in retaining talented individuals at the executive andsenior managerial levels and that these arrangements help to promote stability and continuity of our executives and senior managementteam. Further, we believe that the interests of our stockholders will be best served if the interests of these members of our managementare aligned with theirs. We believe that providing change in control benefits lessens or eliminates any potential reluctance ofmembers of our management to pursue potential change in control transactions that may be in the best interests of the stockholders.We also believe that it is important to provide severance benefits to members of our management, to promote stability and focuson the job at hand.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We also provide benefitsto the executive officers that are generally available to all regular full-time employees of our company, including our medicaland dental insurance, and a 401(k) plan. Further, we do not have deferred compensation plans, pension arrangements or post-retirementhealth coverage for our executive officers or employees. All of our employees not specifically under contract are “at-will”employees, which means that their employment can be terminated at any time for any reason by either us or the employee.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <i>         Determination ofCompensation Amounts        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        A number of factorsimpact the determination of compensation amounts for our NEOs, including the individual’s role in the company and individualperformance, length of service with the company, competition for talent, individual compensation package, assessments of internalpay equity and industry data. Stock price performance has generally not been a factor in determining annual compensation becausethe price of our common stock is subject to a variety of factors outside of our control.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 85; Value: 51 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         65         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <i>         Industry SurveyData        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In collaboration withStreeterWyatt, we establish and maintain a list of peer companies to best assure ourselves that we are compensating our executiveson a fair and reasonable basis, as set forth above under the heading “Objectives of our Compensation Program.” We alsoutilize StreeterWyatt-prepared data for below-executive level personnel, which data focuses on biotechnology companies that canbe considered peers in terms of numerous variables including phase of development, size, therapeutic and technological focus amongothers. The availability of peer data is used by the Compensation Committee strictly as a guide in determining compensation levelswith regard to salaries, cash bonuses and performance related annual equity grants to all employees. However, the availabilityof this data does not imply that the Compensation Committee is under any obligation to exactly follow peer companies in compensationmatters.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <i>         Determination ofBase Salaries        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        As a guideline forNEO base salary, we perform formal benchmarks against respective comparable positions in our established peer group. We adjustsalaries based on our assessment of our NEOs’ levels of responsibility, experience, overall compensation structure and individualperformance. The Compensation Committee is not obliged to raise salaries purely on the availability of data. Merit-based increasesto salaries of executive officers are based on our assessment of individual performance and the relationship to applicable salaryranges. Cost of living adjustments may also be a part of that assessment.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <i>         Performance BonusPlan        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Concurrently with thebeginning of each calendar year, preliminary corporate goals that reflect our business priorities for the coming year are preparedby the CEO with input from the other executive officers. These goals are weighted by relative importance. The draft goals and proposedweightings are presented to the Compensation Committee and the Board and discussed, revised as necessary, and then approved byour board of directors. The Compensation Committee then reviews the final goals and their weightings to determine and confirm theirappropriateness for use as performance measurements for purposes of the bonus program. The goals and/or weightings may be re-visitedduring the year and potentially restated in the event of significant changes in corporate strategy or the occurrence of significantcorporate events. Following the agreement of our Board on the corporate objectives, the goals are then shared with all employeesin a formal meeting(s), and are reviewed periodically throughout the year.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <i>         Determination ofEquity Incentive Compensation        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        To assist us in assessingthe reasonableness of our equity grant amounts, we have reviewed StreeterWyatt supplied information. Such information includedequity data from a cross-section of similar companies in our industry.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <i>         Equity Grant Practices        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        All stock options and/orrestricted stock granted to the NEOs and other executives are approved by the Compensation Committee. Exercise prices for optionsare set at the closing price of our common stock on the date of grant. Grants are generally made: (i) on the employee’s startdate and (ii) at board of director meetings held once each year and following annual performance reviews. However, grants havebeen made at other times during the year. The size of year-end grants for each NEO is assessed against our internal equity guidelines.Current market conditions for grants for comparable positions and internal equity may also be assessed. Also, grants may be madein connection with promotions or job-related changes in responsibilities. In addition, on occasion, the Compensation Committeemay make additional special awards for extraordinary individual or company performance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <i>         Compensation SettingProcess        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Annually, at a meetingof our Board of Directors and the Compensation Committee, overall corporate performance and relative achievement of the corporategoals for the prior year are assessed. The relative achievement of each goal is assessed and quantified and the summation of theindividual components results in a corporate goal rating, expressed as percentages. The Compensation Committee then approves thefinal disbursement of salary increases, cash bonuses and option or restricted stock grants.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 86; Value: 51 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         66         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Compensation Committeelooks to the CEO’s performance assessments of the other NEOs and his recommendations regarding a performance rating for each,as well as input from the other members of our board of directors. These recommendations may be adjusted by the Compensation Committeeprior to finalization. For the CEO, the Compensation Committee evaluates his performance, taking into consideration input fromthe other members of our board of directors, and considers the achievement of overall corporate objectives by both the CEO specificallyand the company generally. The CEO is not present during the Compensation Committee’s deliberations regarding his compensation.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Compensation Committeehas the authority to directly engage, at our company’s expense, any compensation consultants or other advisors (such as StreeterWyatt)that it deems necessary to determine the amount and form of employee, executive and director compensation. In determining the amountand form of employee, executive and director compensation, the Compensation Committee has reviewed and discussed historical salaryinformation as well as salaries for similar positions at comparable companies. However, the availability of this data does notimply that the Compensation Committee is under any obligation to exactly follow peer companies’ compensation practices.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We paid consultantfees to StreeterWyatt of $20,000 during the year ended December 31, 2020. NEOs may have indirect input in the compensation resultsfor other executive officers by virtue of their participation in the performance review and feedback process for the other executiveofficers.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <a name="aph165213a019">        </a>        <b>         ITEM 11. EXECUTIVE COMPENSATION        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Summary Compensation Table        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The following tableprovides information regarding the compensation earned during the years ended December 31, 2020 and 2019 for our named executiveofficers.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt">           <font style="font-size: 10pt">            <b>             Name/Position            </b>           </font>          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             Year            </b>           </font>          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             Salary            </b>           </font>          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             Bonus (1)            </b>           </font>          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             Option            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Awards (2)            </b>           </font>          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             All Other            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Compensation            </b>           </font>          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             Total            </b>           </font>          </td>          <td style="padding-bottom: 1.5pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="width: 25%">           <font style="font-size: 10pt">            Sandesh Seth           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 11%; text-align: center">           <font style="font-size: 10pt">            2020           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="width: 9%; text-align: right">           <font style="font-size: 10pt">            578,191           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="width: 9%; text-align: right">           <font style="font-size: 10pt">            315,000           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="width: 9%; text-align: right">           <font style="font-size: 10pt">            938,537           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="width: 12%; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="width: 9%; text-align: right">           <font style="font-size: 10pt">            1,831,728           </font>          </td>          <td style="width: 1%">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-size: 10pt">            2019           </font>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            561,350           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            300,000           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            241,367           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            1,102,717           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-size: 10pt">            Mark Berger           </font>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-size: 10pt">            2020           </font>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            415,000           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            100,000           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            314,958           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            829,958           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-size: 10pt">            2019           </font>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            405,000           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            85,000           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            64,364           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            554,364           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-size: 10pt">            Dale Ludwig           </font>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-size: 10pt">            2020           </font>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            375,000           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            105,000           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            337,453           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            817,453           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-size: 10pt">            2019           </font>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            334,750           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            97,500           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            64,364           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            496,614           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-size: 10pt">            Steve O’Loughlin           </font>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-size: 10pt">            2020           </font>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            330,000           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            90,000           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            398,640           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            818,460           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-size: 10pt">            2019           </font>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            293,550           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            85,000           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            64,364           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            442,914           </font>          </td>          <td>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: .25in">           <font style="font-size: 10pt">            (1)           </font>          </td>          <td>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">            The bonus disclosed in this column relates        to performance in the prior year, but was contingent upon board approval, and was paid in the year disclosed.           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">           </p>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">           <font style="font-size: 10pt">            (2)           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            The dollar amounts in this column represent the aggregate grant date fair value of all option awards granted during the indicated year. These amounts have been calculated in accordance with FASB ASC Topic 718, using the Black-Scholes option-pricing model. For a discussion of valuation assumptions, see Note 6 to our financial statements. These amounts do not necessarily correspond to the actual value that may be recognized from the option awards by the NEOs.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>        </tbody>       </table>       <!-- Field: Page; Sequence: 87; Value: 51 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         67         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Director Compensation        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The following tablesets forth the compensation of our non-employee directors for the year ended December 31, 2020:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td style="border-bottom: Black 1.5pt solid">           <font style="font-size: 10pt">            <b>             Name            </b>           </font>          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             Fees             <br/>             Earned            </b>           </font>          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             Stock            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Awards            </b>           </font>          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             Option            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Awards            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             (1)(2)            </b>           </font>          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             All Other            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Compensation            </b>           </font>          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             Total            </b>           </font>          </td>          <td style="padding-bottom: 1.5pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td colspan="2">          </td>          <td>          </td>          <td>          </td>          <td colspan="2">          </td>          <td>          </td>          <td>          </td>          <td colspan="2">          </td>          <td>          </td>          <td>          </td>          <td colspan="2">          </td>          <td>          </td>          <td>          </td>          <td colspan="2">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="width: 40%">           <font style="font-size: 10pt">            Jeffrey W. Chell (2)           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="width: 9%; text-align: right">           <font style="font-size: 10pt">            51,000           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 9%; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="width: 9%; text-align: right">           <font style="font-size: 10pt">            56,240           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 9%; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="width: 9%; text-align: right">           <font style="font-size: 10pt">            107,240           </font>          </td>          <td style="width: 1%">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-size: 10pt">            David Nicholson           </font>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            63,000           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            56,240           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            119,240           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-size: 10pt">            Ajit J. Shetty           </font>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            58,500           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            56,240           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            114,740           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-size: 10pt">            Richard Steinhart           </font>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            63,000           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            56,240           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            119,240           </font>          </td>          <td>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">           <font style="font-size: 10pt">            (1)           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            The dollar amounts in this column represent the aggregate grant date fair value of all option awards granted during the indicated year. These amounts have been calculated in accordance with FASB ASC Topic 718, using the Black-Scholes option-pricing model. For a discussion of valuation assumptions, see Note 7 to our financial statements. These amounts do not necessarily correspond to the actual value that may be recognized from the option awards by the NEOs.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in; text-align: justify">           <font style="font-size: 10pt">            (2)           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            At December 31, 2020, the aggregate number of option awards outstanding for each director was as follows: (i) for Dr. Chell, 21,666, (ii) for Dr. Nicholson, 28,328, (iii) for Dr. Shetty, 21,666, and (iv) for Mr. Steinhart, 26,664.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Our non-employee directorsare paid an annual fee of $40,000 and receive annual option grants. Dr. Nicholson as Lead Director receives an additional annualfee of $10,000. Board committee members receive the following compensation:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td style="border-bottom: Black 1.5pt solid">           <font style="font-size: 10pt">            <b>             BOD Committee            </b>           </font>          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             Chairman            </b>           </font>          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             Member            </b>           </font>          </td>          <td style="padding-bottom: 1.5pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td colspan="2">          </td>          <td>          </td>          <td>          </td>          <td colspan="2">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="width: 78%">           <font style="font-size: 10pt">            Audit           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="width: 8%; text-align: right">           <font style="font-size: 10pt">            20,000           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="width: 8%; text-align: right">           <font style="font-size: 10pt">            6,000           </font>          </td>          <td style="width: 1%">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-size: 10pt">            Compensation           </font>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            10,000           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            5,000           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-size: 10pt">            Corporate Governance           </font>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            7,500           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            3,000           </font>          </td>          <td>          </td>         </tr>        </tbody>       </table>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="text-align: justify">          </td>         </tr>        </tbody>       </table>       <!-- Field: Page; Sequence: 88; Value: 51 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         68         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END- 2020        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The following tablesets forth all unexercised options that have been awarded to our named executives by the Company that were outstanding as of December31, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 10pt; text-indent: -10pt; padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td colspan="8" style="text-align: center; border-bottom: Black 1.5pt solid">           <font style="font-size: 10pt">            <b>             Option Awards            </b>           </font>          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td colspan="7" style="text-align: center; border-bottom: Black 1.5pt solid">           <font style="font-size: 10pt">            <b>             Stock Awards            </b>           </font>          </td>          <td style="padding-bottom: 1.5pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="border-bottom: Black 1.5pt solid; text-align: left">           <font style="font-size: 10pt">            <b>             Name            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             (a)            </b>           </font>          </td>          <td style="text-align: center; padding-bottom: 1.5pt">          </td>          <td style="text-align: center; padding-bottom: 1.5pt">          </td>          <td style="text-align: center; border-bottom: Black 1.5pt solid">           <font style="font-size: 10pt">            <b>             Number of            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Securities            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Underlying            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Unexercised            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Options            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             (#)            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             (Exercisable) (b)            </b>           </font>          </td>          <td style="text-align: center; padding-bottom: 1.5pt">          </td>          <td style="text-align: center; padding-bottom: 1.5pt">          </td>          <td style="text-align: center; border-bottom: Black 1.5pt solid">           <font style="font-size: 10pt">            <b>             Number of            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Securities            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Underlying            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Unexercised            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Options            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             (#)            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             (Unexercisable) (c)            </b>           </font>          </td>          <td style="text-align: center; padding-bottom: 1.5pt">          </td>          <td style="text-align: center; border-bottom: Black 1.5pt solid">           <font style="font-size: 10pt">            <b>             Equity            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Incentive            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Plan            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Awards:            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Number of            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Securities            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Underlying            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Unexercised Unearned            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Options            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             (#)            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             (d)            </b>           </font>          </td>          <td style="text-align: center; padding-bottom: 1.5pt">          </td>          <td style="text-align: center; border-bottom: Black 1.5pt solid">           <font style="font-size: 10pt">            <b>             Option            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Exercise            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Price            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             ($)            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             (e)            </b>           </font>          </td>          <td style="text-align: center; padding-bottom: 1.5pt">          </td>          <td style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid">           <font style="font-size: 10pt">            <b>             Option            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Expiration             <br/>             Date            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             (f)            </b>           </font>          </td>          <td style="text-align: center; padding-bottom: 1.5pt">          </td>          <td style="text-align: center; border-bottom: Black 1.5pt solid">           <font style="font-size: 10pt">            <b>             Number of            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Shares or            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Units of            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Stock That            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Have Not            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Vested            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             (#)            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             (g)            </b>           </font>          </td>          <td style="text-align: center; padding-bottom: 1.5pt">          </td>          <td style="text-align: center; border-bottom: Black 1.5pt solid">           <font style="font-size: 10pt">            <b>             Market            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Value of            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Shares            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             or Units            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             of Stock            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             That            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Have Not            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Vested            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             ($)            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             (h)            </b>           </font>          </td>          <td style="text-align: center; padding-bottom: 1.5pt">          </td>          <td style="text-align: center; border-bottom: Black 1.5pt solid">           <font style="font-size: 10pt">            <b>             Equity            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Incentive            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Plan            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Awards:            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Number            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             of            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Unearned            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Shares,            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Units or            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Other            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Rights            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             That            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Have Not            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Vested            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             (#)            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             (i)            </b>           </font>          </td>          <td style="text-align: center; padding-bottom: 1.5pt">          </td>          <td style="text-align: center; border-bottom: Black 1.5pt solid">           <font style="font-size: 10pt">            <b>             Equity            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Incentive            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Plan            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Awards:            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Market or            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Payout            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Value of            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Unearned            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Shares,            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Units or            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Other            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Rights            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             That            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Have Not            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Vested            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             ($)            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             (j)            </b>           </font>          </td>          <td style="text-align: center; padding-bottom: 1.5pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 10pt; text-indent: -10pt">          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td style="white-space: nowrap; text-align: center">          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="text-indent: -0.125in; padding-left: 0.125in; width: 23%">           <font style="font-size: 10pt">            Sandesh Seth           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 7%; text-align: right">           <font style="font-size: 10pt">            832           </font>          </td>          <td style="width: 1%">           <font style="font-size: 10pt">            <sup>             (1)            </sup>           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 7%; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 7%; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 7%; text-align: right">           <font style="font-size: 10pt">            45.05           </font>          </td>          <td style="width: 1%">          </td>          <td style="white-space: nowrap; width: 9%; text-align: center">           <font style="font-size: 10pt">            8/30/2022           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 7%; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 7%; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 7%; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 7%; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="width: 1%">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 10pt; text-indent: -10pt">          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            832           </font>          </td>          <td>           <font style="font-size: 10pt">            <sup>             (1)            </sup>           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            45.05           </font>          </td>          <td>          </td>          <td style="white-space: nowrap; text-align: center">           <font style="font-size: 10pt">            12/19/2022           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 10pt; text-indent: -10pt">          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            9,333           </font>          </td>          <td>           <font style="font-size: 10pt">            <sup>             (1)            </sup>           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            183.90           </font>          </td>          <td>          </td>          <td style="white-space: nowrap; text-align: center">           <font style="font-size: 10pt">            9/23/2024           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 10pt; text-indent: -10pt">          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            5,000           </font>          </td>          <td>           <font style="font-size: 10pt">            <sup>             (1)            </sup>           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            107.40           </font>          </td>          <td>          </td>          <td style="white-space: nowrap; text-align: center">           <font style="font-size: 10pt">            2/15/2025           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 10pt; text-indent: -10pt">          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            16,666           </font>          </td>          <td>           <font style="font-size: 10pt">            <sup>             (1)            </sup>           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            59.70           </font>          </td>          <td>          </td>          <td style="white-space: nowrap; text-align: center">           <font style="font-size: 10pt">            4/15/2026           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 10pt; text-indent: -10pt">          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            22,831           </font>          </td>          <td>           <font style="font-size: 10pt">            <sup>             (2)            </sup>           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            2,167           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            41.70           </font>          </td>          <td>          </td>          <td style="white-space: nowrap; text-align: center">           <font style="font-size: 10pt">            3/14/2027           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 10pt; text-indent: -10pt">          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            19,333           </font>          </td>          <td>           <font style="font-size: 10pt">            <sup>             (2)            </sup>           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            14,000           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            23.487           </font>          </td>          <td>          </td>          <td style="white-space: nowrap; text-align: center">           <font style="font-size: 10pt">            7/13/2028           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 10pt; text-indent: -10pt">          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            17,000           </font>          </td>          <td>           <font style="font-size: 10pt">            <sup>             (2)            </sup>           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            33,000           </font>          </td>          <td style="text-align: right">          </td>          <td style="text-align: right">           -          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            6.96           </font>          </td>          <td>          </td>          <td style="white-space: nowrap; text-align: center">           <font style="font-size: 10pt">            7/12/2029           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 10pt; text-indent: -10pt">          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            11,125           </font>          </td>          <td>           <font style="font-size: 10pt">            <sup>             (2)            </sup>           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            127,937           </font>          </td>          <td style="text-align: right">          </td>          <td style="text-align: right">           -          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            9.55           </font>          </td>          <td>          </td>          <td style="white-space: nowrap; text-align: center">           <font style="font-size: 10pt">            8/12/2030           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 10pt; text-indent: -10pt">          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td style="white-space: nowrap; text-align: center">          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="text-indent: -0.125in; padding-left: 0.125in">           <font style="font-size: 10pt">            Mark Berger           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            10,016           </font>          </td>          <td>           <font style="font-size: 10pt">            <sup>             (3)            </sup>           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            217           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            31.20           </font>          </td>          <td>          </td>          <td style="white-space: nowrap; text-align: center">           <font style="font-size: 10pt">            1/17/2027           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 10pt; text-indent: -10pt">          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            4,833           </font>          </td>          <td>           <font style="font-size: 10pt">            <sup>             (2)            </sup>           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            3,500           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            23.487           </font>          </td>          <td>          </td>          <td style="white-space: nowrap; text-align: center">           <font style="font-size: 10pt">            7/13/2028           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 10pt; text-indent: -10pt">          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            4,533           </font>          </td>          <td>           <font style="font-size: 10pt">            <sup>             (2)            </sup>           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            8,800           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            6.96           </font>          </td>          <td>          </td>          <td style="white-space: nowrap; text-align: center">           <font style="font-size: 10pt">            7/12/2029           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 10pt; text-indent: -10pt">          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            3,733           </font>          </td>          <td>           <font style="font-size: 10pt">            <sup>             (2)            </sup>           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            42,934           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            9.55           </font>          </td>          <td>          </td>          <td style="white-space: nowrap; text-align: center">           <font style="font-size: 10pt">            8/12/2030           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 10pt; text-indent: -10pt">          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td style="white-space: nowrap; text-align: center">          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="text-indent: -0.125in; padding-left: 0.125in">           <font style="font-size: 10pt">            Dale Ludwig           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            4,933           </font>          </td>          <td>           <font style="font-size: 10pt">            <sup>             (4)            </sup>           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            1,733           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            21.69           </font>          </td>          <td>          </td>          <td style="white-space: nowrap; text-align: center">           <font style="font-size: 10pt">            1/08/2028           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 10pt; text-indent: -10pt">          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            4,533           </font>          </td>          <td>           <font style="font-size: 10pt">            <sup>             (2)            </sup>           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            8,800           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            6.96           </font>          </td>          <td>          </td>          <td style="white-space: nowrap; text-align: center">           <font style="font-size: 10pt">            7/12/2029           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 10pt; text-indent: -10pt">          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            4,000           </font>          </td>          <td>           <font style="font-size: 10pt">            <sup>             (2)            </sup>           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            46,000           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            9.55           </font>          </td>          <td>          </td>          <td style="white-space: nowrap; text-align: center">           <font style="font-size: 10pt">            8/12/2030           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 10pt; text-indent: -10pt">          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td style="white-space: nowrap; text-align: center">          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="text-indent: -0.125in; padding-left: 0.125in">           <font style="font-size: 10pt">            Steve O’Loughlin           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            3,333           </font>          </td>          <td>           <font style="font-size: 10pt">            <sup>             (1)            </sup>           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            53.70           </font>          </td>          <td>          </td>          <td style="white-space: nowrap; text-align: center">           <font style="font-size: 10pt">            9/28/2025           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 10pt; text-indent: -10pt">          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            1,666           </font>          </td>          <td>           <font style="font-size: 10pt">            <sup>             (1)            </sup>           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            59.70           </font>          </td>          <td>          </td>          <td style="white-space: nowrap; text-align: center">           <font style="font-size: 10pt">            4/15/2026           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 10pt; text-indent: -10pt">          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            3,083           </font>          </td>          <td>           <font style="font-size: 10pt">            <sup>             (2)            </sup>           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            250           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            41.70           </font>          </td>          <td>          </td>          <td style="white-space: nowrap; text-align: center">           <font style="font-size: 10pt">            3/14/2027           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 10pt; text-indent: -10pt">          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            5,123           </font>          </td>          <td>           <font style="font-size: 10pt">            <sup>             (2)            </sup>           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            3,710           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            23.487           </font>          </td>          <td>          </td>          <td style="white-space: nowrap; text-align: center">           <font style="font-size: 10pt">            7/13/2028           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 10pt; text-indent: -10pt">          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            4,533           </font>          </td>          <td>           <font style="font-size: 10pt">            <sup>             (2)            </sup>           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            8,800           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            6.96           </font>          </td>          <td>          </td>          <td style="white-space: nowrap; text-align: center">           <font style="font-size: 10pt">            7/12/2029           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 10pt; text-indent: -10pt">          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            4,725           </font>          </td>          <td>           <font style="font-size: 10pt">            <sup>             (2)            </sup>           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            54,341           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            9.55           </font>          </td>          <td>          </td>          <td style="white-space: nowrap; text-align: center">           <font style="font-size: 10pt">            8/12/2030           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">           <font style="font-size: 10pt">            (1)           </font>          </td>          <td>           <font style="font-size: 10pt">            Fully vested.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-size: 10pt">            (2)           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            Pursuant to the terms of the Company’s 2013 Stock Plan, 2% of these options vest each month from the date of grant.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">           <font style="font-size: 10pt">            (3)           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            28% of these options vested on January 17, 2018, and the remaining 75% vest in equal increments of 2% per month of the from January 17, 2018 over the following three-year period.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">           <font style="font-size: 10pt">            (4)           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            28% of these options vested on January 8, 2019, and the remaining 75% vest in equal increments of 2% per month from January 8, 2019 over the following three-year period.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 89; Value: 51 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         69         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Indemnification of Directors and Officers        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Section 102(b)(7) ofthe Delaware General Corporation Law allows a corporation to provide in its certificate of incorporation that a director of thecorporation will not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary dutyas a director, except where the directors breached the duty of loyalty, failed to act in good faith, engaged in intentional misconductor knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporatelaw or obtained an improper personal benefit. Our certificate of incorporation provides for this limitation of liability.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Section 145 of theGeneral Corporation Law of the State of Delaware provides that a Delaware corporation may indemnify any person who was, is or isthreatened to be made, party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrativeor investigative (other than an action by or in the right of such corporation), by reason of the fact that such person is or wasan officer, director, employee or agent of such corporation or is or was serving at the request of such corporation as a director,officer employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys’fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with suchaction, suit or proceeding, provided such person acted in good faith and in a manner he reasonably believed to be in or not opposedto the corporation’s best interests and, with respect to any criminal action or proceeding, had no reasonable cause to believethat his conduct was illegal. A Delaware corporation may indemnify any persons who are, or were, a party to any threatened, pendingor completed action or suit by or in the right of the corporation by reason of the fact that such person is or was a director,officer, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys’fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit, providedsuch person acted in good faith and in a manner he reasonably believed to be in or not opposed to the corporation’s bestinterests, provided that no indemnification is permitted without judicial approval if the officer, director, employee or agentis adjudged to be liable to the corporation. Where an officer or director is successful on the merits or otherwise in the defenseof any action referred to above, the corporation must indemnify him against the expenses which such officer or directors has actuallyand reasonably incurred.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Section 145 furtherauthorizes a corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employeeor agent of the corporation or is or was serving at the request of the corporation as a director, officer, employee or agent ofanother corporation or enterprise, against any liability asserted against him and incurred by him in any such capacity, or arisingout of his status as such, whether or not the corporation would otherwise have the power to indemnify him under Section 145.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Our bylaws providethat we will indemnify our directors and officers to the fullest extent authorized by the General Corporation Law of the Stateof Delaware.  Expenses (including attorneys’ fees) incurred by an officer or director of the Corporation in defendingany civil, criminal, administrative or investigative action, suit or proceeding may be paid by the Company in advance of the finaldisposition of such action, suit or proceeding upon receipt of an undertaking by or on behalf of such director or officer to repaysuch amount if it shall ultimately be determined that such person is not entitled to be indemnified by the Company as authorizedunder Delaware law.  Such expenses (including attorneys’ fees) incurred by former directors and officers or otheremployees and agents of the Company or by persons serving at the request of the Company as directors, officers, employees or agentsof another corporation, partnership, joint venture, trust or other enterprise may be so paid upon such terms and conditions, ifany, as the Company deems appropriate.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The indemnificationrights set forth above shall not be exclusive of any other right which an indemnified person may have or hereafter acquire underany bylaw, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in such person’s officialcapacity and as to action in another capacity while holding such office, and shall continue as to a person who has ceased to bea director, officer, employee, or agent and shall inure to the benefit of the heirs, executors, and administrators of such person.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We maintain a generalliability insurance policy that covers liabilities of directors and officers of our corporation arising out of claims based onacts or omissions in their capacities as directors or officers. We have also entered in to Indemnification Agreements with ourexecutive officers and directors.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        At the present time,there is no pending litigation or proceeding involving a director, officer, employee, or other agent of ours in which indemnificationwould be required or permitted. We are not aware of any threatened litigation or proceeding that may result in a claim for suchindemnification.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 90; Value: 51 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         70         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <a name="aph165213a020">        </a>        <b>         ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERSAND MANAGEMENT        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The following tableshows the beneficial ownership of our Common Stock as of March 26, 2021 held by (i) each person known to us to be the beneficialowner of more than five percent (5%) of any class of our shares; (ii) each director; (iii) each executive officer; and (iv) alldirectors and executive officers as a group.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Beneficial ownershipis determined in accordance with the rules of the SEC, and generally includes voting power and/or investment power with respectto the securities held.  Shares of Common Stock subject to options and warrants currently exercisable or which may becomeexercisable within 60 days of March 26, 2021, are deemed outstanding and beneficially owned by the person holding such optionsor warrants for purposes of computing the number of shares and percentage beneficially owned by such person, but are not deemedoutstanding for purposes of computing the percentage beneficially owned by any other person.  Except as indicated inthe footnotes to this table, the persons or entities named have sole voting and investment power with respect to all shares ofour Common Stock shown as beneficially owned by them.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Unless otherwise indicated,the principal address of each of the persons below is c/o Actinium Pharmaceuticals, Inc., 275 Madison Ave, 7th floor, New York,NY 10016.        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td style="border-bottom: Black 1.5pt solid">           <font style="font-size: 10pt">            <b>             Named Executive Officers and Directors            </b>           </font>          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             Number of            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Shares of            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Common            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Stock            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Beneficially            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             Owned            </b>           </font>          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             Percentage             <br/>             of             <br/>             Ownership             <sup>              (a)             </sup>            </b>           </font>          </td>          <td style="padding-bottom: 1.5pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="width: 76%">           <font style="font-size: 10pt">            Sandesh Seth           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 9%; text-align: right">           <font style="font-size: 10pt">            140,124           </font>          </td>          <td style="width: 1%">           <font style="font-size: 10pt">            <sup>             (1)            </sup>           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 9%; text-align: right">           <font style="font-size: 10pt">            *           </font>          </td>          <td style="width: 1%">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-size: 10pt">            Steve O’Loughlin           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            32,019           </font>          </td>          <td>           <font style="font-size: 10pt">            <sup>             (2)            </sup>           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            *           </font>          </td>          <td>           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-size: 10pt">            Mark Berger, M.D.           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            31,516           </font>          </td>          <td>           <font style="font-size: 10pt">            <sup>             (3)            </sup>           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            *           </font>          </td>          <td>           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-size: 10pt">            Dale Ludwig, Ph.D.           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            20,799           </font>          </td>          <td>           <font style="font-size: 10pt">            <sup>             (4)            </sup>           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            *           </font>          </td>          <td>           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-size: 10pt">            Jeffrey W. Chell, M.D.           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            8,766           </font>          </td>          <td>           <font style="font-size: 10pt">            <sup>             (5)            </sup>           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            *           </font>          </td>          <td>           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-size: 10pt">            David Nicholson, Ph.D.           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            16,511           </font>          </td>          <td>           <font style="font-size: 10pt">            <sup>             (6)            </sup>           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            *           </font>          </td>          <td>           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-size: 10pt">            Ajit S. Shetty, Ph.D.           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            10,123           </font>          </td>          <td>           <font style="font-size: 10pt">            <sup>             (7)            </sup>           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            *           </font>          </td>          <td>           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-size: 10pt">            Richard I. Steinhart           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            14,680           </font>          </td>          <td>           <font style="font-size: 10pt">            <sup>             (8)            </sup>           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            *           </font>          </td>          <td>           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-size: 10pt">            <b>             All Directors and Officers as a Group (8 persons)            </b>           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            274,538           </font>          </td>          <td>           <font style="font-size: 10pt">            <sup>             (9)            </sup>           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            1.4           </font>          </td>          <td>           <font style="font-size: 10pt">            %           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0px">          </td>          <td style="width: 0.25in">           *          </td>          <td style="text-align: justify">           less than 1%          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           (a)          </td>          <td style="text-align: justify">           Based on 18,774,278 shares of common stock outstanding as of March 26, 2021.          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td style="text-align: justify">          </td>         </tr>        </tbody>       </table>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: .25in">           (1)          </td>          <td style="text-align: justify">           Includes warrants to purchase an aggregate of 2,158 shares of common stock of the Company at an exercise price of $23.51 per share, exercisable on a cashless basis, and warrants to purchase an aggregate of 3,320 shares of common stock of the Company at an exercise price of $23.51 per share, exercisable on a cashless basis issued to Amrosan, LLC, a partnership in which the majority member interest is owned by the family of Mr. Seth, and warrants to purchase 1,907 shares of common stock at an exercise price of $15.61515 per share. Excludes warrants to purchase an aggregate of 12,518 shares of common stock of the Company at par value per share, exercisable on a cashless basis issued to Amrosan, LLC as the warrants are not exercisable upon less than 90 days’ notice. The holder may waive the 90-day exercise notice requirement by giving 65 days prior notice of such waiver. Excludes warrants to purchase an aggregate of 11,767 shares of common stock issued to Carnegie Hill Asset Partners, an irrevocable trust linked to Mr. Seth’s family and warrants to purchase an aggregate of 24,035 shares of common stock issued to Bioche Asset Management, LLC, a partnership in which the majority member interest is owned by the family of Mr. Seth, whose terms are the same as those issued to Amrosan LLC. On August 30, 2012 and December 19, 2012, Mr. Seth was granted options to purchase an aggregate of 1,664 shares of common stock at an exercise price of $45.05 per share. On September 23, 2014, Mr. Seth was granted an option to purchase 9,333 shares of common stock with an exercise price of $183.90 per share. On February 18, 2015, Mr. Seth was granted an option to purchase 5,000 shares of common stock with an exercise price of $107.40 per share. On April 15, 2016, Mr. Seth was granted an option to purchase 16,666 shares of common stock at an exercise price of $59.70 per share. On March 14, 2017, Mr. Seth was granted options to purchase an aggregate of 24,998 shares of common stock at an exercise price of $41.70 per share. On July 13, 2018, Mr. Seth was granted an option to purchase 33,333 shares of common stock at an exercise price of $23.487 per share. On July 12, 2019, Mr. Seth was granted an option to purchase 50,000 shares of common stock at an exercise price of $6.96 per share. On August 12, 2020, Mr. Seth was granted an option to purchase 139,062 shares of common stock at an exercise price of $9.55 per share. All options are subject to vesting. Within 60 days of March 26, 2021, options to purchase 127,358 shares of common stock will have vested. Includes 5,381 shares of common stock.          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>        </tbody>       </table>       <!-- Field: Page; Sequence: 91; Value: 51 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         71         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="width: 0.25in; text-align: justify">           <font style="font-size: 10pt">            (2)           </font>          </td>          <td style="text-align: justify">           On October 1, 2015, Mr. O’Loughlin        was granted options to purchase 3,333 shares of common stock with an exercise price of $53.70 per share. On April 15,        2016, Mr. O’Loughlin was granted options to purchase of 1,666 shares of common stock at an exercise price of $59.70        per share. On March 14, 2017, Mr. O’Loughlin was granted options to purchase 3,333 shares of common stock at an exercise        price of $41.70 per share. On July 13, 2018, Mr. O’Loughlin was granted an option to purchase 8,833 shares of common stock        at an exercise price of $23.487 per share. On July 12, 2019, Mr. O’Loughlin was granted an option to purchase 13,333 shares        of common stock at an exercise price of $6.96 per share. On August 12, 2020, Mr. O’Loughlin was granted an option to purchase        59,066 shares of common stock at an exercise price of $9.55 per share. All options are subject to vesting. Within 60 days        of March 26, 2021, options to purchase 30,836 shares of common stock will have vested. Includes 1,183 shares of common stock.          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">           <font style="font-size: 10pt">            (3)           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            On January 17, 2017, Dr. Berger was granted an option to purchase 10,833 shares of common stock with an exercise price of $31.20 per share. On July 13, 2018, Dr. Berger was granted an option to purchase 8,333 shares of common stock at an exercise price of $23.487 per share. On July 12, 2019, Dr. Berger was granted an option to purchase 13,333 shares of common stock at an exercise price of $6.96 per share. On August 12, 2020, Dr. Berger was granted an option to purchase 46,667 shares of common stock at an exercise price of $9.55 per share. All options are subject to vesting. Within 60 days of March 26, 2021, options to purchase 30,766 shares of common stock will have vested. Includes 750 shares of common stock.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>        </tbody>       </table>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in; text-align: justify">           <font style="font-size: 10pt">            (4)           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            On January 8, 2018, Dr. Ludwig was granted an option to purchase 6,666 shares of common stock with an exercise price of $21.69 per share. On July 12, 2019, Dr. Ludwig was granted an option to purchase 13,333 shares of common stock at an exercise price of $6.96 per share. On August 12, 2020, Dr. Ludwig was granted an option to purchase 50,000 shares of common stock at an exercise price of $9.55 per share. All options are subject to vesting. Within 60 days of March 26, 2021, options to purchase  20,466 shares of common stock will have vested. Includes 333 shares of common stock.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>        </tbody>       </table>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in; text-align: justify">           <font style="font-size: 10pt">            (5)           </font>          </td>          <td style="text-align: justify">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">            On April 27, 2018, Dr. Chell wasgranted an option to purchase 2,500 shares of common stock with an exercise price of $10.41 per share. On July 13, 2018, Dr. Chellwas granted an option to purchase 2,500 shares of common stock at an exercise price of $23.487 per share. On July 12, 2019, Dr.Chell was granted an option to purchase 8,333 shares of common stock at an exercise price of $6.96 per share. On August 12, 2020,Dr. Chell was granted an option to purchase 8,333 shares of common stock at an exercise price of $9.55 per share. All optionsare subject to vesting. Within 60 days of March 26, 2021, options to purchase 8,766 shares of common stock will have vested.           </p>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">           <font style="font-size: 10pt">            (6)           </font>          </td>          <td style="text-align: justify">           On February 12, 2012, Dr. Nicholson was granted an option to purchase 1,665 shares of common stock at an exercise price of $23.51 per share and on August 12, 2012 and December 19, 2012, Dr. Nicholson was granted options to purchase an aggregate of 1,664 shares of common stock at an exercise price of $45.05 per share. On February 18, 2015, Dr. Nicholson was granted an option to purchase 833 shares of common stock with an exercise price of $107.40 per share. On April 15, 2016, Dr. Nicholson was granted an option to purchase 2,500 shares of common stock at an exercise price of $59.70 per share. On March 14, 2017, Dr. Nicholson was granted an option to purchase 2,500 shares of common stock at an exercise price of $41.70 per share. On July 13, 2018, Dr. Nicholson was granted an option to purchase 2,500 shares of common stock at an exercise price of $23.487 per share. On July 12, 2019, Dr. Nicholson was granted an option to purchase 8,333 shares of common stock at an exercise price of $6.96 per share. On August 12, 2020, Dr. Nicholson was granted an option to purchase 8,333 shares of common stock at an exercise price of $9.55 per share. All options are subject to vesting. Within 60 days of March 26, 2021, options to purchase 16,178 shares of common stock will have vested. Includes 333 shares of common stock.          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td>           (7)          </td>          <td style="text-align: justify">           On March 28, 2017, Dr. Shetty was granted an option to purchase 2,500 shares of common stock with an exercise price of $47.40 per share. On July 13, 2018, Dr. Shetty was granted an option to purchase 2,500 shares of common stock at an exercise price of $23.487 per share. On July 12, 2019, Dr. Shetty was granted an option to purchase 8,333 shares of common stock at an exercise price of $6.96 per share. On August 12, 2020, Dr. Shetty was granted an option to purchase 8,333 shares of common stock at an exercise price of $9.55 per share. All options are subject to vesting. Within 60 days of March 26, 2021, options to purchase 10,123 shares of common stock will have vested. Includes 757 shares of common stock.          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td>           (8)          </td>          <td style="text-align: justify">           On December 16, 2013, Mr. Steinhart was granted an option to purchase 1,665 shares of common stock at an exercise price of $201.00 per share. On February 18, 2015, Mr. Steinhart was granted an option to purchase 833 shares of common stock at an exercise price of $107.40 per share. On April 15, 2016, Mr. Steinhart was granted an option to purchase 2,500 shares of common stock at an exercise price of $59.70 per share. On March 14, 2017, Mr. Steinhart was granted an option to purchase 2,500 shares of common stock at an exercise price of $41.70 per share. On July 13, 2018, Mr. Steinhart was granted an option to purchase 2,500 shares of common stock at an exercise price of $23.487 per share. On July 12, 2019, Mr. Steinhart was granted an option to purchase 8,333 shares of common stock at an exercise price of $6.96 per share. On August 12, 2020, Mr. Steinhart was granted an option to purchase 8,333 shares of common stock at an exercise price of $9.55 per share. All options are subject to vesting. Within 60 days of March 26, 2021, options to purchase 14,364 shares of common stock will have vested. Includes 316 shares of common stock.          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td>           (9)          </td>          <td style="text-align: justify">           Includes warrants to purchase 7,385 shares of common stock, vested options to purchase 258,100 shares of common stock and 9,053 shares of common stock.          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>        </tbody>       </table>       <!-- Field: Page; Sequence: 92; Value: 51 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         72         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <a name="aph165213a021">        </a>        <b>         ITEM 13. CERTAIN RELATIONSHIPS AND RELATEDTRANSACTIONS, AND DIRECTOR INDEPENDENCE        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Transactions with Related Persons        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        None.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Non-Competition Agreements        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Our executive officershave signed non-competition agreements, which provide that all inventions become the immediate property of us and require inventionassignments. The agreements provide that the executive officers will hold proprietary information in the strictest confidence andnot use the confidential information for any purpose not expressly authorized by us.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <a name="aph165213a022">        </a>        <b>         ITEM 14. PRINCIPAL ACCOUNTANT FEES ANDSERVICES        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The table below showsthe aggregate fees billed for professional services for the audits and audit-related fees of the Company’s annual financialstatements included in Form 10-K for the years ending December 31, 2020 and 2019, respectively, by Marcum LLP.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td style="padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             Year Ended            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             December 31,            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             2020            </b>           </font>          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             Year Ended            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             December 31,            </b>           </font>           <br/>           <font style="font-size: 10pt">            <b>             2019            </b>           </font>          </td>          <td style="padding-bottom: 1.5pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="width: 78%">           <font style="font-size: 10pt">            Audit Fees           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="width: 8%; text-align: right">           <font style="font-size: 10pt">            130,004           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="width: 8%; text-align: right">           <font style="font-size: 10pt">            116,000           </font>          </td>          <td style="width: 1%">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-size: 10pt">            Audit – Related Fees           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            83,630           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            33,000           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-size: 10pt">            Tax Fees           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-bottom: 1.5pt">           <font style="font-size: 10pt">            All Other Fees           </font>          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="padding-bottom: 1.5pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 4pt">           <font style="font-size: 10pt">            <b>             Total            </b>           </font>          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           <font style="font-size: 10pt">            213,634           </font>          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           <font style="font-size: 10pt">            149,000           </font>          </td>          <td style="padding-bottom: 4pt">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">        <i>         Audit Fees.        </i>        This category includes the audit of our annualconsolidated financial statements, reviews of our financial statements included in our Form 10-Qs and services that are normallyprovided by our independent registered public accounting firm in connection with its engagements for those years.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">        <i>         Audit-Related Fees.        </i>        This category consists of assuranceand related services by our independent registered public accounting firm that are reasonably related to the performance of theaudit or review of our financial statements and are not reported above under “Audit Fees.” The services for the feesdisclosed under this category include consents regarding equity issuances.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Pre-Approval Policy        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In 2015, the AuditCommittee adopted policies and procedures for the pre-approval of audit and non-audit services performed by the independent registeredpublic accountants pursuant to which the Audit Committee generally is required to pre-approve the audit and permissible non-auditservices performed by the independent registered public accountants in order to ensure that the provision of such services doesnot impair the registered accountants’ independence.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        All of the services rendered by Marcum in2020 were pre-approved by the Audit Committee.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">       </p>       <!-- Field: Page; Sequence: 93; Value: 51 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         73         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <a name="aph165213a023">        </a>        <b>         PART IV        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <a name="aph165213a024">        </a>        <b>         ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr>          <td style="border-bottom: Black 1.5pt solid; vertical-align: top; text-align: center">           <font style="font-size: 10pt">            <b>             Exhibit            </b>            <br/>            <b>             Number            </b>           </font>          </td>          <td style="padding-bottom: 1.5pt; vertical-align: bottom">          </td>          <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: justify">           <font style="font-size: 10pt">            <b>             Description            </b>           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; width: 9%; text-align: center">           <font style="font-size: 10pt">            1.1           </font>          </td>          <td style="vertical-align: bottom; width: 1%">          </td>          <td style="vertical-align: bottom; width: 90%; text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390016017124/f8k092816ex1i_actinium.htm">            <font style="font-size: 10pt">             Underwriting Agreement, dated September 28, 2016, by and between H.C. Wainwright &amp; Co., LLC and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 1.1 to Form 8-K filed on September 29, 2016).            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: justify">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            1.2           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390017002475/fs32017ex1ii_actiniumpharma.htm">            <font style="font-size: 10pt">             At Market Issuance Sales Agreement, dated March 16, 2017, between FBR Capital Markets &amp; Co, and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 1.2 to Form S-3 filed on March 16, 2017).            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: justify">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            1.3           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390017008244/f10q0617ex10v_actinium.htm">            <font style="font-size: 10pt">             Amended and Restated At-the-Market Market Issuance Sales Agreement, dated July 3, 2017, among FBR Capital Markets &amp; Co., MLV &amp; Co. LLC, JonesTrading Institutional Services LLC, and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.5 to Form 10-Q filed on August 4, 2017).            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: justify">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            1.4           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390017007992/f8k072817ex1i_actinium.htm">            <font style="font-size: 10pt">             Underwriting Agreement, dated as of July 28, 2017, by and between Actinium Pharmaceuticals, Inc. and Oppenheimer &amp; Co. Inc. as representative of the several underwriters party thereto (incorporated by reference to Exhibit 1.1 to Form 8-K filed on July 28, 2017).            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: justify">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            1.5           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390018001918/f8k021518ex1-1_actinium.htm">            <font style="font-size: 10pt">             Dealer-Manager Agreement, dated February 15, 2018, between Maxim Group LLC and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 1.1 to Form 8-K filed on February 15, 2018).            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            1.6           </font>          </td>          <td>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390019006723/f8k041819ex1-1_actinium.htm">            <font style="font-size: 10pt">             Underwriting Agreement, dated April 18, 2019, by and between Actinium Pharmaceuticals, Inc. and William Blair &amp; Company, LLC (incorporated by reference to Exhibit 1.1 to Form 8-K filed on April 18, 2019).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            1.7           </font>          </td>          <td>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390020010060/ea120946ex1-1_actinium.htm">            <font style="font-size: 10pt">             Underwriting Agreement, dated as of April 21, 2020, by and between Actinium Pharmaceuticals, Inc. and H.C. Wainwright &amp; Co., LLC. (incorporated by reference to Exhibit 1.1 to Form 8-K filed on April 24, 2020).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            1.8           </font>          </td>          <td>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390020020895/ea125182ex1-2_actinium.htm">            <font style="font-size: 10pt">             Capital on Demand™ Sales Agreement, dated August 7, 2020, by and between Actinium Pharmaceuticals, Inc. and JonesTrading Institutional Services LLC (incorporated by reference to Exhibit 1.2 to Registration Statement on Form S-3 filed on August 7, 2020).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            2.1           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000107878212003323/f8k122112_ex2z1.htm">            <font style="font-size: 10pt">             Share Exchange Agreement, dated December 28, 2012, by and among Cactus Ventures, Inc., Actinium Pharmaceuticals, Inc., Diane S. Button, and the shareholders of Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 2.1 to Form 8-K filed on January 2, 2013).            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: justify">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            2.2           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390013001029/f8k031113ex10i_cactus.htm">            <font style="font-size: 10pt">             Share Exchange Agreement, dated March 11, 2013, by and among Cactus Ventures, Inc., Actinium Pharmaceuticals, Inc, and the shareholders of Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 to Form 8-K filed on March 11, 2013).            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: justify">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            2.3           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390013004770/fs12013a1ex2iii_actinium.htm">            <font style="font-size: 10pt">             Share Exchange Agreement, dated August 22, 2013, by and among Actinium Pharmaceuticals, Inc, Actinium Corporation, and the shareholders of Actinium Corporation (incorporated by reference to Exhibit 2.3 to Form S-1/A filed on August 22, 2013).            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: justify">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            3.1           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390013001911/f8k041113ex3i_actinium.htm">            <font style="font-size: 10pt">             Certificate of Incorporation of Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.1 of the Company’s Form 8-K filed with the SEC on April 17, 2013).            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: justify">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            3.2           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390014000604/fs12014ex3v_actinium.htm">            <font style="font-size: 10pt">             Certificate of Amendment to Certificate of Incorporation filed January 7, 2014 (incorporated by reference to Exhibit 3.5 to Form S-1 filed on January 31, 2014).            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: justify">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            3.3           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390014000688/f8k020314ex3i_actinium.htm">            <font style="font-size: 10pt">             Certificate of Amendment to Certificate of Incorporation filed February 3, 2014. (incorporated by reference to Exhibit 3.1 to Form 8-K filed on February 7, 2014).            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: justify">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            3.4           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390015001553/f8k022615ex3i_actinium.htm">            <font style="font-size: 10pt">             Certificate of Amendment to Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to Form 8-K filed on March 4, 2015).            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: justify">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            3.5           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390018002270/f8k022618ex3-1_actinium.htm">            <font style="font-size: 10pt">             Certificate of Amendment to Actinium’s Certificate of Incorporation, as amended, filed on February 26, 2018 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on February 26, 2018).            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: justify">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            3.6           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390019004269/f10k2018ex3-7_actinium.htm">            <font style="font-size: 10pt">             Certificate of Amendment to Actinium’s Certificate of Incorporation, as amended, filed on March 6, 2019 (incorporated by reference to Exhibit 3.7 to Form 10-K filed on March 15, 2019).            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: justify">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            3.7           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390020015104/ea123121ex3-1_actiniumpharma.htm">            <font style="font-size: 10pt">             Certificate of Amendment to Certificate of Incorporation, as amended, filed on June 16, 2020 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on June 16, 2020).            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: justify">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; text-align: center">           <font style="font-size: 10pt">            3.8           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390018010603/f10q0618ex3-1_actinium.htm">            <font style="font-size: 10pt">             Amended and Restated Bylaws, dated August 8, 2018 (incorporated by reference to Exhibit 3.1 to Form 10-Q filed on August 9, 2018).            </font>           </a>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <!-- Field: Page; Sequence: 94; Value: 51 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         74         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; text-align: center; width: 9%">           <font style="font-size: 10pt">            3.9           </font>          </td>          <td style="vertical-align: bottom; width: 1%">          </td>          <td style="vertical-align: bottom; text-align: justify; width: 90%">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390020011052/ea121342ex3-1_actinium.htm">            <font style="font-size: 10pt">             Amendment to the Amended and Restated Bylaws, dated May 7, 2020 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on May 5, 2020).            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            4.1           </font>          </td>          <td>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390014000604/fs12014ex4viii_actinium.htm">            <font style="font-size: 10pt">             Form of Common Stock Warrant, dated December 27, 2013 and January 10, 2014 (incorporated by reference to Exhibit 4.8 to Form S-1 filed on January 31, 2014).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            4.2           </font>          </td>          <td>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390015000762/f8k020615ex4i_actinium.htm">            <font style="font-size: 10pt">             Form of Warrant (incorporated by reference to Exhibit 4.1 to Form 8-K filed on February 6, 2015).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            4.3           </font>          </td>          <td>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390017007992/f8k072817ex10i_actinium.htm">            <font style="font-size: 10pt">             Form of Warrant (incorporated by reference to Exhibit 10.1 to Form 8-K filed on July 28, 2017).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            4.4           </font>          </td>          <td>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390018001918/f8k021518ex4-1_actinium.htm">            <font style="font-size: 10pt">             Form of Warrant Agency Agreement between Action Stock Transfer Corporation and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 4.1 to Form 8-K filed on February 15, 2018).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            4.5           </font>          </td>          <td>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390018001918/f8k021518ex4-2_actinium.htm">            <font style="font-size: 10pt">             Form of Series A Warrant (incorporated by reference to Exhibit 4.2 to Form 8-K filed on February 15, 2018).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            4.6           </font>          </td>          <td>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390018001918/f8k021518ex4-3_actinium.htm">            <font style="font-size: 10pt">             Form of Series B Warrant (incorporated by reference to Exhibit 4.3 to Form 8-K filed on February 15, 2018).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            4.7           </font>          </td>          <td>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390018001918/f8k021518ex4-4_actinium.htm">            <font style="font-size: 10pt">             Form of Non-Transferable Subscription Rights Certificate (incorporated by reference to Exhibit 4.4 to Form 8-K filed on February 15, 2018).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            4.8           </font>          </td>          <td>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390018002270/f8k022618ex4-1_actinium.htm">            <font style="font-size: 10pt">             Revised Form of Non-Transferable Subscription Rights Certificate. (incorporated by reference to Exhibit 4.1 to Form 8-K filed on February 26, 2018).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            4.9           </font>          </td>          <td>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390018015315/f10q0918ex4-1_actinium.htm">            <font style="font-size: 10pt">             Amendment to Warrant to Purchase Common Stock, dated November 8, 2018, issued to Amrosan LLC (incorporated by reference to Exhibit 4.1 to Form 10-Q filed on November 9, 2018).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            4.10           </font>          </td>          <td>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390018015315/f10q0918ex4-2_actinium.htm">            <font style="font-size: 10pt">             Amendment to Warrant to Purchase Common Stock, dated November 8, 2018, issued to Carnegie Hill Partners (incorporated by reference to Exhibit 4.2 to Form 10-Q filed on November 9, 2018).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            4.11           </font>          </td>          <td>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390018015315/f10q0918ex4-3_actinium.htm">            <font style="font-size: 10pt">             Amendment to Warrant to Purchase Common Stock, dated November 8, 2018, issued to Bioche Asset Management, LLC (incorporated by reference to Exhibit 4.3 to Form 10-Q filed on November 9, 2018).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            4.12           </font>          </td>          <td>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390019006723/f8k041819ex4-1_actinium.htm">            <font style="font-size: 10pt">             Form of Warrant (incorporated by reference to Exhibit 4.1 to Form 8-K filed on April 18, 2019).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            4.13           </font>          </td>          <td>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390020010060/ea120946ex4-1_actinium.htm">            <font style="font-size: 10pt">             Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to Form 8-K filed on April 24, 2020).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            4.14           </font>          </td>          <td>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390020015271/ea123189ex4-1_actinium.htm">            <font style="font-size: 10pt">             Form of Pre-Funded Common Stock Warrant (incorporated by reference to Exhibit 4.1 to Form 8-K filed on June 18, 2020).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            4.15*           </font>          </td>          <td>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            <a href="f10k2020ex4-15_actinium.htm">             Description of securities            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            10.1#           </font>          </td>          <td>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390016011534/f10k2015ex10xxxxxvi_actinium.htm">            <font style="font-size: 10pt">             Third Amendment to the 2013 Amended and Restated Stock Plan, effective as of December 22, 2015 (incorporated by reference to Exhibit 10.56 to Form 10-K filed on March 11, 2016).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            10.2           </font>          </td>          <td>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390016011534/f10k2015ex10lvii_actinium.htm">            <font style="font-size: 10pt">             Office Space License Agreement, dated March 19, 2016, by and between Actinium Pharmaceuticals, Inc. and Relmada Therapeutics, Inc. (incorporated by reference to Exhibit 10.57 to Form 10-K filed on March 11, 2016).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            10.3#           </font>          </td>          <td>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390016019421/f8k121316ex1i_actiniumpharma.htm">            <font style="font-size: 10pt">             Fourth Amendment to the 2013 Amended and Restated Stock Plan, effective as of December 13, 2016 (incorporated by reference to Exhibit 1.1 to Form 8-K filed on December 14, 2016).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            10.4#           </font>          </td>          <td>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390017002461/f10k2016ex10lix_actinium.htm">            <font style="font-size: 10pt">             Fifth Amendment to the 2013 Amended and Restated Stock Plan, as amended (incorporated by reference to Exhibit 10.59 to Form 10-K filed on March 16, 2017).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            10.5#           </font>          </td>          <td>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390017002461/f10k2016ex10lx_actinium.htm">            <font style="font-size: 10pt">             Amendment to Employment Agreement, dated March 16, 2017, by and between Actinium Pharmaceuticals, Inc. and Dragan Cicic. (incorporated by reference to Exhibit 10.60 to Form 10-K filed on March 16, 2017).            </font>           </a>          </td>         </tr>        </tbody>       </table>       <p style="margin: 0">       </p>       <p style="margin: 0">       </p>       <!-- Field: Page; Sequence: 95; Value: 51 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         75         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="margin: 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center; width: 9%">           <font style="font-size: 10pt">            10.6           </font>          </td>          <td style="width: 1%">          </td>          <td style="text-align: justify; width: 90%">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390017002461/f10k2016ex10lxi_actinium.htm">            <font style="font-size: 10pt">             Amendment to Actinium Pharmaceuticals, Inc. Warrant to Purchase Common Stock, dated March 14, 2017 issued to Sandesh Seth (incorporated by reference to Exhibit 10.61 to Form 10-K filed on March 16, 2017).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            10.7           </font>          </td>          <td>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390017002461/f10k2016ex10lxii_actinium.htm">            <font style="font-size: 10pt">             Amendment to Actinium Pharmaceuticals, Inc. Warrant to Purchase Common Stock, dated March 14, 2017 issued to Amrosan LLC (incorporated by reference to Exhibit 10.62 to Form 10-K filed on March 16, 2017).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            10.8           </font>          </td>          <td>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390017002461/f10k2016ex10lxiii_actinium.htm">            <font style="font-size: 10pt">             Warrant to Purchase Common Stock of Actinium Pharmaceuticals, Inc., dated March 14, 2017, issued to Sandesh Seth (incorporated by reference to Exhibit 10.63 to Form 10-K filed on March 16, 2017).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            10.9#           </font>          </td>          <td>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390017002461/f10k2016ex10lxiv_actinium.htm">            <font style="font-size: 10pt">             Offer Letter, dated December 27, 2016, by and between Dr. Mark S. Berger and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.64 to Form 10-K filed on March 16, 2017).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            10.10           </font>          </td>          <td>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390017002461/f10k2016ex10lxv_actinium.htm">            <font style="font-size: 10pt">             Confidential Information and Invention Assignment Agreement, dated December 27, 2016, by and between Dr. Mark S. Berger and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.65 to Form 10-K filed on March 16, 2017).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            10.11#           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390017002461/f10k2016ex10lxvi_actinium.htm">            <font style="font-size: 10pt">             Indemnification Agreement, dated March 16, 2017, by and between Actinium Pharmaceuticals, Inc. and Mark S. Berger (incorporated by reference to Exhibit 10.66 to Form 10-K filed on March 16, 2017).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            10.12#           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390017002910/f8k032717ex10i_actinium.htm">            <font style="font-size: 10pt">             Director Agreement, dated March 28, 2017, between Ajit S. Shetty and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 to Form 8-K filed on March 28, 2017).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            10.13#           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390017002910/f8k032717ex10ii_actinium.htm">            <font style="font-size: 10pt">             Indemnity Agreement, dated March 28, 2017, between Ajit S. Shetty and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.2 to Form 8-K filed on March 28, 2017).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            10.14           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390017002910/f8k032717ex10iii_actinium.htm">            <font style="font-size: 10pt">             Confidential Information and Invention Assignment Agreement, dated March 28, 2017, between Ajit S. Shetty and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.3 to Form 8-K filed on March 28, 2017).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            10.15#           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390017004962/f8k050517ex10i_actinium.htm">            <font style="font-size: 10pt">             Amendment to Amended and Restated Consulting Agreement, dated May 5, 2017, by and between Actinium Pharmaceuticals, Inc. and Sandesh Seth (incorporated by reference to Exhibit 10.1 to Form 8-K filed on May 11, 2017).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            10.16#           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390017005183/f10q0317ex10ii_actinium.htm">            <font style="font-size: 10pt">             Offer Letter, dated September 17, 2015, between Steve O’Loughlin and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 to Form 10-Q filed on May 15, 2017).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            10.17#           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390017005183/f10q0317ex10iii_actinium.htm">            <font style="font-size: 10pt">             Indemnification Agreement, dated May 15, 2017, between Steve O’Loughlin and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.2 to Form 10-Q filed on May 15, 2017).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            10.18           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390017008244/f10q0617ex10i_actinium.htm">            <font style="font-size: 10pt">             Assignment and Consent Agreement, dated June 6, 2017, between 275 Madison Avenue RPW 1 LLC and 275 Madison Avenue RPW 2 LLC, Relmada Therapeutics, Inc., and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 to Form 10-Q filed on August 4, 2017).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            10.19           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390017008244/f10q0617ex10iii_actinium.htm">            <font style="font-size: 10pt">             Amended and Restated License Agreement, Dated June 8, 2017, between Relmada Therapeutics, Inc., and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.3 to Form 10-Q filed on August 4, 2017).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            10.20#           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390017008244/f10q0617ex10iv_actinium.htm">            <font style="font-size: 10pt">             Offer Letter, dated May 26, 2017, between Nitya G. Ray and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.4 to Form 10-Q filed on August 4, 2017).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            10.21#           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390017008244/f10q0617ex10vi_actinium.htm">            <font style="font-size: 10pt">             Agreement, dated June 6, 2017, between Sergio Traversa and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.6 to Form 10-Q filed on August 4, 2017).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            10.22#           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390017008244/f10q0617ex10vii_actinium.htm">            <font style="font-size: 10pt">             Consulting Agreement, dated May 22, 2017, between Dragan Cicic and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.7 to Form 10-Q filed on August 4, 2017).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            10.23#           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390017008244/f10q0617ex10viii_actinium.htm">            <font style="font-size: 10pt">             Separation and Settlement Agreement, dated May 12, 2017, between Kaushik Dave and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.8 to Form 10-Q filed on August 4, 2017).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            10.24#           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390017008244/f10q0617ex10ix_actinium.htm">            <font style="font-size: 10pt">             Separation and Settlement Agreement, dated May 12, 2017, between Dragan Cicic and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.9 to Form 10-Q filed on August 4, 2017).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            10.25#           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390018003091/f10k2017ex10-56_actinium.htm">            <font style="font-size: 10pt">             Sixth Amendment to the 2013 Amended and Restated Stock Plan, as amended (incorporated by reference to Exhibit 10.56 to Form 10-K filed on March 16, 2018).            </font>           </a>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 96; Value: 51 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         76         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="width: 9%; text-align: center">           <font style="font-size: 10pt">            10.26#           </font>          </td>          <td style="width: 1%; text-align: justify">          </td>          <td style="width: 90%; text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390018003091/f10k2017ex10-57_actinium.htm">            <font style="font-size: 10pt">             Offer Letter, effective January 2, 2018, between Dale L. Ludwig and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.57 to Form 10-K filed on March 16, 2018).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            10.27#           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390018003091/f10k2017ex10-58_actinium.htm">            <font style="font-size: 10pt">             Indemnification Agreement, dated January 5, 2018, between Dale L. Ludwig and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.58 to Form 10-K filed on March 16, 2018).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            10.28#           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390018003091/f10k2017ex10-59_actinium.htm">            <font style="font-size: 10pt">             Offer Letter, effective January 31, 2018, between Anil Kapur and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.59 to Form 10-K filed on March 16, 2018).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            10.29#           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390018003091/f10k2017ex10-60_actinium.htm">            <font style="font-size: 10pt">             Indemnification Agreement, dated February 8, 2018, between Anil Kapur and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.60 to Form 10-K filed on March 16, 2018).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            10.30#           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390018005261/f8k042718ex10-1_actinium.htm">            <font style="font-size: 10pt">             Director Agreement, dated April 27, 2018, by and between Actinium Pharmaceuticals, Inc. and Jeffrey W. Chell (incorporated by reference to Exhibit 10.1 to Form 8-K filed on May 1, 2018).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            10.31#           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390018005261/f8k042718ex10-2_actinium.htm">            <font style="font-size: 10pt">             Indemnity Agreement, dated April 27, 2018, by and between Actinium Pharmaceuticals, Inc. and Jeffrey W. Chell (incorporated by reference to Exhibit 10.2 to Form 8-K filed on May 1, 2018).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            10.32           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390018005261/f8k042718ex10-3_actinium.htm">            <font style="font-size: 10pt">             Confidential Information and Invention Assignment Agreement, dated April 27, 2018, by and between Actinium Pharmaceuticals, Inc. and Jeffrey W. Chell (incorporated by reference to Exhibit 10.3 to Form 8-K filed on May 1, 2018).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            10.33#           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390018010603/f10q0618ex10-1_actinium.htm">            <font style="font-size: 10pt">             Employment Agreement, dated August 8, 2018, by and between Actinium Pharmaceuticals, Inc. and Sandesh Seth (incorporated by reference to Exhibit 10.1 to Form 10-Q filed on August 9, 2018).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            10.34#           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390018010603/f10q0618ex10-2_actinium.htm">            <font style="font-size: 10pt">             Employment Agreement, dated August 8, 2018, by and between Actinium Pharmaceuticals, Inc. and Steve O’Loughlin (incorporated by reference to Exhibit 10.2 to Form 10-Q filed on August 9, 2018).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            10.35           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390018014103/f8k101918ex10-1_actinium.htm">            <font style="font-size: 10pt">             Purchase Agreement, dated October 18, 2018, by and between Actinium Pharmaceuticals, Inc. and Lincoln Park Capital Fund, LLC (incorporated by reference to Exhibit 10.1 to Form 8-K filed on October 18, 2018).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            10.36           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390018014103/f8k101918ex10-2_actinium.htm">            <font style="font-size: 10pt">             Registration Rights Agreement, dated October 18, 2018, by and between Actinium Pharmaceuticals, Inc. and Lincoln Park Capital Fund, LLC (incorporated by reference to Exhibit 10.2 to Form 8-K filed on October 18, 2018).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            10.37#           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390019004269/f10k2018ex10-37_actinium.htm">            <font style="font-size: 10pt">             Consulting Agreement, dated December 21, 2018, between Actinium Pharmaceuticals, Inc. and Nitya Ray (incorporated by reference to Exhibit 10.37 to Form 10-K filed on March 15, 2019).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            10.38           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390019004269/f10k2018ex10-38_actinium.htm">            <font style="font-size: 10pt">             Amended and Restated At Market Issuance Sales Agreement, dated December 28, 2018, by and among Actinium Pharmaceuticals, Inc. and B. Riley FBR, Inc. and JonesTrading Institutional Services LLC (incorporated by reference to Exhibit 10.38 to Form 10-K filed on March 15, 2019).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            10.39           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390019004269/f10k2018ex10-39_actinium.htm">            <font style="font-size: 10pt">             Seventh Amendment to the 2013 Amended and Restated Stock Plan, as amended (incorporated by reference to Exhibit 10.39 to Form 10-K filed on March 15, 2019).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            10.40           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390020015271/ea123189ex10-1_actinium.htm">            <font style="font-size: 10pt">             Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to Form 8-K filed on June 18, 2020).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            10.41           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390020022334/f10q0620ex10-2_actinium.htm">            <font style="font-size: 10pt">             Amendment to Warrant to Purchase Common Stock of Actinium Pharmaceuticals, Inc., dated March 14, 2017, issued to Sandesh Seth (incorporated by reference to Exhibit 10.2 to Form 10-K filed on August 14, 2020).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            10.42#           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390020022334/f10q0620ex10-3_actinium.htm">            <font style="font-size: 10pt">             Employment Agreement, dated August 12, 2020, by and between Actinium Pharmaceuticals, Inc. and Sandesh Seth (incorporated by reference to Exhibit 10.3 to Form 10-Q filed on August 14, 2020).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            10.43#           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390020022334/f10q0620ex10-4_actinium.htm">            <font style="font-size: 10pt">             Employment Agreement, dated August 12, 2020, by and between Actinium Pharmaceuticals, Inc. and Steve O’Loughlin (incorporated by reference to Exhibit 10.4 to Form 10-Q filed on August 14, 2020).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            10.44#           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390020022334/f10q0620ex10-5_actinium.htm">            <font style="font-size: 10pt">             Employment Agreement, dated August 12, 2020, by and between Actinium Pharmaceuticals, Inc. and Dale Ludwig (incorporated by reference to Exhibit 10.5 to Form 10-Q filed on August 14, 2020).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            10.45#           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390020022334/f10q0620ex10-6_actinium.htm">            <font style="font-size: 10pt">             Employment Agreement, dated August 12, 2020, by and between Actinium Pharmaceuticals, Inc. and Mark Berger (incorporated by reference to Exhibit 10.6 to Form 10-Q filed on August 14, 2020).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            14.1           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000107878212003323/f8k122112_ex14z1.htm">            <font style="font-size: 10pt">             Code of Ethics (incorporated by reference to Exhibit 14.1 to Form 8-K filed on January 2, 2013).            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            21.1           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390015001800/f10k2014ex21i_actinium.htm">            <font style="font-size: 10pt">             List of Subsidiaries (incorporated by reference to Exhibit 21.1 to Form 10-K filed on March 16, 2015).            </font>           </a>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <!-- Field: Page; Sequence: 97; Value: 51 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         77         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center; width: 9%">           <font style="font-size: 10pt">            23.1           </font>          </td>          <td style="text-align: justify; width: 1%">          </td>          <td style="text-align: justify; width: 90%">           <font style="font-size: 10pt">            <a href="f10k2020ex23-1_actinium.htm">             Consent of Marcum LLP.            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            31.1           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <a href="f10k2020ex31-1_actinium.htm">            <font style="font-size: 10pt">             Certification of Principal Executive Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            31.2           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <a href="f10k2020ex31-2_actinium.htm">            <font style="font-size: 10pt">             Certification of Principal Financial and Accounting Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            32.1*           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <a href="f10k2020ex32-1_actinium.htm">            <font style="font-size: 10pt">             Certification of Principal Executive Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            32.2*           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <a href="f10k2020ex32-2_actinium.htm">            <font style="font-size: 10pt">             Certification of Principal Financial and Accounting Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            101.INS  **           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            XBRL Instance Document           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">           <font style="font-size: 10pt">            101.SCH **           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            XBRL Taxonomy Schema           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            101.CAL **           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            XBRL Taxonomy Calculation Linkbase           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">           <font style="font-size: 10pt">            101.DEF **           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            XBRL Taxonomy Definition Linkbase           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-size: 10pt">            101.LAB **           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            XBRL Taxonomy Label Linkbase           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">           <font style="font-size: 10pt">            101.PRE **           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            XBRL Taxonomy Presentation Linkbase           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0px">          </td>          <td style="width: 0.5in">           <font style="font-size: 10pt">            *           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            Filed herewith.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-size: 10pt">            **           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            Furnished herewith.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-size: 10pt">            #           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            Indicates a management contract or compensatory plan or arrangement.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 98; Value: 51 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         78         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         <a name="aph165213a025">         </a>         SIGNATURES        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Pursuant to the requirementsof the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td>           <font style="font-size: 10pt">            Dated: March 31, 2021           </font>          </td>          <td colspan="2">           <font style="font-size: 10pt">            <b>             ACTINIUM PHARMACEUTICALS, INC.            </b>           </font>          </td>         </tr>         <tr>          <td style="vertical-align: top; width: 62%">          </td>          <td style="vertical-align: top; width: 3%">          </td>          <td style="vertical-align: bottom; width: 35%">          </td>         </tr>         <tr>          <td style="vertical-align: top">          </td>          <td style="vertical-align: top">           <font style="font-size: 10pt">            By:           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom">           <font style="font-size: 10pt">            /s/ Sandesh Seth           </font>          </td>         </tr>         <tr>          <td style="vertical-align: top">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom">           <font style="font-size: 10pt">            Sandesh Seth           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            Chairman and Chief Executive Officer (Duly Authorized Officer,            <br/>            Principal Executive Officer)           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-size: 10pt">            By:           </font>          </td>          <td style="border-bottom: Black 1.5pt solid">           <font style="font-size: 10pt">            /s/ Steve O’Loughlin           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            Steve O’Loughlin           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            Chief Financial Officer            <br/>            (Duly Authorized Officer,            <br/>            Principal Financial and Accounting Officer)           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Pursuant to the requirementsof the Securities Exchange Act of 1934, this report has been signed below by the following person on behalf of the Registrant andin the capacities and on the dates indicated.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="border-bottom: Black 1.5pt solid; width: 34%">           <font style="font-size: 10pt">            <b>             Signature            </b>           </font>          </td>          <td style="padding-bottom: 1.5pt; width: 1%">          </td>          <td style="border-bottom: Black 1.5pt solid; width: 43%; text-align: center">           <font style="font-size: 10pt">            <b>             Title            </b>           </font>          </td>          <td style="padding-bottom: 1.5pt; width: 1%">          </td>          <td style="border-bottom: Black 1.5pt solid; width: 21%; text-align: center">           <font style="font-size: 10pt">            <b>             Date            </b>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-bottom: Black 1.5pt solid">           <font style="font-size: 10pt">            /s/ Sandesh Seth           </font>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            Chairman and Chief Executive Officer           </font>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-size: 10pt">            March 31, 2021           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-size: 10pt">            Sandesh Seth           </font>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            (Principal Executive Officer)           </font>          </td>          <td>          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-bottom: Black 1.5pt solid">           <font style="font-size: 10pt">            /s/ Jeffrey Chell           </font>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            Director           </font>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-size: 10pt">            March 31, 2021           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-size: 10pt">            Jeffrey Chell           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-bottom: Black 1.5pt solid">           <font style="font-size: 10pt">            /s/ David Nicholson           </font>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            Director           </font>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-size: 10pt">            March 31, 2021           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-size: 10pt">            David Nicholson           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-bottom: Black 1.5pt solid">           <font style="font-size: 10pt">            /s/ Richard I. Steinhart           </font>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            Director           </font>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-size: 10pt">            March 31, 2021           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-size: 10pt">            Richard I. Steinhart           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top">          <td style="border-bottom: Black 1.5pt solid">           <font style="font-size: 10pt">            /s/ Ajit J. Shetty           </font>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            Director           </font>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-size: 10pt">            March 31, 2021           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-size: 10pt">            Ajit J. Shetty           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: center">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        79       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Rule-Page -->       <div style="width: 100%">        <div style="font-size: 1pt; border-top: Black 1.5pt solid">        </div>       </div>       <!-- Field: /Rule-Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>      </text>     </description>    </filename>   </sequence>  </type> </document></body>